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Résumé 
Les habitudes de consommation de substances psychoactives, le stress, l’obésité et 
les traits cardiovasculaires associés seraient en partie reliés aux mêmes facteurs génétiques. 
Afin d’explorer cette hypothèse, nous avons effectué, chez 119 familles multi-
générationnelles québécoises de la région du Saguenay-Lac-St-Jean, des études 
d’association et de liaison pangénomiques pour les composantes génétiques : de la 
consommation  usuelle d’alcool, de tabac et de café, de la réponse au stress physique et 
psychologique, des traits anthropométriques reliés à l’obésité, ainsi que des mesures du 
rythme cardiaque (RC) et de la pression artérielle (PA). 58000 SNPs et 437 marqueurs 
microsatellites ont été utilisés et l’annotation fonctionnelle des gènes candidats identifiés a 
ensuite été réalisée. 
 Nous avons détecté des corrélations phénotypiques significatives entre les 
substances psychoactives, le stress, l’obésité et les traits hémodynamiques. Par exemple, les 
consommateurs d’alcool et de tabac ont montré un RC significativement diminué en 
réponse au stress psychologique. De plus, les consommateurs de tabac avaient des PA plus 
basses que les non-consommateurs.  Aussi, les hypertendus présentaient des RC et PA 
systoliques accrus en réponse au stress psychologique et un indice de masse corporelle 
(IMC) élevé, comparativement aux normotendus. D’autre part, l’utilisation de tabac 
augmenterait les taux corporels d’épinéphrine, et des niveaux élevés d’épinéphrine ont été 
associés à des IMC diminués. Ainsi, en accord avec les corrélations inter-phénotypiques, 
nous avons identifié plusieurs gènes associés/liés à la consommation de substances 
psychoactives, à la réponse au stress physique et psychologique, aux traits reliés à l’obésité 
et aux traits hémodynamiques incluant CAMK4, CNTN4, DLG2, DAG1, FHIT, GRID2, 
ITPR2, NOVA1, NRG3 et PRKCE. Ces gènes codent pour des protéines constituant un 
réseau d’interactions, impliquées dans la plasticité synaptique, et hautement exprimées dans 
le cerveau et ses tissus associés. De plus, l’analyse des sentiers de signalisation pour les 
gènes identifiés (P = 0,03) a révélé une induction de mécanismes de Potentialisation à 
Long Terme.  
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 Les variations des traits étudiés seraient en grande partie liées au sexe et au statut 
d’hypertension. Pour la consommation de tabac, nous avons noté que le degré et le sens des 
corrélations avec l’obésité, les traits hémodynamiques et le stress sont spécifiques au sexe 
et à la pression artérielle. Par exemple, si des variations ont été détectées entre les hommes 
fumeurs et non-fumeurs (anciens et jamais), aucune différence n’a été observée chez les 
femmes. Nous avons aussi identifié de nombreux traits reliés à l’obésité dont la corrélation 
avec la consommation de tabac apparaît essentiellement plus liée à des facteurs génétiques 
qu’au fait de fumer en lui-même. Pour le sexe et l’hypertension, des différences dans 
l’héritabilité de nombreux traits ont également été observées. En effet, des analyses 
génétiques sur des sous-groupes spécifiques ont révélé des gènes additionnels partageant 
des fonctions synaptiques : CAMK4, CNTN5, DNM3, KCNAB1 (spécifique à 
l’hypertension), CNTN4, DNM3, FHIT, ITPR1 and NRXN3 (spécifique au sexe). Ces 
gènes codent pour des protéines interagissant avec les protéines de gènes détectés dans 
l’analyse générale. De plus, pour les gènes des sous-groupes, les résultats des analyses des 
sentiers de signalisation et des profils d’expression des gènes ont montré des 
caractéristiques similaires à celles de l’analyse générale. 
 La convergence substantielle entre les déterminants génétiques des substances 
psychoactives, du stress, de l’obésité et des traits hémodynamiques soutiennent la notion 
selon laquelle les variations génétiques des voies de plasticité synaptique constitueraient 
une interface commune avec les différences génétiques liées au sexe et à l’hypertension. 
Nous pensons, également, que la plasticité synaptique interviendrait dans de nombreux 
phénotypes complexes influencés par le mode de vie. En définitive, ces résultats indiquent 
que des approches basées sur des sous-groupes et des réseaux amélioreraient la 
compréhension de la nature polygénique des phénotypes complexes, et des processus 
moléculaires communs qui les définissent. 
 
Mots-clés : cartographie génique, substances psychoactives, traits reliés à l’obésité, stress 
psychologique, stress physique, rythme cardiaque, pression artérielle, synapse, analyse de 
sous-groupes, réseau de gènes, réseau de phénotypes. 
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Abstract 
Links among substance use, obesity, stress and related cardiovascular outcomes 
may be in part due to shared genetic factors. To investigate this hypothesis, we performed 
genome-wide linkage and association scans for genetic components of habitual alcohol, 
tobacco and coffee use, response to mental and physical stress, obesity related 
anthropometric traits and heart rate (HR) and blood pressure (BP) measurements in 119 
multigenerational French Canadian families from founder population of Saguenay-Lac-St-
Jean region using 58000 SNPs and 437 microsatellite markers and followed with functional 
annotation on resulted genes.  
We found significant phenotypic correlations among substance use, obesity, stress 
and hemodynamic traits. For instance, alcohol and tobacco users had attenuated HR 
response to mental stress; moreover, tobacco users had lower BP compared to non users; 
Hypertensives had stronger HR and systolic blood pressure (SBP) response to mental stress 
and higher body mass index (BMI), compared to normotensives; Use of tobacco seemed to 
increase the epinephrine level in body and higher epinephrine level was correlated with 
lower BMI. Consistent with phenotypic relatedness, we found numerous shared genes 
associated / linked to substance use, obesity-related traits, response to mental and physical 
stress and hemodynamic traits including CAMK4, CNTN4, DLG2, DAG1, FHIT, GRID2, 
ITPR2, NOVA1, NRG3 and PRKCE forming protein interaction network, involved in 
synaptic plasticity and highly expressed in brain related tissues; moreover, pathway 
analysis on identified genes pointed (P = 0.03) to Long-Term Potentiation pathway. 
Large portions of variation of studied traits were explained by sex and hypertension 
status, focusing on tobacco use we noted that degree and the direction of correlations of 
obesity, hemodynamic and stress related traits with tobacco use vary according to sex and 
hypertension status; for instance, while in males, current tobacco users were slender 
compared to never or former tobacco users, there were no such differences in females; 
moreover, we found several obesity related traits that their correlations with smoking 
behavior seemingly root in genetic factors rather than smoking effect itself. Sex- and 
hypertension differences in heritabilities of many of these traits were also observed; 
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meanwhile, specific subgroup genetic analyses uncovered additional shared synaptic genes 
among these traits including CAMK4, CNTN5, DNM3, KCNAB1 (Hypertension-specific), 
CNTN4, DNM3, FHIT, ITPR1 and NRXN3 (Sex-specific) having protein interactions with 
genes driven from general analysis; moreover, the results of pathway analysis and reported 
gene expression profiles of resulted genes from subgroup analyses revealed similar 
characteristics to those from general analysis.  
The substantial overlap among genomic determinants of substance use, stress, 
obesity and hemodynamic traits supports the notion that the genetic variations in pathways 
of synaptic plasticity may be a common interface behind them as well as observed sex and 
hypertension genetic differences, we also think synaptic plasticity may underlie many 
complex phenotypes in which life style is a contributing factor; moreover, our findings 
indicate considering subgroup and network-based approaches enhance understanding of 
polygenic nature of complex phenotypes as well as shared molecular underpinnings among 
them. 
 
Keywords : genetic mapping, substance use, obesity-related traits, mental stress, physical 
stress, heart rate, blood pressure, synapse, subgroup analysis, gene network, phenotype 
network 
v 
 
Table des matières 
 
Résumé .................................................................................................................................... i 
Abstract ................................................................................................................................. iii 
Table des matières .................................................................................................................. v 
Liste des tableaux ................................................................................................................ viii 
Liste des figures ..................................................................................................................... x 
Liste des sigles et abréviations .............................................................................................. xi 
Remerciements .................................................................................................................... xiv 
Introduction ............................................................................................................................ 1 
1.1 Pleiotropy ............................................................................................................... 1 
1.2 Genetic mapping .................................................................................................... 4 
1.2.1 Family-based vs. case and control association studies ...................................... 4 
1.2.2 Genome wide linkage and association analysis ................................................. 5 
1.2.3 Founder populations ........................................................................................... 6 
1.3 Saguenay-Lac-Saint-Jean population ..................................................................... 7 
1.4 Substance use ......................................................................................................... 9 
1.5 Substance use and stress ...................................................................................... 12 
1.6 Substance use and hypertension ........................................................................... 18 
1.7 Substance use and obesity .................................................................................... 22 
1.8 Stress and hypertension ........................................................................................ 26 
1.9 Stress and obesity ................................................................................................. 29 
1.10 Obesity and hypertension ..................................................................................... 34 
1.11 Current project ..................................................................................................... 38 
1.12 References ............................................................................................................ 41 
Article1 ................................................................................................................................. 63 
2.1 Abstract ................................................................................................................ 64 
2.2 Introduction .............................................................................................................. 65 
2.3 Methods and Procedures ...................................................................................... 66 
2.3.1 Family cohort ................................................................................................... 66 
vi 
 
2.3.2 Phenotyping ..................................................................................................... 67 
2.3.3 Phenotypic correlation tests ............................................................................. 68 
2.3.4 Estimation of heritability ................................................................................. 69 
2.3.5 Genotyping ....................................................................................................... 69 
2.3.6 Genetic analysis ............................................................................................... 70 
2.3.7 Functional annotations ..................................................................................... 71 
2.4 Results .................................................................................................................. 72 
2.4.1 General characteristics of phenotypes .............................................................. 72 
2.4.2 Phenotypic correlation results .......................................................................... 73 
2.4.3 Heritability estimates ....................................................................................... 74 
2.4.4 Genetic findings and functional annotation ..................................................... 74 
2.5 Discussion ............................................................................................................ 77 
2.6 References ............................................................................................................ 82 
Article 2 .............................................................................................................................. 137 
3.1 Abstract .............................................................................................................. 138 
3.2 Introduction ........................................................................................................ 140 
3.3 Methodology ...................................................................................................... 141 
3.3.1 Family cohort ................................................................................................. 141 
3.3.2 Phenotypes ..................................................................................................... 142 
3.3.3 Phenotypic correlations and statistical adjustments ....................................... 144 
3.3.4 Genotypes ....................................................................................................... 144 
3.3.5 Genetic analysis ............................................................................................. 145 
3.4 Results ................................................................................................................ 146 
3.4.1 General characteristics of phenotypes and phenotypic correlations .............. 146 
3.4.2 Genetic results ................................................................................................ 150 
3.5 Discussion .......................................................................................................... 151 
3.6 References .......................................................................................................... 159 
Discussion .......................................................................................................................... 193 
4.1 Shared genetic factors among polygenic disorders ............................................ 193 
4.2 Synaptic plasticity .............................................................................................. 195 
4.3 Network thinking ............................................................................................... 197 
vii 
 
4.4 Epistasis and pleiotropy ..................................................................................... 197 
4.5 Sex and hypertension differences....................................................................... 198 
4.6 Smoking initiation and persistence .................................................................... 200 
4.7 Network based genome-wide scan ..................................................................... 201 
4.8 Disease classification and profiling ................................................................... 203 
4.9 Drug network ..................................................................................................... 204 
4.10 Conclusion ......................................................................................................... 205 
4.11 References .......................................................................................................... 207 
Appendice 1 ....................................................................................................................... 214 
 
viii 
 
Liste des tableaux 
 
Article 1 
Table 1. Distribution of substance use traits by sex and hypertension status and their 
correlations with sex, age and hypertension ................................................................ 88 
Table 2. Descriptive statistics of quantitative traits distributed by sex, hypertension status 
and in entire cohort along their correlations with sex, age and hypertension .............. 89 
Table 3. Correlation of obesity-related traits, stress responses and HR and BP data with 
substance use ................................................................................................................ 93 
Table 4. Heritability (H2r) estimates of studied traits by sex and hypertension status and in 
general .......................................................................................................................... 97 
Table 5. Candidate loci driven by joint linkage and family-based association analysis .... 102 
Table 6. Shared candidate SNPs among the studied traits driven from family based 
association analysis .................................................................................................... 104 
Table 7. Hypertension-specific and sex-specific candidate loci driven by joint linkage and 
family-based association analysis .............................................................................. 114 
Table 8. Hypertension-specific and sex-specific shared candidate SNPs among the studied 
traits driven from family based association analysis.................................................. 117 
Table 9. Comparing the gene expression profiles among the shared genes driven from 
general analysis, sex-specific and hypertension-specific analysis ............................. 128 
 
Article 2 
Table 1. Characteristics of tobacco use statuses ................................................................ 168 
Table 2. Distribution of tobacco use traits by sex and hypertension status along with their 
correlations with sex, age and hypertension .............................................................. 169 
Table 3. Descriptive statistics of obesity, stress and hemodynamic related traits distributed 
by sex, hypertension and tobacco use statuses ........................................................... 170 
Table 4. Correlation of obesity, stress and hemodynamic related traits with tobacco use 176 
ix 
 
Table 5. Correlation of obesity, stress and hemodynamic related traits with tobacco use in 
females and males ...................................................................................................... 181 
Table 6. Correlation of obesity, stress and hemodynamic related traits with tobacco use in 
hypertensives and normotensives ............................................................................... 186 
Table 7. Significantly shared SNPs between tobacco use and correlated obesity, stress and 
hemodynamic related traits ........................................................................................ 191 
Table 8. Bivariate association analysis on significantly shared SNPs ............................... 192 
 
 
 
 
 
 
 
  
x 
 
Liste des figures 
 
Introduction 
Figure 1. Stress-induced activation of the HPA axis. .......................................................... 17 
 
Article1 
Figure 1. Joint linkage and association analysis identified SNPs inside ITPR2 gene 
associated to tobacco use and HR response within a common area of linkage for these 
traits ............................................................................................................................ 133 
Figure 2. Gene expression heat map for commonly associated genes driven from general 
analysis across 65 human tissues ............................................................................... 134 
Figure 3. Overview of protein interactions among genes driven from general, sex-specific 
and hypertension-specific analysis ............................................................................. 135 
Figure 4. Hypothetical model of interaction among stress, synaptic plasticity, substance use 
obesity and related-cardiovascular outcomes ............................................................. 136 
  
xi 
 
Liste des sigles et abréviations 
 
ACTH: adrenocorticotropic hormone 
Asn: asparagine 
Asp: aspartic acid 
BMI: body mass index 
BP: blood pressure 
cAMP: cyclic adenosine monophosphate 
CBG: corticosteroid-binding globulin 
Chr: chromosome 
CHUM: centre hospitalier de l’université de montréal 
cM: centi morgan 
CNS: central nervous system 
CRF: corticotropin releasing factor 
DBP: diastolic blood pressure 
EP: epinephrine 
FBAT: family-based association test 
GABA: gama-aminobutyric acid 
GEE: generalized estimating equation 
GnRH: gonadotropin-releasing hormone 
GWAS: genome-wide association study 
H2r: heritability 
HPA: hypothalamic-pituitary-adrenal 
HR: heart rate 
xii 
 
HSP: heat shock protein 
HT: hypertension 
HWE: hardy-weinberg equilibrium 
IBD: identity-by-descent 
IP3: inositol trisphosphate 
km: kilometer 
LD: linkage disequilibrium 
LDL: low-density lipoprotein 
LOD: logarithm of odds 
LTP: long-term potentiation pathway 
MAF: minor allele frequency 
MAP: mean arterial pressure 
MAPK: mitogen-activated protein kinase 
N: number 
NAc: nucleus accumbens 
NE: norepinephrine 
NIH: national institutes of health 
NPL: non-parametric linkage 
NPY: neuropeptide y 
OMIM: online mendelian inheritance in man 
P: p-value 
POMC: proopiomelanocortin 
PP: pulse pressure 
QTL: quantitative trait loci 
RAAS: renin-angiotensin-aldosterone system  
xiii 
 
SBP: systolic blood pressure 
SE: standard error 
SLSJ: saguenay-lac-st-jean 
SNP: single-nucleotide polymorphism 
SNS: sympathetic nervous system 
T1D: type 1 diabetes 
T2D: type 2 diabetes 
VTA: ventral tegmental area 
WTCCC: wellcome trust case control consortium 
 
xiv 
 
 Remerciements 
I would like to express my sincere gratitude to my supervisor, Dr. Pavel Hamet, 
who provided me with countless hours of mentoring as well as resources that I needed, 
without his constant direction and support this project would not have been possible. He 
has been invaluable in helping me develop interesting dissertation topics and teaching me 
so much about genetics of cardiovascular disorders and risk factors. 
Thanks to Dr. Ondrej Šeda who checked every step of my project, gave me 
insightful comments and advices and helped me to improve my writings. I would like to 
thank my thesis committee members; Dr.  Daniel Sinnett, Dr. Bianca D'Antono and Dr. 
Richard Bertrand, who provided important directions and wise advices in their varied areas 
of expertise. Thanks to Dr. Johanne Tremblay for reviewing my results and giving me 
important comments. 
I would like to thank the current and former members of Dr. Hamet’s and Dr. 
Trembly’s group; Milan Petrovich, Dr. Ivan Arenas, Mahine Ivanga, Audrey Noël, Johanna 
Sandoval, Pierre-Luc Brunelle, Alexandru Gurau, Marie-Noel Nadeau, Dr. Pierre Dumas, 
France Robin, Érika Fisseler, Francine Allie, and Diane Legault. I would like to sincerely 
thank the families who have participated in Cardiogene project. Without their participation, 
these studies would not be possible. 
A very special thank to my family and friends for their supports and understandings, 
for always being there when I need them and sharing their moments with me. 
I am thankful to GENESIS ICE Team and Programmes de biologie moléculaire for 
giving me training awards. This work was supported by funds from the National Institutes 
of Health Specialized Center of Research, Canadian Institutes of Health Research, and by a 
grant from the Canadian Institutes of Health Research and the Heart and Stroke Foundation 
of Canada to the GENESIS ICE Team. 
 
  
 
 
 
 Introduction 
 
1.1 Pleiotropy 
One of the interesting observations of George Mendel during his study of 
inheritance in pea plants (Pisum sativum) was about the color of various plant parts. 
Particularly he found complete relatedness among seed coat color with flower color as well 
as axillary pigmentation. Mendel noticed that always plants with colored seed coats have 
colored flowers and colored leaf axils and plants with colorless seed coats always have 
white flowers and no pigmentation on their axils.1 
Today, we know that Mendel's observation of complete association of phenotypes 
was the result of pleiotropy or the phenomenon in which a single gene influences multiple 
phenotypic traits. Accordingly, a new variation that happens in the gene may have an 
influence on some or all traits simultaneously. The underlying mechanism for instance can 
be because of the product of the gene is used by different cell types, or has a signaling 
function on a variety of targets.2 
In some cases the influence of the mutation in final outcomes is straightforward; for 
example, the liver enzyme phenylalanine hydroxylase converts amino acid phenylalanine to 
amino acid tyrosine which is precursor for neurotransmitters like dopamine and 
norepinephrine, the hormone thyroxine, and the pigment melanin; thus, mutation in this 
gene can affect multiple body systems.3 
However pleiotropy is not always straightforward and there are cases that mutation 
in a gene is beneficial for one trait and detrimental for the other trait.  For example, the 
product of the TP53 gene has the ability to interrupt cell proliferation. It helps prevent 
cancer by stopping cells with DNA damage from dividing, but this ability can be 
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deleterious when it suppresses the division of stem cells which enables the body to renew 
and replace deteriorating tissues. Another example is the sickle cell anemia in regions that 
malaria is endemic, a single-nucleotide substitution at the sixth amino acid position of the β 
hemoglobin chain replaces glutamic acid with valine this causes a drastic change of 
erythrocyte shape (sickle-cell anemia); however, this mutation in regions that malaria is 
endemic protects against invasion of the protozoan parasite (Plasmodium falciparum) that 
causes malaria.4-6 
This type of pleiotropy is called antagonistic pleiotropy which happens when one 
gene controls for more than one trait where at least one of these traits is beneficial to the 
organism's fitness and at least one is detrimental. It can make a major constraint on natural 
selection and results in more staying power of the genes with antagonistic pleiotropy in the 
evolutionary context.4; 6; 7 
Although evidences of pleiotropy have been primarily found through the studies of 
simple disorders with proven Mendelian inheritance, recent studies suggest that the logic of 
pleiotropic genetic polymorphisms also extends to human disorders that have complex and 
largely unknown genetic factors. Previous studies reported numerous examples of a gene 
associated with disorders that are quite distinct. For example after a comprehensive search 
of NIH Genetic Association Database, Liu et al8 found genes like angiotensin I converting 
enzyme (ACE), tumor necrosis factor alpha (TNF), tumor protein 53 (TP53) and 
apolipoprotein E (APOE) associated to more than 50 diseases. These genetic sharings 
among disorders have brought the concept of human disease network which indicates 
diseases themselves form a network in which two disorders are connected if they share at 
least one gene. Evidences form genetic and epidemiological studies also showed that 
certain hereditary disorders often co-occur significantly more or significantly less 
frequently than what is expected by chance which suggest there is a genetic component that 
predisposes its carriers to multiple disorders, or that protects against some disorders while 
predisposing to others.8-12 
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Dudley et al13 systematically investigated the pleiotropy by doing the first genome-
wide study of genetic pleiotropy. Authors created single gene deletion strains, representing 
all 4700 nonessential genes in yeast and analyzed the growth of these strains under 21 
different conditions. They found 551 mutant strains, exhibited growth defect in only one or 
two conditions and 216 strains showed growth defects in 3–14 conditions, their findings 
indicated a much higher degree of pleiotropy than what is expected by chance even among 
the most dissimilar conditions tested and point to the importance of pleiotropy in biological 
systems. 
Rzhetzky et al12 reviewed 1.5 million medical records involving 161 diseases 
represent a broad spectrum of disorders affecting diverse physiological systems and 
computed pairwise correlations of disease co-occurrences. They found that disease 
phenotypes form a highly connected network of strong pairwise correlations; moreover, 
they noted striking tendencies for certain diseases to co-occur in individuals. They pointed 
that unlike the familiar model of “unique malady–unique (disjoint with others) set of 
broken genes” which is applicable to most Mendelian disorders, most complex phenotypes 
are probably rooted in genetic variations that are significantly shared (in either a 
competitive or cooperative manner) by multiple disease phenotypes and they recommend 
the design of genetic linkage or association strategies that analyze multiple complex 
disorders jointly for the disorders appeared to be correlated. 
Using the data from Online Mendelian Inheritance in Man (OMIM) database that 
represents and up-to-date repository of all known disease genes and the disorders, Goh et 
al11 constructed a network of human diseases in which two disorders are connected to each 
other if they share at least one gene. Although they found clustering among the disease of 
the same class but the resulted network did not fall into many single nodes corresponding to 
specific disorders or grouped into small clusters of a few closely related disorders; instead, 
it form a large network of human diseases. Of 1,284 disorders in OMIM database, 867 had 
at least one link to other disorders, and 516 disorders form a giant component, suggesting 
that the genetic origins of most diseases, to some extent, are shared with other diseases. 
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In another study, Barrenas et al14 investigated shared genetic architecture of 
complex diseases studied using Genome Wide Association studies data from GWAS 
Catalog containing SNPs published with p-values less than 10-5. They found from the 54 
studied complex disorders, 26 disorders are sharing at least one gene. 
 
1.2 Genetic mapping 
1.2.1 Family-based vs. case and control association studies 
Association studies examine the co-occurrence of a genomic markers and a 
phenotype in order to assess the contribution of genomic variants to a phenotype in specific 
population. Different types of association-based designs are used for mapping the genomic 
determinates of complex disorders. The two most widely used strategies are case-control 
studies of unrelated subjects and family-based designs.15 
Case-control association study of unrelated subjects is the most simple and 
commonly used approach. A case-control study compares two groups that are expected to 
differ in their prevalence of disease-susceptibility alleles. Sufficiently large study 
populations can be readily assembled without the need to enroll family members of the 
recruited participants; however, population stratification may lead to spurious association 
and hence bias the findings. Population stratification happens when there is a systematic 
difference in allele frequencies among subpopulations in the dataset possibly due to 
different ancestry. In this case, false positive association can occur because of the 
confounding effects of population stratification. A number of approaches have been 
proposed to detect and account for population stratification in population based studies; 
however, it may be difficult to remove this effect in all situations; furthermore, there can be 
obscure relatedness in the samples collected for case-control studies that can violate the 
initial statistical assumptions.15-18 
5 
 
 
Family-based association methods evaluate whether particular alleles are 
transmitted from parents down to affected offspring in a proportion that is different from 
what is expected from Mendelian transmissions, an excess sharing of specific allele among 
the affected subjects indicates that a disease-susceptibility locus for a trait of interest is 
linked and associated with the marker locus. Because both linkage and association are 
required to reject the null hypothesis; hence, family based association tests avoid false 
positives that arise when association is present but linkage is not as might happen in the 
presence of population stratification.15; 16; 19 
Collecting a sample of unrelated cases and controls is easier compared to collecting 
family-based samples; moreover, to get the same power as a case-control study design, a 
larger number of family-based samples will have to be ascertained and genotyped. 
Nonetheless, although case control studies are more feasible, family-based designs are still 
more appropriate mainly because unlike population-based studies, family-based designs are 
robust against population substructure, and significant findings always imply both linkage 
and association; moreover, compared to case-control designs, families tend to be less 
heterogeneous regarding exposure to environmental factors that are related to the disease 
etiology.15; 16 
 
1.2.2 Genome wide linkage and association analysis 
There are two main strategies for mapping the genomic factors behind the complex 
traits which are linkage analysis and association mapping. Both methods allow 
comprehensive scan of the entire genome for disease genes in a hypothesis-independent 
manner without having knowledge of the biology of disorder; however, each method has 
benefits and drawbacks.19; 20 
Linkage analysis tests for co-segregation of a genomic marker and disease 
phenotype within a family in order to determine if the marker and the disease gene are 
physically linked. It estimates the recombination fraction between a disease locus of 
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unknown location and genomic markers of known location and evaluates whether this 
recombination fraction is significantly different from 0.5 (The situation that the disease 
locus is not linked to the genetic markers). Therefore, linkage analysis unlike the 
association studies requires a genetic map; in addition, compared to genome wide 
association studies, much lower number of markers are required for genome wide linkage 
analysis; for instance, a typical genome wide linkage analysis can be performed with about 
600 markers corresponding to marker-marker intervals of  5 centi Morgan (cM).20; 21 
Linkage analysis has been the primary method for identifying genes underlying 
Mendelian disorders. Although there are examples of disease alleles of modest effect that 
have been detected by linkage analysis, this approach has been more successful in detecting 
genes with large effect; whereas, most of the genetic variance in complex disorders can be 
attributed to genes of modest effect which are more likely to be captured with association 
studies. Besides, association studies provide greater resolution of location than linkage 
studies since they do not rely on recombination rate.19-22 
Overall, in many ways both linkage and association provide complementary data 
and using a joint approach allows combining the merits of both methods; for instance, 
performing association tests within region flagged by linkage signals will provide more 
robust results and also remarkably reduce the number of SNPs for multiple testing.21 
 
1.2.3 Founder populations 
Linkage and association analysis can be augmented by the study of founder 
population. A founder population is descended from a limited number of individuals 
(founders) as a consequence of some type of bottleneck.23 Samples of individuals from 
founder populations have already proved greatly useful in mapping genes that underlie 
Mendelian disorders. It is becoming increasingly apparent that studies locating genes 
underlying complex phenotypes also benefit from the study of samples from founder 
population in several ways.24-26 
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In a founder population fewer numbers of haplotypes being segregated through the 
generations compared to outbred population. This reduces the number of markers for 
genome wide scans; moreover, in a more outbred population with considerably higher 
numbers of haplotypes, the causative allele is more likely to be located on several 
haplotypic backgrounds, thereby diluting signals to an extent that prevent its identification 
by genetic means; then, the value of population isolates and their genomic LD patterns may 
thus be even greater when lower-frequency variants are considered.24-26 
Founder populations display higher degree of genetic homogeneity because of the 
limited number of founders (and thus a limited gene pool) and absence of migration, this 
diminish the risk of unidentified population stratification that can bias results and 
compromise the interpretation of genetic association studies; in addition, extensive allelic 
and locus heterogeneity, a key feature of common complex diseases that can obscure the 
association signal within disease-associated genomic regions is lower in founder population 
compared to outbred populations.24-26 
Unlike the monogenic disorders where the genetic composition of an individual 
often solely determines the disease phenotype, environmental factors are critical risk factors 
in complex diseases; therefore, since environmental risk factors are generally more uniform 
in founder populations than in large outbred populations, probing the genetic determinants 
of complex disorders seemingly are easier in a founder population compared to outbred 
population. Furthermore, the availability of extensive genealogical records in a founder 
population can provide large genealogies which are potentially very informative in genetic 
studies.24-27 
 
1.3 Saguenay-Lac-Saint-Jean population  
The French colonization of Quebec began from 1608 until 1760 in which about 
8000 to 10000 people who came from France, permanently established themselves in the 
province. This establishment has been referred to as the first founder effect.28-30 
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This founder effect was further augmented in some sub populations of Quebec 
including the Saguenay-Lac-St-Jean (SLSJ) region located about 200 km northeast of 
Quebec City. The initial settlement of SLSJ region occurred in the 19th century, all regions 
of the province of Quebec have contributed to the growth of SLSJ population, but the 
majority of migrants (about 75%) in  the  earliest  decades came  from Charlevoix,  a  
region located  on  the  north shore  of the St. Lawrence River which is about 200 km south 
and east of Saguenay. The settling of the Charlevoix region itself started in 1675 in which 
599 founders of mostly French descent moved to this region from the Quebec City area. 
There has been relatively little migration into the SLSJ region after 1870, and the 
population has intrinsic growth from 5200 in 1852 to about 300,000 at present.29; 31-33 
As a consequence of the SLSJ population history, the prevalence of several 
recessive disorders is higher in the SLSJ region than in other populations such as myotonic 
dystrophy, spastic ataxia, tyrosinemia, agenesis of the corpus callosum and vitamin D-
dependent rickets. 31; 34; 35 Labuda et al31 using a demographic model suggested the 
historical age of the founder effect in SLSJ is about 12 generations; therefore, in this 
population with fewer number of haplotypes being segregated over the time, even longer 
stretches of LD and less heterogeneity are expected compared to older founder populations. 
Founder effect also causes limited allelic diversity; for example, a single 
homozygous mutation was found in 80% of patients with hereditary tyrosinemia type I, and 
only three mutations were found in 94% of patients with cystic fibrosis pointing to the 
reduced genetic heterogeneity in this population. It is also reported that large blocks of 
ancestral DNA flank the disease mutations in this population; specifically, recent studies 
have demonstrated that ancestral haplotypes spanning about 8-10 cM are common to 40%-
60% of affected chromosomes and blocks about 4-6 cM being common to nearly 80% of 
populations with rare diseases from this region.31; 36-38 
Moreover, extensive genealogical records exist in the BALSAC population register 
maintained at the inter-university Institute for Population Research provides additional 
benefits for genetic studies.163 The register contains ascending genealogies dating back to 
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the original 17th-century settlers; they have been constructed on the basis of parish records 
of baptisms, marriages, and burials of 1,500,000 individuals. To date, all records have been 
computerized, and families reconstituted into a genealogically linked database.27; 39 
 
1.4 Substance use 
Alcohol, tobacco and coffee are among the most commonly consumed psychoactive 
substances in the world. Their concurrent use has been consistently shown across a wide 
variety of populations. Previous studies have reported relatively strong correlations 
between smoking and alcohol consumption and smoking and coffee consumption. Coffee 
and alcohol consumption are also correlated especially when either substance is used 
heavily. 40-43 Abuse and dependence risks have been demonstrated for these substances and 
some researchers postulate that there is a relationship between the use of these substances 
and that of illicit drugs; moreover, in comparison with other substances, the high 
prevalence of alcohol, tobacco and coffee use allows for significant statistical power in a 
practically sized sample. Probing the relatedness of these legal psychoactive substances 
may also provide information for elucidating factors contributing to the use, abuse, and 
dependence of other drugs; moreover, such information can provide tips for prevention, 
intervention and treatment programs.40-43 
Several models have been proposed to explain the correlations in consumption of 
these substances; for instance, biobehavioral models suggest that  the use of one substance 
prompts the use of other types of substances, personality  models  point to presence of  
underlying psychological trait or set of traits that predispose an individual  to polysubstance 
use and the neurogenetic models suggest, the commonalities in the use of substances are 
due to common  neural  pathways  and  receptors in which psychoactive substances act and  
interact.40; 43; 44 
Genetic studies utilizing twins and family approaches have shown that substance 
use is substantially heritable;46 in addition, animal studies also point to the importance of 
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genetic factors; for example, under similar environmental settings, the Lewis rats more 
readily self-administer drugs of abuse compared to Fischer 344 rats which indicate 
differences in genetic liability, additional studies showed that these strains differ in 
properties of their mesolimbic dopamine system.45 Clinical and experimental studies also 
documented that genetic factors operate at all steps of substance use, including 
vulnerability to initiation, continued use, propensity to become dependent and relapse to 
drug taking or drug seeking after a period of abstinence. In this context, different genetic 
models have been proposed to account for the clustering in the use of these substances. One 
prevailing hypothesis indicates that there is a general non-specific genetic risk factor that 
increases subjects’s liability to use multiple psychoactive substances for instance a common 
neural pathway.44; 46 
In fact, although psychoactive substances have their specific receptors, mechanisms 
of action and pharmacological effects, all appear to influence brain's reward pathways by 
producing a series of common functional effects after both acute and chronic 
administration. Reward system includes dopaminergic neurons in ventral tegmental area 
(VTA) of the midbrain and their targets in nucleus accumbens (NAc) and prefrontal cortex. 
The VTA-NAc pathway is one of the most important substrates for the acute rewarding 
effects of all drug of abuse and research over the past several decades has documented how 
each drug, regardless of its distinct mechanism of action, coincide on the ventral tegmental 
area and nucleus accumbens with common acute functional effects. Enhancement of 
dopaminergic transmission in nucleus accumbens has been implicated in the mechanism of 
reinforcement of almost all psychoactive substances. All addictive drugs facilitate 
dopamine transmission, In fact determining the role of dopamine has been an important 
focus of biomedical research in addiction. Chronic drug states are also appear to induce 
similar changes in central corticotropin releasing factor (CRF) systems. Abrupt withdrawal 
from virtually any drug of abuse leads to activation of CRF-containing neurons in the 
amygdale. Activation of these neurons during drug withdrawal partly is responsible for the 
negative emotional symptoms as well as many of the somatic symptoms that occur upon 
drug withdrawal and therefore may contribute to drug craving and relapse.44; 46; 47 
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In this context, another model proposes that genetic risk factors are largely 
substance specific such as variation in receptor systems specific to individual drugs of 
abuse. For instance, nicotine acts through specific nicotinic receptors distributed throughout 
the central and peripheral nervous systems. Caffeine has similar structure to adenosine and 
its principal mode of action appears to be on adenosine receptors. Less is known about 
alcohol specific receptor systems in the brain, but it has been shown to affect gama-
aminobutyric acid (GABA) ergic neurons and glutamatergic systems as well as serotonin 
and endorphin release.40; 41; 43; 44 
Number of studies investigated the source of covariations among substance uses 
across populations. Kozlowski et al42 looked at the relationships among the frequencies of 
use of various drugs in two drug abusing populations. They found that among their studied 
drugs, use of tobacco, alcohol, and caffeine are directly related to one another and they 
concluded that use of these substances may be governed by similar factors. 
Swan et al40 performed a multivariate genetic analysis of tobacco, alcohol, and 
coffee consumption in a cohort of 173 monozygotic and 183 dizygotic male twin pairs from   
Twin  Registry of white male World War II veterans to determine the extent of genetic and 
environmental overlap in the observed correlations among these substances. Their best 
fitting model found a common genetic component which they called it polysubstance use 
factor underlying the observed correlations among alcohol, tobacco and coffee use. 
Residual genetic variances specific to the use of each substance were also identified; 
moreover, they found no significant role for common environmental variance in their 
hypothesized polysubstance use factor.  
In another study performed by Hettema et al41 in a sample of 774 monozygotic and 
809 dizygotic male and female twin pairs from members of the population-based Virginia 
Twin Registry. Authors probed whether the overlap of use of tobacco, alcohol, and caffeine 
is due to non-specific shared genetic or environmental substance use factors or due to 
factors that are highly substance specific. Their findings suggest that the variance is 
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proportioned into both shared and specific genetic and environmental factors that are of 
moderate size. 
In a more recent study, Li et al48 conducted a meta-analysis on the basis of manually 
integrating 2343 items of cross-platform data linking genes and chromosome regions to 
addiction from peer-reviewed publications spanning 30 years from 1976 to 2006. Focusing 
on 396 genes that were supported by two or more independent items of evidence they found 
18 statistically significant enriched pathways in which Long-term depression, Gap junction 
and Long-term potentiation were the most significant pathways. Focusing on alcohol, 
nicotine, cocaine and opioid they identified five common and interlinked pathways behind 
these substances including Long-term potentiation, MAPK (mitogen-activated protein 
kinase) signalling pathway and Neuroactive ligand–receptor interaction that had been 
previously implicated in addiction as well as two new pathways; GnRH (gonadotropin-
releasing hormone) signalling pathway and Gap junctions.  
Many studies that have investigated the importance of genes in use of psychoactive 
substances also suggest substantial contributions from the environment. Among various 
environmental factors that may influence substance use, stress seem to be an important 
factor, it has been reported that stress increases the vulnerability of individuals to 
acquisition of substance self-administration and it is considered as an important factor in 
addiction research.46; 49; 50 
 
1.5 Substance use and stress 
The term stress was first employed in a biological context by the endocrinologist, 
Hans Selye in the 1930s. He described the hypothalamic-pituitary-adrenal axis as the 
system whereby the body copes with stress and found the principal remaining problems and 
misconceptions surrounding the clinical application and theoretical evaluation of the stress 
concept.51; 52  
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Stress is a well-known risk factor and precursor to use of psychoactive substances. 
Several models of substance abuse consider acute or chronic stress as an important 
contributing factor in development of substance abuse such as stress-coping model of 
addiction, Marlatt's relapse prevention model, tension reduction hypothesis and self-
medication hypotheses. These models mainly point that people use substances to reduce 
negative affections and enhance positive moods under acute and chronic stress conditions.53 
Numerous studies in experimental and clinical research documented that stressors 
facilitate the acquisition of psychoactive substances, stressors can also increase the rate and 
dosage of substance use and stressors can cause relapse to, or reinstatement of drug taking 
even after a prolonged drug-free period.46; 53; 54 
A growing body of evidences point to a number of biological connections between 
substance use and stress. Based on findings from clinical studies, one model postulates that 
stress leads to state-related changes in the brain reward circuits resulting in a greater 
sensitivity to the reinforcing properties of drugs, and thereby increasing the motivation to 
use drugs compulsively. In fact, chronic exposure to either stressors or substance abuse 
appears to exert many similar changes in the brain’s reward pathway via dopaminergic and 
glutamatergic neurotransmitter systems. For example both stress and substance use increase 
the release of dopamine in nucleus accumbens, activation of dopaminergic pathway either 
by stressors or drugs exerts similar changes in growth factors, transcription factors and 
second messenger cascades in the midbrain ventral tegmental area and its terminal fields, 
following exposures to either stressors or substance abuse reorganization of synaptic 
connections of reward pathway has been observed; moreover, other studies have pointed to 
the importance of gluamergic system in the reward pathway, for instance, it was reported 
that immobilization stress, morphine and cocaine all induce the up-regulation of the GluR1 
subunit of the AMPA receptor for glutamate in the VTA.47; 55; 56 
While reward pathway appeared to be the central players in addiction, evidences 
like tendency to relapse years after a prolonged drug-free period indicate that brain regions 
that are involved in memory and learning may also have function in addiction. In fact, an 
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influential hypothesis points that addiction represents a pathological yet strong form of 
learning and memory.  Previous studies documented that drug seeking can get inhibited by 
disrupting the reconsolidation of drug-related memories and stress on the other hand is 
known to influence different stages of memory and learning. For example, it has been 
shown in rats that immobilization stress facilitates morphine self-administration if it comes 
after the onset of the drug availability session indicating the importance of associative 
leanings.44; 47; 56 
 The brain structures that are involved in memory and learning, such as 
hippocampus and extended amygdala are connected with brain reward pathway and 
interestingly both stress and drug exposure impact the structure and function of these 
regions. In general, similar neuroplasticity or neuroadaptations seem to occur in these 
regions after exposure to stress or drugs.56-58 
The recruitment of brain-stress systems within the extended amygdala provides a 
powerful mechanism for seeking and taking psychoactive substances and evidences suggest 
dysregulation of amygdale influence both stress response and substance use; for instance, it 
has been reported, rats with the damaged amygdala are less responsive to dangerous stimuli 
and are more sensitive to cocaine use compared to normal group. 59 Neurogenesis is very 
active in the hippocampus; similar to stress, chronic exposure to drugs of abuse also impact 
the neurogenesis and neural structure and function in hippocampus and similar to reward 
pathway, both stress and drugs of abuse appear to influence these brain structures via 
dopaminergic and glutamatergic neurotransmitter systems as well as via glucocorticoids 
released upon activation of HPA axis to alter neural structure and function.56; 60 
A main component of body’s response to stressors is the hypothalamic-pituitary-
adrenal (HPA) axis (Figure 1). HPA axis activation or suppression influences use of 
psychoactive substances. Hormones released upon activation of HPA axis like 
glucocorticoids can alter neural structure and function in reward pathway as well as 
learning and memory processes and basal levels of stress hormones seem to contribute to 
behavioral responses and neuroadaptations to drug exposure; for example, substances like 
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cocaine, morphine, nicotine, and alcohol are reported to be differentially reliant on stress 
hormones for their behavioral impact. Drug-induced activation of HPA axis allows 
glucocorticoids to sensitize the reward pathway. This sensitization of the reward system 
would make the subjects more responsive to drugs of abuse and, consequently, more 
vulnerable to the development of addiction.46; 47; 56 
Substance use can change the activity of HPA axis; for instance, it has been found 
that patient with heroin dependence are having a hypo-responsive HPA system and those 
with dependence on cocaine show a hyper-responsive HPA axis;46 in addition, Lewis 
inbred rats that more readily self-administer drugs of abuse compared to Fischer 344 rats 
are also having hypo-responsive HPA axis responses to stress exposure and it has been 
shown that exposure to stressors increases corticosterone  and/or ACTH 
(adrenocorticotropic hormone) levels in F344 but not in Lewis rats.46; 61 
Previous studies using opioid antagonists documented that the endogenous opioid 
system, via opioid receptors demonstrate inhibitory control over the HPA axis (Figure 1); 
moreover, mice lacking the mu opiate receptor gene (OPRM1) show dramatically reduced 
or absent analgesia, reward, physical dependence and respiratory depression in response to 
opiates. The most common coding region polymorphism in this gene is a variant (A118G) 
that changes asparagine (Asn) to aspartic acid (Asp) at amino acid position 40. In vitro 
studies showed that beta-endrophine binds to the new form, 118G (Asp40) with threefold 
greater affinity than the prototype 118A (Asn40) receptor; besides, clinical studies found 
that carriers of 118G allele showed a greater HPA response to opioid antagonist than 
subjects with the only prototype 118A allele. Additionally, people with the 118G allele had 
a more favorable clinical response to treatment for alcoholism with the opioid antagonists. 
This indicates that the difference in response to treatment may be mediated by the impact of 
the receptor on HPA axis activation; moreover, it has been reported that basal amounts of 
cortisol in subjects with the 118G allele are significantly higher than in volunteers with the 
only prototype form in a stress-minimized setting condition.46; 62-64 
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Another evidence of genic link among HPA axis, stress response and addiction was 
identified through the studies on COMT gene, which encodes an enzyme that catalyzes the 
degradative metabolism of catecholamine neurotransmitters dopamine, norepinephrine and 
epinephrine, as well as hydroxylated estrogens. A common variant in exon 4 of this gene 
change valine to methionine at amino acid 158. Methionine form has greater thermolability 
and a three- to fourfold lower enzymatic activity than the prototype valine form. Genetic 
linkage and association studies pointed that this variant may be involved in several 
centrally mediated traits. Several studies documented that the low-activity of methionine 
form is associated with increased risk of alcoholism; moreover, it has been repoted that this  
variant influences HPA axis function; for instance, after administration of naloxone, 
subjects with homozygous methionine form had higher increases in their plasma ACTH 
and cortisol than heterozygous or homozygous subjects for prototype valine form.46; 65-67 
Endocannabinoid system that mediates the psychoactive effects of cannabis has also 
been elucidated as a critical regulator of the stress response through its ability to modulate 
the sensitivity and activation of the HPA axis (Figure 1). Under conditions of acute stress, 
the endocannabinoid system tonically restrains activation of the HPA axis and disruption of 
endocannabinoid signaling in the other hand increases the activity of the HPA axis and is 
associated with an inability to adapt to chronic stress.164-166 
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Figure 1. Stress-induced activation of the HPA axis.  
Stressors cause increased synthesis and release of hypothalamic corticotropin releasing factor 
(CRF) into blood circulation. By binding to its specific receptor in the anterior pituitary, CRF 
induces synthesis of proopiomelanocortin (POMC) and release into the circulation of 
adrenocorticotropic hormone (ACTH) and beta-endorphin, which are derived from processing of 
POMC. ACTH acts on its specific receptor in the cortex of adrenal gland and induces release of the 
glucocorticoid hormones. Glucocrticoids exert negative feedback regulation at both the 
hypothalamus and the pituitary to decrease the activity of HPA axis. In addition to negative 
feedback regulation by glucocorticoids, the endogenous opioid and cannabinoids systems tonically 
constrain activation of the HPA axis. 
Anterior pituitary 
CRF
ACTH
Glucocorticoids 
Endogenous opioids 
POMCBeta endrophine 
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Hypothalamus
CRF
Adrenal
Glucocorticoids
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1.6 Substance use and hypertension 
Excessive alcohol intake increases the risk of many diseases and is reported to be 
the commonest cause of reversible hypertension. Reduction of heavy alcohol intake is 
considered in hypertension management programs; however, considerable research 
suggests that moderate alcohol consumption is associated with health benefits including a 
decreased risk of hypertension.  It appears that the effect of alcohol use on hypertension is 
in a form of J-shaped correlation suggesting the benefits of moderate alcohol intake; 
however, the modulatory effect of alcohol on hypertension also depends on other factors 
including environmental factors as well as genetic factors. 68; 69; 71 For example, the level of 
sodium intake is positively correlated with increased blood pressure only at low calcium 
intake and this correlation was more significant in subjects who consume high amounts of 
alcohol.70 Genetic factors also influence the mediatory effect of alcohol on hypertension; 
for instance, variations in alcohol-metabolizing enzymes such as CYP2E1, ADH2, and 
ALDH2 genes modify the intake of alcohol and as a result the relationship between alcohol 
intake and blood pressure.68 Another interesting example of genetic link between 
hypertension and alcohol use comes from the study of apolipoprotein E gene (APOE).  
APOE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents 
and hence is important in regulation of serum low-density lipoprotein (LDL) cholesterol 
concentration. The APOE gene accounts for approximately 7% of the population variance 
in total LDL cholesterol levels. This gene exerts its heightening impact on LDL cholesterol 
through the APOE4 allele which is associated with higher LDL cholesterol, while carriers 
of the APOE2 allele have lower LDL cholesterol levels.68; 72 
Findings from the Framingham Offspring Study showed that the effects of alcohol 
intake on LDL cholesterol are mediated in part by variations in APOE gene. Corella et al73 
noted that in the group of male non-drinkers, LDL cholesterol was not significantly 
different across APOE allele groups; however, in the group of male drinker the expected 
difference was observed where subjects with APOE4 allele had higher LDL cholesterol 
compared to the APOE2 allele carriers; moreover, they found LDL cholesterol in men with 
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the APOE2 allele was significantly lower in drinkers than in nondrinkers but was 
significantly higher in drinkers than in non-drinkers in men with the APOE4 allele.  
APOE alleles also appear to impact the blood pressure;72 for instance, in a recent 
study, authors did a meta-analysis of six studies comprising 1812 cases and 1762 controls 
in an effort to systematically investigate the association between APOE gene variations and 
high blood pressure. They found that presence of APOE4 allele is associated with increased 
risk of developing hypertension.74 
One study75 found that in males that are moderate or heavy drinkers, the APOE2 
allele may enhance the blood pressure-elevating effects of alcohol, whereas the APOE4 
allele seems to abolish it. These interactions among alcohol intake, APOE allele type and 
blood pressure were not detected in females, suggesting a sex-specific effect; however, 
another study found no relationship between decrease in blood pressure with alcohol 
restriction and apolipoprotein APOE genotypes,76 which points to the requirements for 
further studies.68; 77  
Another example comes from the study of GNAS1 gene that encodes the alpha 
subunit of G-protein involved in cAMP-dependent pathway by activating adenylate 
cyclase. Chen et al78 assessed the interaction between the polymorphism T393C in this gene 
and alcohol consumption in association with hypertension in a Japanese population 
consisted of 699 hypertensives and 1609 normotensives. Their results suggest that the 
apparent effect of the T393C polymorphism on blood pressure depends on alcohol 
consumption. They found that the T393C polymorphism significantly interacted with 
drinking status in association with systolic blood pressure; moreover, while subjects with 
the TT or TC genotype consistently had a higher probability of hypertension, higher 
systolic blood pressure, and higher diastolic blood pressure than CC homozygotes in non-
drinkers and light drinkers. This relation was invert in the group of moderate to heavy 
drinker where subjects with the CC genotype consistently had a higher probability of 
hypertension and higher SBP and DBP than subjects with the TT and TC genotypes. 
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While there are a substantial number of studies that documented the adverse effects 
of smoking on health, the role of smoking as a risk factor for hypertension is not 
established. Tobacco smoking temporarily raises blood pressure (BP) probably through 
vasoconstriction and accelerated heart rate; nonetheless, results from epidemiologic studies 
have generally shown that smokers have lower BP compare to nonsmokers; meanwhile, 
former smokers have BP similar to those of nonsmokers. Gene-environment interaction 
findings pointed that genetic factors are important mediator of the effect of tobacco 
smoking on hypertension.79; 80; 167 
In the same cohort in which authors found a significant interaction between the 
T393C polymorphism in GNAS1 gene and alcohol use in the pathogenesis of hypertension 
78, they81 also observed that the TT and TC genotypes of the T393C polymorphism have a 
risk-increasing effect on development of hypertension in non heavy smokers and heavy 
smoking significantly decreased the effect. In contrast, the CC genotype had a relatively 
protective effect on the development of hypertension in non-heavy smokers, and heavy 
smoking did not modify the effect significantly. Authors concluded that since subjects with 
the TT and TC genotypes are more common compared to those with the CC genotype; 
hence, their findings are consistent with the evidences that smokers have lower BP 
compared to nonsmokers. They also pointed that the observed protective effect of smoking 
is not attributable to the phenomenon that smokers have lower body mass index than 
nonsmokers because the T393C polymorphism appears to have no significant interaction 
with body mass index in association with hypertension. 
Another line of evidence of genes and smoking interaction in the development of 
high blood pressure came from studies of ACE gene which encodes angiotensin I 
converting enzyme (peptidyl-dipeptidase A) that is involved in renin-angiotensin system 
and catalyzes the conversion of decapeptide angiotensin I to octapeptide angiotensin II. A 
variation in this gene result in D allele which is associated with increased ACE activity 
compared to I allele. In a cohort of 412 non-smokers, 2794 former smokers and 1508 
current smokers, Schut et al82 assessed the relationship between the ACE I/D 
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polymorphism, systolic (SBP) and diastolic (DBP) blood pressures and risk of hypertension 
in each group. They found a significant association between the ACE I/D polymorphism, 
SBP and the risk of hypertension in smokers. Individuals who smoke and carry the D allele 
showed significantly increased SBP and an increased risk of hypertension compared with 
those who smoked and had the II genotype; meanwhile, they found no relation between the 
ACE genotype and blood pressure or risk of hypertension in non-smokers and former 
smokers groups. 
Caffeinated beverages are widely used in societies. It is not clear whether there is a 
causal relationship between caffeine and hypertension. Findings from studies that 
investigated the effect of coffee intake and hypertension are inconsistent while some 
showed no effect, other studies found positive relation or inverse relation. It has been 
suggested that these discrepancies in results may be in part due to differences in genetic 
risk factors.83; 84 
Cytochrome P450 1A2 or CYP1A2 is the main enzyme responsible for the 
metabolism of caffeine. A variation in this gene results in allele A and F. Subjects 
homozygote for allele A are fast caffeine metaboizers compared to those with FF and AF 
genotypes. Palatini et al84 investigated the effect of coffee intake on the risk of developing 
hypertension among individuals screened for stage 1 hypertension. They noted that after 8.2 
years of follow-up the heavy coffee drinkers homozygote for allele A have 9 mmHg lower 
BP than their counterparts with FF and AF genotypes.84 Consistent with this finding, 
another study suggested that coffee consumption increases the risk of myocardial infarction 
only among individuals with slow caffeine metabolism genotypes.85 These findings point to 
the importance of genetic factors in studying the relation of coffee intake with 
hypertension. 
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1.7 Substance use and obesity 
In 1949 Donald Hebb proposed that starvation is a learned behavior, in which eating 
is initially reinforcing because it revokes unpleasant body signals e.g. change in nutrient 
levels and hunger hormones in the blood and over the time it finally becomes an organized 
behavior. Findings from studies that investigated the biological connections among 
substance use and feeding behavior also appear to accumulate at the neurobiological level 
and suggest the importance of findings from the field of drug addiction in obesity 
research.86-89 
Opioid receptor subtypes that as mentioned earlier provide genic link among 
substance use and stress also influence the regulation of food intake. The opiate antagonist, 
naloxone inhibits feeding in mammals, slugs, snails and even in amoebae; while, opioid 
contributes to increased food intake by delaying satiety signals during a meal.87; 90; 91 
Rats that are fed palatable diet are more sensitive to the anorectic effects of the 
opioid receptor antagonists. This indicates that palatable foods are also able to change the 
activity of endogenous opiate system. Findings from experimental studies also documented 
that the opiate receptors and their ligands are dysregulated in several animal models of 
obesity for example mu receptors are up regulated in diet-induced obese rats and 
concentrations of endogenous opioid peptides were elevated in obese mice having the 
mutated form of leptin gene, consistently clinical studies showed that obese subjects have 
higher level of beta-endorphin compared to normal subjects.44; 92 
Among various opioid receptor subtypes that play a role in regulating energy 
balance, the mu opioid receptors appear to have more important function.  Mu receptors are 
mostly located in brain areas controlling feeding and rewarding behavior. Modifications of 
mu opiate receptors have been reported in the hypothalamus of rats susceptible to obesity 
induced by eating a high fat diet. Recent studies on rodents indicate that the stimulation of 
mu opioid receptors preferentially increases the intake of highly palatable foods whereas 
their block exerts anorectic effects; moreover, there are evidences that administration of 
opioid agonist, morphine into the nucleus accumbens of rats increases food intake. These 
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findings suggest opioid receptors control the appetite through the hedonic processes 
associated with reward pathway.44; 91; 92 
Similar to opioid system, endocannabinoid system has also been reported to be 
directly involved in feeding regulation, infact the ability of cannabis to promote eating has 
been known for many centuries. Interstingly, now there are convincing evidences that link 
both endocannabinoid system and opioid system in the reciprocal modulation of hedonic 
factors that mediate feeding behavior.168-170 It has been shown that stimulation of 
cannabinoid type 1 receptor by cannabinoids heightened intensity of food craving and 
enhanced appreciation of food;168-170 this subsequently led to development of specific 
cannabinoid type 1 receptor antagonists such as Rimonabant as anti-obesity medication.171 
 Both feeding and drug use involve learned habits and preferences that are stamped 
in by the reinforcing properties of powerful and repetitive rewards. Pharmacological 
blockade of, or experimental damage to forebrain dopamine systems attenuates free feeding 
and lever-pressing for food reward, as well as the rewarding effects of psychoactive 
substances. Neuroimaging scans suggest reduced brain activity of dopamine may contribute 
to obesity as well as drug addiction.44; 92; 93 
In fact, highly palatable food appeared to have properties that promote dependence; 
moreover, similar to drugs of abuse, palatable food can activate the brain reward system. 
Dopamine reuptake inhibitor, methylphenidate increases brain synaptic dopamine, produces 
anorexia, and finally reduces the intake of highly palatable food. In animal models of 
obesity including obese Zucker rats, leptin-deficient ob/ob mice and seasonally obese 
animals treatment with dopamine receptors D2 and D1 agonists reverses the obesity; 
however, connection between dopamine receptors and food intake does not appear to be 
straightforward. Dopamine acts through several dopamine receptors (D1–D5) which seem 
to mediate distinct effects on food intake and food preference. It has been noted that 
selective activation of Dopamine receptor D1 (DRD1) resulted in increased caloric intake 
and preference for highly palatable foods, whereas combined activation of DRD2 and 
DRD3 receptors showed an opposite effect. The reduced activity of dopamine neurons and 
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dopamine D2 receptor availability in the ventral striatum are also reported to be associated 
with both obesity and drug addiction. Repeated stimulation of the reward pathways through 
highly palatable food may lead to neurobiological adaptations similar to substance abuse 
that eventually increase the compulsive nature of overeating characterized by frequent drive 
to initiate eating.87; 93-96 
In comparison to drugs of abuse that activates the reward pathway in a rather direct 
pharmacological way, palatable food appeared to act through both, fast sensory inputs as 
well as slower post ingestive processes such as adiposity signals, leptin and insulin that 
have important function in energy regulations; however, leptin and insulin are thought to 
decrease food intake partly by modifying the reward value of food, for instance, 
intraventricular administered leptin and insulin are able to decrease sucrose self-
administration, additional support of the influence of satiety signals on reward pathway 
came from the observation of insulin and leptin receptors on the ventral tegmental area 
which is a key structure of the brain reward circuitry.97-99 
Studies in rats documented that removing the endogenous corticosterone source, 
largely or completely eliminate obesity. Administration of glucocorticoids has been shown 
to markedly increase food intake. HPA axis can modulate the influence of leptin and insulin 
on food intake. Increased glucocorticoid concentrations have been associated with insulin 
resistance as well as leptin resistance; thus, elevated levels of cortisol could lead to 
impaired sensitization of satiety signals and inadequate adjustment for excess weight gain 
of the organism. Glucocorticoids like cortisol can influence drug use and food intake also 
through reward pathway. In basal conditions, administration of glucocorticoids increase 
dopamine release in the nucleus accumbens, whereas suppression of glucocorticoid 
secretion has the opposite effects; moreover, the opioid receptors that play important role in 
food intake through the reward pathway, are having connections with HPA axis. Variations 
in mu opioid receptor influence the level of glucocorticoids; besides, it has been shown that 
the expression of the mu opioid receptors and hence, opioid sensitivity is modulated by 
glucocorticoids for instance the expression of the mu opioid receptors are diminished in 
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CRH-deficient mice but it can be reversed by corticosterone administration. Endogenous 
opioids are a group of the neurotransmitters that are released upon activation of HPA axis. 
They act as part of body’s powerful defense mechanism against the detrimental effects of 
stress. Opioids decrease the activity of the HPA axis on different levels in order to 
terminate and attenuate the stress response, providing a negative feedback control 
mechanism. As mentioned earlier, opioid release increases palatable food intake and 
palatable food sustains opioid release. Thus, food intake resembles a powerful tool to 
decrease HPA axis activation. If HPA axis activation becomes chronic and eating is learned 
to be effective, hence highly palatable food may have the properties similar to psychoactive 
substances.87; 92; 93 
Genome wide scans also provide evidences of genic link between obesity and 
substance use. Findings from these studies suggest that obesity is a centrally mediated trait 
and share common neurobiological basis with substance use.86; 100; 101 
 A recent genome wide association study performed on more than 30,000 subjects 
participating in 8 large cohort studies found NRXN3 gene associated to obesity. 101 NRXN3 
is part of a family of central nervous adhesion molecules and is highly expressed in the 
central nervous system; it is thought to be involved in synaptic plasticity. Prior studies of 
NRNX3 point to the important role of this gene in alcohol dependence, cocaine addiction, 
and illegal substance abuse. One study found that short-term cocaine exposure in mice is 
sufficient to increase the expression of NRXN3 in the globus pallidus; many of the 
neuronal pathways in these sub-cortical regions of the brain are involved in learning and 
reward training.101; 102 
Findings on the two other well-replicated obesity genes, MC4R and FTO103-106; 187 
also suggest that obesity and addiction may share common neurologic underpinnings. Both 
of these genes are coding brain proteins. Variations in FTO gene appeared to impact food 
intake and selection and MC4R has been found to be associated with centrally-mediated 
phenomena including binge eating behavior. The FTO gene is almost expressed throughout 
the body, but is mainly abundant in feeding-related areas in the hypothalamus like the 
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arcuate nucleus. The arcuate nucleus has a direct projection to the lateral hypothalamic area 
which is implicated in reward and is one of the sites where electrical brain stimulation is 
most rewarding. The MC4R gene is also abundantly expressed in the arcuate nucleus as 
well as lateral hypothalamic area. Neurons of lateral hypothalamic area contain the 
neurotransmitter orexin which has been implicated in drug addiction. 86; 103-107 Another 
example of genic link between substance use and obesity comes from the study of 
dopamine receptor D2 (DRD2) gene. Individuals carrying the A1 allele of the Taq1A 
polymorphism that is located around 10 kb downstream of DRD2 gene have reduced brain 
DRD2 receptor density compared to those having the prototype form; in addition, this allele 
has been found to be correlated with obesity and persistent substance abuse.86; 87  
 
1.8 Stress and hypertension 
Regular exposure to stress as it happens in daily life may favor the development of 
chronic blood pressure elevation. It has been shown that exaggerated cardiovascular 
response to stress at young age may be predictive of the future development of 
hypertension. Findings from twin studies indicate that genetic factors account for 40% to 
60% of the variance in cardiovascular reactivity to stress. It is postulated that repeated 
exposure to stress in combination with genetic susceptibility and unfavorable 
environmental factors may eventually lead to manifestation of hypertension. Various 
systems are reported to be behind stress induced hypertension and numerous genic 
variations have been found that links these systems to stress induced hypertension.52; 108-114  
The sympathetic nervous system (SNS) which is part of the autonomic nervous 
system has an important role in mobilizing the body's resources under stress. Repeated 
exposure to environmental stress increases the activity of SNS and excessive activity of 
SNS in the long term appears to be positively associated with hypertension; for instance, 
peripheral vasoconstriction and increased renal tubular sodium reabsorption which are the 
consequences of long-term sympathoactivation, raise blood pressure too.115-117 
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Activation of SNS leads to the release of catecholamines, norepinephrine (NE) and 
epinephrine (EP) interestingly number of genes that are involved in catecholamine 
metabolism and transport are implicated in stress-induced-hypertension; moreover, some 
studies point to adrenergic receptors as a genic link between stress and hypertension which 
can regulate the cardiovascular response to SNS activation. Adrenergic receptor subtypes 
which are receptors for NE and EP influence BP by mediating heart function, renal sodium 
excretion, and vascular tone, another important group of genes that have been implicated in 
stress induced hypertension are dopamine receptors. Dopaminergic activity is involved in 
BP control as a negative modulator of SNS outflow, and there are numerous indications 
that hypertension develops in the absence of a normally functioning dopaminergic system 
for instance DRD5 knockout mice develop hypertension which is also characterized by 
increased SNS activity.109; 118; 119 
One system that is activated as a result of SNS arousal is renin–angiotensin–
aldosterone system (RAAS), an important regulator of blood pressure, over expression of 
renin and its metabolic products increase the blood pressure. The enzymatic cascade of this 
system includes angiotensinogen which is acted upon by renin to produce angiotensin I, 
which is in turn cleaved by a variety of enzymes, including angiotensin converting enzyme 
(ACE) to generate angiotensin II.  This enzyme is a key player for most of the known 
biological activity of this system. Angiotensin II increases blood pressure via direct 
vasoconstriction. It also increases aldosterone production, and their combined effects 
eventually increase sodium and water retention that finally result in a rise in cardiac output 
and delayed BP recovery; besides, the augmented sodium retention enhances 
vasoconstrictive effects of norepinephrine on peripheral vasculature that further increases 
BP. It has been documented that increased angiotensin II production is associated with 
decreased urinary sodium excretion during a behavioral stress period which indicates the 
involvement of this enzyme in controlling stress-induced sodium retention; moreover, 
angiotensin II activates SNS and enhances the effect of NE; for example, infusion of 
angiotensin II increases muscular sympathetic nervous activity and angiotensin converting 
enzyme inhibition appeared to decreases muscular sympathetic nervous activity in 
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normotensive subjects. Other example of candidate genes in renin–angiotensin–aldosterone 
system that are implicated in stress induced hypertension are angiotensinogen (AGT), 
renin, angiotensin-converting enzyme (ACE), the Ang II type 1 receptor (AGTR1), and 
aldosterone synthase (CYP11B2).109; 120-122 
HPA axis is a main component of body’s response to stressors. Activation of HPA 
axis leads to the release of cortisol via a number of intermediate steps. First, the 
hypothalamus, at the base of brain triggers stress responses by producing corticotrophin 
releasing factor (CRF).  Next CRF stimulates the pituitary gland to release 
adrenocorticotropic hormone (ACTH) which promotes cortisol secretion in the cortex of 
adrenal glands. Cortisol is thus a commonly used measure of HPA axis activation, and its 
secretion increases in response to any physical or psychological stress. As such, cortisol is 
often referred to as a stress hormone. Cortisol is related to hypertension; for instance, 
cortisol affects parts of the limbic system involved in the control of blood pressure 
regulation; furthermore, glucocorticoid receptors are also present in the kidney, heart as 
well as vascular smooth muscle of the resistance vessels, thus directly mediating the effect 
of cortisol on blood pressure. A number of monogenic forms of hypertension include 
pathophysiological changes in HPA axis function particularly cortisol biosynthesis and 
function have also been reported which again point to the modulatory effect of HPA axis on 
blood pressure.109; 114; 123-125 
Another link between stress and hypertension comes from the study of heat shock 
proteins (HSP), HSP proteins are involved in cellular response to stress, they are a class of 
functionally related proteins whose their expressions are increased under the transcriptional 
control of heat shock transcription factors when cells are exposed to various stressors.52; 112; 
172 The increased expression of HSPs in response to several stressors has been previously 
reported by our group and other studies. It has been shown that in hypertensives, mRNA 
levels of these HSPs rose more rapidly but were followed by a more rapid decline to 
baseline for both mRNA and proteins as compared to normotensive subjects;173-177 
moreover, subjects with established hypertension have increased levels of HSP 
29 
 
 
antibodies;178 besides, genomic loci containing HSPs have been found to cosegregate with 
cardiovascular traits.111; 179 
In another study by our group, Thifult et al113 used genome-wide linkage analysis to 
identify loci bearing stress-related phenotypes in recombinant congenic strains of mice. In 
A/J mouse strain that exhibits fear memory impairments with deficits in amygdalar long-
term potentiation,180 they identify stress QTL on mouse Chr 1 which was synthenic to a 
cluster of metabolic phenotypes of hypertension in human27 and hypertensive dyslipidemic 
rats.158 Following gene expression analysis, they found Atp1a2 gene in this region which 
was down regulated in the heart and brain of anxious mice compared to controls. 
Interestingly, this gene is also involved in the salt-related hypertension and exerting a major 
action on cardiac output and peripheral resistance,181-183 which further support the 
pleiotropic function of this gene in stress response and hypertension.  
Other important mediators that are implicated in stress-induced-hypertension are 
sodium reabsorption, endothelial system, serotonergic system and sympathetic nervous 
system; besides, growing body of literature have found number of genes involved in these 
systems that link stress to hypertension such as sodium channels in sodium reabsorption 
system, endotheline receptors in endothelial system, serotonin transporters and receptors in 
serotonergic system and cholinergic receptors in parasymphatic system.109; 167 
 
1.9 Stress and obesity 
Stress is known to be related to body weight. Some people lose weight and others 
gain weight in response to stress. It has been suggested that during stressful periods eating 
comfort foods or those high in fat and carbohydrate caloric content helps to reduce 
biological stress system activity and negative affections; in addition, lack of physical 
activity and time to prepare healthy meals during stressful periods further contribute to 
weight gain; however, chronic stress may also lead to weight loss particularly in subjects 
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whom chronic stress is associated with suppressed appetite and increased physical 
activity.126-128 
Evidences suggest that the HPA axis, a central component of stress response and a 
common interface between substance use and cardiovascular disease is also involved in 
pathogenesis of human obesity, in particular characterized by visceral fat distribution.92; 93 
As mentioned in the previous sections, variations in OPRM1 gene encoding mu 
opioid receptor were found associated to obesity and stress response. In fact, opioid 
provides a negative feedback control mechanism by reducing the activity of the HPA axis 
on different levels in order to terminate and attenuate the stress response. Variant 118G in 
exon 1 of the mu opioid receptor gene has a threefold increase in beta-endorphin binding. 
Bart et al129 found that basal amounts of cortisol in subjects with the 118G allele in OPRM1 
gene were significantly higher than in subjects with the prototype 118A allele in a stress-
minimized setting, these findings indicated, mu opioid receptor modulates the HPA axis; 
moreover, it has been shown that the expression of the mu opioid receptor and hence, 
opioid sensitivity is modulated by glucocorticoids for instance its expression is diminished 
in CRH-deficient mice but it can be reversed by corticosterone administration.62; 129; 130 
The endocannabinoid system has also been elucidated as a critical regulator of the 
stress response through its ability to modulate the sensitivity and activation of the HPA 
axis. Disruption of endocannabinoid signaling increases the activity of the HPA axis, which 
could involve a loss of inhibitory regulation of excitatory neurotransmission inside the 
neural stress circuit.164-166 Interestingly, endocannabinoid system is also directly involved in 
feeding regulation. Stimulation of cannabinoid type 1 receptor, for instance by 
cannabinoids in addition to neuropsychiatric effects can also promote strong cravings for, 
and an intensification of the sensory and hedonic properties of food.168-170 this led to the 
findings that the blockage of the cannabinoid type 1 receptor represented a novel 
pharmacological target for body weight reduction and later the discovery and development 
of cannabinoid receptor 1 antagonists.171 
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Glucocorticoids like cortisol or corticosterone that are released into blood stream as 
a result of HPA axis stimulation, mobilize energy resources from adipose and hepatic cells, 
ensuring a supply of energy. Dysregulation of glucocorticoids is related to obesity, for 
example the activity of cortisol on glucocorticoid receptors in both the hypothalamus and 
pituitary which inhibit HPA axis activity seemed to be impaired in visceral obese subjects; 
furthermore, hypercortisolism is correlated with symptoms including weight gain while 
hypocortisolism induce body weight loss. Genetically modified mice that have very low 
levels of glucocorticoids, will not develop obesity even if they maintained on a high-fat 
diet. It has been shown that glucocorticoids promote differentiation of pre-adipocytes into 
mature adipocytes and induce adipose tissue growth.131-134 
Several polymorphisms in the cascade of the HPA axis have been found which 
cause differences in HPA functioning and also involved in obesity development. A 
variation in the exon 2 of POMC gene has been found to cause ACTH insufficiency and 
also associated with early-onset obesity. At the level of glucocorticoid action, a variation in 
intron 1 of the corticosteroid-binding globulin (CBG) has been associated to increased 
proliferation/differentiation of pre-adipocytes, higher salivary cortisol after dexamethasone 
suppression test, higher waist-to-hip ratio and a higher risk of obesity development; 
moreover, variations in the glucocorticoid receptor gene like N363S, NR3C1 and BclI have 
been found associated to obesity;92; 135 moreover, the melanocortin subtype 4 receptor 
(MC4R); a well replicated obesity gene184; 185 which is abundantly expressed in the arcuate 
nucleus and lateral hypothalamic area86 has been implicated in stress-related behaviors as 
well.186 
Connections among HPA axis and other pathway also appear to modulate the food 
intake. It has been shown that unlike glucocorticoids, CRH has anortic effect; for instance, 
obese fa/fa zucker rats are having a reduced level of CRH mRNA expression; moreover, 
intraventricular administration of CRH inhibits food intake in rats. This effect may be 
through pathways involving neuropeptide Y (NPY). Other studies found that while 
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glucocorticoids potentiate the orexigenic actions of NPY, CRH exerts inhibitory control on 
NPY-induced food intake.136; 137 
Additionally, Central dexamethasone (a glucocorticoid receptor agonist) infusion 
stimulate NPY release in the mediobasal hypothalamus of female rats and NPY production 
of cultured hypothalamic neurons, recent studies reported that cortisol up regulates the 
NPY receptors in the abdominal fat by releasing the NPY; in addition, release of NPY and 
activation of the NPY receptors stimulates fat angiogenesis, proliferation and 
differentiation of new adipocytes, thereby linking HPA axis activation, NPY and increased 
abdominal fat storage. NPY appears to decrease anxiety and play an important role in the 
response to stress; therefore, it is also an important mediator of eating in response to 
stress.138-140 
CRH is also suggested to be an important intermediate in the anorectic effects of 
leptin; moreover, rats which bear a mutation in leptin receptor gene have chronic increase 
of HPA axis activity, high levels of corticosterone and prominent visceral obesity. It has 
been shown that glucocorticoids stimulate the release of leptin by adipocytes; moreover, 
glucocorticoids are able to induce leptin resistance and thus attenuate the efficacy of leptin 
to suppress food intake, for instance, it has been shown that anorectic potency of leptin 
enhances in rats undergone adrenalectomy and this enhancement is reversible by 
glucocorticoid replacement. Induction of leptin resistance may also explain why 
glucocorticoid administration in humans results in elevated leptin concentrations and also 
an increased food intake.141-143 
Glucocorticoids also influence release and action of insulin. Glucocorticoids 
interfere with insulin-induced glucose uptake and metabolism in both cultured myocytes 
and adipocytes in vitro. Dexamethasone administration decreases whole body insulin 
sensitivity in vivo. This is associated with a compensatory increase in plasma insulin 
concentration suggesting insulin resistance.92; 93 
Leptin and Insulin are important adiposity and satiety signals that are released into 
the blood stream in proportion to adipose tissue. If obesity happens and adipose tissue 
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grows, increased satiety signals lead to reduced food intake so that excess weight will be 
lost. As mentioned earlier, increased glucocorticoid levels causes insulin resistance and 
leptin resistance; in addition, leptin and insulin are able to influence food intake partly by 
modifying the reward value of food. Insulin and leptin receptors are observed on the ventral 
tegmental area and administration of these hormones seemed to decrease sucrose self-
administration. Therefore, elevated stress induced cortisol for a long period will impair 
sensitization of satiety signals and eventually result in inadequate adjustment for excess 
weight gain.87; 97-99 
The stimulatory effect of glucocorticoids on energy intake appears to be through 
non-homeostatic pathways too. It has been shown that high cortisol levels leads to altered 
food preference and stress is thought to result in food choice for items with a higher content 
of fat and sweet which are perceived as highly rewarding, this suggests that stress 
influences food choice through reward pathway. In fact, several studies found cross links 
among dopamine reward systems and cortisol, or corticotropin releasing factor. Reward 
pathway a common interface between drug abuse and obesity appeared also to mediate the 
stress induced obesity. Cortisol can increase the sensitization of the reward system and 
sensitization of the reward system just like the case of substance abuse can lead to 
excessive intake of highly palatable food; moreover, similar to psychoactive substances, 
palatable food can activate the brain reward system, comprising opioid, dopamine and 
endocannabinoid signaling in the limbic system.47; 92; 93 
Similar to drugs, palatable foods also appear to modify response to stress, for 
instance palatable foods facilitate release of endogenous opioids and dopamine in the 
limbic system. Palatable foods can activate opioid receptors in the ventral tegmental area 
and thereby stimulate cells that release dopamine in the nucleus accumbens and similar to 
psychoactive substances which can create dependency via this system; it has been 
suggested that palatable foods might also create dependency.87; 96 
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1.10  Obesity and hypertension 
Obesity and hypertension are important public health challenges because of their 
high frequency and concomitant risk of cardiovascular, metabolic and kidney diseases. 
Both conditions have reached a pandemic proportion, imposing substantial costs on 
societies. Obesity is an important risk factor for development of hypertension. Findings 
from Framingham Heart Study showed that about 75% and 65% of hypertension cases in 
men and women, respectively, are attributed to obesity. It is also reported that a 5% weight 
gain increases hypertension risk by 20%-30% while weight loss reduces both systolic and 
diastolic blood pressures. Other studies have demonstrated a positive linear correlation 
between blood pressure and BMI in both normotensive and hypertensive subjects and even 
in subjects that were within the normal BMI range. The trial of antihypertensive 
Intervention and Management reported that a 4.5 kg or greater weight loss (about 5% of the 
baseline weight) reduce diastolic blood pressure to the same extent as a single-dose 
antihypertensive treatment. It is documented that not only the degree but also the 
distribution of accumulated body fat is an important risk factor for the development of 
hypertension; for instance, the prevalence of hypertension appears to be higher in 
individuals with upper-body obesity compared to those with lower-body obesity.116; 144-147 
Previous findings from our group also found that hypertensive and normotensive siblings 
drawn from the same families differ significantly by both degree and distribution of body 
fat accumulation and that genetic factors that co-segregate with hypertension appear to play 
a significant role in this difference;148 moreover, the degree of genetic homogeneity 
increases in hypertensive-obese families compared to set of families selected at random or 
selected for hypertension and this improves the power to identify genetic causes of 
hypertension.144; 149 In another study, following genomic analysis in two independent 
samples, Pausova et al187 found that FTO gene, a well-replicated obesity locus, not only is 
related to obesity and insulin resistance, but also associated to hypertension which further 
emphasizes genetic relatedness of obesity and hypertension. 
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Both clinical and experimental data suggest that expansion of blood volume and 
increasing of renal sodium reabsorption are the central features in the development of 
obesity-induced-hypertension. The mechanisms by which obesity contributes to increased 
sodium reabsorption and blood volume expansion are not fully understood; however, 
increased sympathetic nervous system activity and activation of the renin–angiotensin 
system appear to play important roles. In fact, Pharmacological blockage of sympathetic 
activity through the adrenergic receptors attenuates hypertension more in obese subjects 
compared to lean hypertensive subjects; besides, other studies demonstrated that blocking 
of the renin–angiotensin system and of the aldosterone receptors also effectively attenuate 
blood pressure levels.116; 145; 150 
Overweight is associated with increased sympathetic activity. Several observations 
suggest that over activity of the sympathetic nervous system is a major feature in causing 
obesity–hypertension in humans and animal models. For example, peripheral 
vasoconstriction and increased renal tubular sodium reabsorption that raise blood pressure 
are suggested to be the consequences of long-term sympathoactivation. Obese individuals 
are having higher muscle sympathetic neural activity compared to lean individuals; in 
addition, it has been shown that in obese individuals, the activity of sympathic nervous 
system is elevated in kidney which is a central organ in modulating the homeostasis of 
cardiovascular system. The effect of sympathic nervous system on obesity induced 
hypertension is also mediated through the cross links between the sympathic nervous 
system and other factors for example SNS stimulation can result in to renin–angiotensin–
aldosterone system activation.151; 152 
There are numerous evidences that point to the importance of the renin–
angiotensin–aldosterone system in obesity-associated-hypertension. In obese subjects, 
increased circulating angiotensinogen, renin and angiotensin-converting enzyme activity 
have been reported; moreover, plasma renin activity declines with weight loss and this is 
also correlated with reduction in BP; besides, angiotensin converting enzyme inhibition is 
considered as an effective pharmacological means of lowering BP in obese hypertensive 
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humans. Adipose tissue expresses many components of renin–angiotensin–aldosterone 
system this suggests that high circulating angiotensinogen levels may be partially attributed 
to increased fat mass. A significant role of angiotensin II in stimulating renal sodium 
reabsorption and in contributing to obesity–hypertension is supported by the findings that 
treatment of obese dogs and obese hypertensive subjects with an angiotensin-converting 
enzyme inhibitor attenuates sodium retention and decreases blood pressure. The increased 
activation of the renin–angiotensin system appear to enhances the  sympathetic activity, for 
instance, pharmalogical findings showed that blockage of angiotensin II receptor and  
angiotensin converting enzyme inhibition reduce muscle sympathetic neural activity; 
moreover, infusion of angiotensin II increases muscle sympathetic neural activity.116; 145; 150 
Leptin is another mediator of obesity-induced-hypertension. Leptin is a 167 amino 
acid hormone which is expressed and secreted by adipocytes in proportion to fat mass. The 
effects of this peptide are mediated by receptors (Ob-R) which most of them located in the 
hypothalamus. Leptin decreases appetite and increases energy spending mainly by 
increasing the activity of sympathic nervous system. It appears that most obese persons are 
insensitive to endogenous leptin production; moreover, in obese people an interaction 
between high leptin levels and increased renal sympathetic tone has been observed. In fact 
the effect of leptin on blood pressure elevation can be prevented by blockage of 
sympathetic activity through the adrenergic receptors; in addition, it has been shown that 
infusion of leptin increases the sympathetic outflow to adipose tissue, kidneys, skeletal 
muscle vasculature and the neural traffic to the adrenal.116; 153-155 
On the other hand, hormones like glucocorticoids or insulin can influence the level 
of serum leptin concentration. In fact, cortisol along with insulin and leptin creating a finely 
balanced system in order to provide sufficient fuel for the organism proportionate to 
needs.92; 156 
 In rats, marked leptin sensitivity was gradually diminished with glucocorticoid 
replacement and larger doses of glucocorticoids leads to overeating and consequently to 
obesity. Glucocorticoids stimulate secretion of leptin by adiposities; however, 
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glucocorticoids also reduce the efficacy of leptin to suppress food intake and therefore 
induce leptin resistance. The elevated level of insulin can affect leptin levels and increase 
the leptin concentration after meal.92; 93; 131 
A growing number of studies suggest chronic stimulation of HPA axis and resulting 
excess glucocorticoid exposure may play a potential role in the development of obesity. 
Several DNA polymorphisms related to HPA axis functioning are also associated to the 
development of obesity and hypertension for instance hypercortisolism as it is observed in 
Cushing's syndrome causes symptoms like hypertension, insulin resistance, leptin 
resistance (as mentioned above) hyperglycemia and rapid weight gain. The increased 
cortisol secretion in primary obesity has been reported; besides, fatty tissue expresses 
enzyme, 11 Beta-hydroxysteroid dehydrogenase type 1 that convert cortisone to cortisol 
which result in higher cortisol availability and therefore glucocorticoid receptor activation. 
It is also reported that the activity of this enzyme is significantly elevated in the fatty tissue 
from obese humans and rodents.131; 132; 145; 157 
Glucocorticoids also are able to influence the action and release of insulin, another 
endocrine adiposity signal and produce diabetogenic effects. Cortisol has been shown to 
directly inhibit insulin secretion from pancreatic beta cells and impair insulin initiated 
translocation of the intracellular glucose transporter (GLUT4) eventually leading to insulin 
resistance. Insulin resistance appears to contribute to hypertension through different 
mechanisms, such as vascular damage caused by chronic abnormalities in lipid and glucose 
metabolism; moreover, insulin resistance results in excess levels of circulating insulin in 
the body and a greater insulin response to glucose overload, observed in obese subjects. 
Insulin can cause sympathoactivation of different tissues, including the kidney, and may 
result in a modest increase in renal tubular sodium reabsorption and tissue renin–
angiotensin–aldosterone system activation. However it appears this increased of activation 
of symphatic nervous system is not related to a corresponding rise in blood pressure and it 
has been suggested that insulin resistance may contribute to hypertension through other 
mechanisms such as abnormalities in lipid and glucose metabolism.92; 145; 150 
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1.11  Current project 
Previous findings from our group provided evidences of the presence of common 
genomic determinants among group of related traits. For instance, following systematic 
genome wide linkage analysis of 213 blood pressure, anthropometric, and metabolic traits 
in a cohort of 120 French Canadian families from Saguenay–Lac St-Jean region of Quebec, 
clusters of overlapping quantitative-trait loci were found on several chromosomes including 
blood pressure QTLs co localized with renin and sodium QTLs on chromosome 3 and 
anthropometric trait QTLs on chromosome 1 that co localized with insulin levels QTLs; 27 
moreover, the identified cluster on chromosome 1 overlapped with a cluster of 
triacylglycerol and blood pressure QTLs in rats158 and open-field emotional reactivity in 
mice.113 In another study, FTO gene, a well-replicated obesity locus, was found in two 
independent samples, not only related to obesity and insulin resistance, but also associated 
to hypertension.187 
Current genome-wide scans are normally analyzing different phenotypes in isolation 
and ignore genes that are showing pleiotropic effect and important to the pathogenesis of 
correlated human traits. Identification of such pleiotropic genes can provide several benefits 
including identification of mechanistic links among related disorders, influencing the way 
disorders are grouped and classified; moreover, detection of such genes can expand the 
application of drugs for; example, if two disorders are as a result of abnormalities in the 
same biological process then the medication that is used for one can be examined for the 
other.11; 159-161 
Motivated by above reasons, we aimed to investigate for shared genomic factors of 
habitual alcohol, tobacco and coffee use, response to mental and physical stress, obesity-
related anthropometric traits and heart rate and blood pressure measurements. Alcohol, 
tobacco and coffee are the most commonly consumed psychoactive substances in the 
world; their concurrent use has been consistently shown across a wide variety of 
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populations.41 Stress has been found both in experimental and clinical research to relate to 
initiation, intensification and relapse to substance use;47; 53 besides, both stress and 
substance use are considered as contributing factors to the development of cardiovascular 
disease and cardiovascular risk factors including obesity.52; 87; 93; 162; 167 
HPA axis, the main component of body’s response to stressors has been implicated 
in substance use,  obesity and regulation of cardiovascular system;44; 46; 62; 92; 109 moreover, 
number of genes having function in HPA axis have been found to connect these traits, for 
instance, the mu opioid receptor (OPRM1) has been found to influence response to 
stressors, food intake and substance use;46; 62; 87 however, like other polygenic traits, 
substance use, obesity, stress and cardiovascular traits have multifactorial etiology with a 
substantial complex genetic component and further studies are required to uncover the 
genetic nature and relations among these traits; therefore, we hypothesized that the links 
among substance use habits, obesity, stress and related cardiovascular outcomes may be in 
part due to shared genetic factors.  
To investigate this hypothesis, we performed genome-wide linkage and association 
for genomic determinants of habitual alcohol, coffee and tobacco use, obesity-related 
anthropometric data, cardiovascular components of the behavioral response to mental stress 
of mathematical tests, changes in plasma cathecolamines after orthostatic test as the 
biomarkers of responses to mental and physical stress as well as 24-hour heart rate and 
blood pressure data in a cohort of 119 families from founder population of SLSJ who have 
been previously recruited to identify the genetic factors of hypertension;27  furthermore, 
because sex and hypertension were found to explain significant portions of variations of 
these traits, the analyses were followed by sex and hypertension specific linkage and 
association analysis, we also subjected the candidate gene list driven from genetic analysis 
to functional annotation using the growing knowledge of gene information to explore the 
underlying biological meanings. 
In addition, inclusion of former smokers in this study prompted us to investigate 
whether the observed correlation between tobacco use and obesity, hemodynamic and stress 
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related traits roots in environmental effect (smoking itself) and/or the influence of 
underlying genetic factors; therefore, to investigate this hypothesis, we probed the 
phenotypic and genotypic relatedness of tobacco use with hemodynamic, obesity and stress 
related traits by picking the smoking initiation and persistence phenotypes as well as 
significantly correlated traits with them and subjecting these phenotypes to univariate and 
bivariate family-based genome wide scans. 
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2.1 Abstract 
Links among substance use habits, obesity, stress and related cardiovascular 
outcomes may be in part due to shared genetic factors. To investigate this assumption, we 
performed genome-wide linkage and association tests for genetic components of habitual 
alcohol, tobacco and coffee use, response to mental and physical stress, obesity-related 
anthropometric traits and heart rate (HR) and blood pressure (BP) measurements in 119 
multigenerational French Canadian families from Saguenay–Lac St-Jean population using 
58000 SNPs and 437 microsatellite markers and followed with functional annotation on 
resulted genes. Current tobacco users were slender compared to former and never smokers. 
Habitual alcohol and/or tobacco users showed significantly attenuated HR response to 
mental stress as compared to non users; besides, hypertensives had stronger HR and SBP 
response to mental stress. We found shared genes associated / linked to substance use, 
obesity-related traits, response to mental and physical stress and HR and BP data including 
CAMK4, CNTN4, DLG2, DAG1, FHIT, GRID2, ITPR2, NOVA1, NRG3 and PRKCE 
forming protein interaction network, involved in synaptic plasticity and highly expressed in 
brain related tissues. Pathway analysis on identified genes pointed (P = 0.03) to Long-term 
potentiation pathway. Specific subgroup analyses uncovered additional shared synaptic 
genes including CAMK4, CNTN5, DNM3, KCNAB1 (Hypertension-specific), CNTN4, 
DNM3, FHIT, ITPR1 and NRXN3 (Sex-specific) having protein interactions with genes 
driven from general analysis; moreover, the results of pathway analysis and reported gene 
expression profiles of resulted genes from specific analyses revealed similar characteristics 
to those from general analysis. The substantial overlap among genomic factors of these 
traits supports the notion that the genetic variations in pathways of synaptic plasticity may 
be a common interface behind substance use, stress, obesity, HR, BP and the observed sex- 
and hypertension-specific genetic differences. 
Keywords: genetic mapping, substance use, obesity-related traits, mental stress, 
physical stress, heart rate, blood pressure, synapse 
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2.2 Introduction 
Alcohol, tobacco and coffee are among the most commonly consumed psychoactive 
substances in the world; their concurrent use has been consistently shown across a wide 
variety of populations.1 Stress has been found both in experimental and clinical research to 
relate to initiation, intensification and relapse to substance use;2 besides, both stress and 
substance use are considered as contributing factors to development of cardiovascular 
disease and cardiovascular risk factors including obesity.3-5; 7 
Substance use, obesity, stress and cardiovascular disorder are complex traits having 
multifactorial etiology with a substantial genetic component.4; 6; 7 HPA axis, the main 
component of body’s response to stressors is also implicated in substance use,  obesity and 
cardiovascular disorder; 8-12 for instance, the mu opioid receptor (OPRM1), a regulator of 
HPA axis,  has been found to influence response to stressors, food intake and substance 
use;3; 8; 12 however, the genetic nature and relations among these entities are still largely 
elusive and further studies are required.  
We hypothesized that the connections among substance use habits, obesity, stress 
and related cardiovascular outcomes may be in part due to shared genetic factors. To 
investigate this hypothesis, we performed genome-wide linkage and association analysis for 
genomic determinants of habitual alcohol, coffee and tobacco use, obesity-related 
anthropometric data, cardiovascular components of the behavioral response to mental stress 
of mathematical tests and changes in plasma catecholamines after orthostatic test as the 
biomarkers of responses to mental and physical stress as well as 24-hour heart rate (HR) 
and blood pressure (BP) data in a cohort of 119 families from founder population of SLSJ 
that have been previously recruited to identify the genetic factors of hypertension;13 
furthermore, because sex and hypertension appeared to explain significant portions of 
variations of these traits,19 the analysis were followed by sex and hypertension specific 
linkage and association analysis, we also subjected the identified candidate genes to 
functional annotation using the growing knowledge of gene information to explore the 
underlying biological meanings. 
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2.3 Methods and Procedures 
2.3.1 Family cohort 
Families were selected from the population of SLSJ region located in northeastern 
Quebec which is representing one of the largest founder populations in North America.13; 14 
Founder effect provides several benefits for mapping the genomic determinants of 
polygenic disorders; for instance, allelic and locus heterogeneity, key features of common 
complex diseases that can obscure the association signals within disease-associated 
genomic regions are lower in founder population compared to general populations, the 
likelihood of population stratification that introduces errors and bias the results is also low 
in a founder population and the large size of LD blocks in a founder population reduces the 
number of markers for whole genome scan studies;13; 15 moreover, the availability of 
extensive genealogical records of this population which is dating back to the original 17th-
century settlers provides additional benefits for genetic studies.13 
Details about families and extensive phenotyping have been described previously.13; 
16-19 In summary, families with catholic French Canadian origin were ascertained by the 
presence of at least one sib pair between the ages 18 to 55 years with hypertension and 
dyslipidemia. Additional selection criteria were the absence of (1) secondary hypertension, 
(2) diastolic blood pressure (DBP) >110 mmHg and the use of BP-lowering medications (3) 
body mass index (BMI) ≥ 35 kg/m2 (4) diabetes mellitus (5) renal dysfunction (6) liver 
disease, (7) malignancy, (8) pregnancy, and (9) substance abuse, including alcohol. Once 
affected sib pairs were selected, all first- and second-degree relatives aged >18 years were 
invited to participate in the study, independent of health status. The recruited population 
included 119 families (average generations of 2.58) comprising 897 subjects and 1617 sib 
pairs. 
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The Research Ethics Committee of Complexe Hospitalier de la Sagamie 
(Chicoutimi, Quebec), Université du Québec à Chicoutimi, and the Centre hospitalier de 
l’Université de Montréal reviewed and approved the study. Written consents of all subjects 
were obtained prior to the commencement of data collection. 
 
2.3.2 Phenotyping 
Phenotyping for habitual substance use was carried out using questionnaires; 
individuals were asked about alcohol, coffee or tobacco use during clinical interviews. 
Those using a substance on regular basis were grouped as affected and those who never or 
occasionally use a substance were considered as unaffected; moreover, for non tobacco 
users, the information about their former status of tobacco use was also collected. 
HR and BP changes to the mental stress of mathematical tests were used as markers 
of response to mental stress.  The subjects were asked to sit for 10 minutes before the test; 
next, they passed 2 minutes arithmetic test. In parallel, HR, diastolic blood pressure (DBP) 
and systolic blood pressure (SBP) were measured every 5 minutes before the test (3 times), 
for every 2 minutes during the test (2 times) and every 2 minutes after the test (6 times). 
Stress response was defined as the differences in the first HR and BP values of math test 
and the average values of resting position before the test. The difficulty of test was 
increased at each level and the test was adjusted to assure some failure for all subjects. 
During an orthostatic stress test, the plasma epinephrine (EP) and norepinephrine 
(NE) levels were monitored in blood samples taken from subjects once during 60 minutes 
supine and 10 minutes standing position; these data were used as biomarkers of response to 
physical stress. 
Phenotyping for obesity consisted of 3 global and 11 regional measurements.53 The 
global measures included BMI as well as total body fat derived from skinfold 
measurements and determined by bioimpedance (RJL Systems Inc). The regional measures 
included 5 skinfolds (biceps, triceps, subscapular, suprailiac, and thigh) as well as 6 
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extremity circumferences (upper arm, waist, hip, proximal thigh, middle thigh, and distal 
thigh). 
BP and HR were measured every 20 minutes during the day and every 45 minutes 
during the night with an Accutracker II monitor (Sun Tech Medical Instruments, Inc.) for 
24 hours.13 Using these data, the pulse pressure (PP) was defined as the difference between 
SBP and DBP and mean arterial pressure (MAP) was defined as one third SBP plus two 
third DBP.  
The inverse normal transformation was subsequently done on quantitative 
phenotype data to ensure a normal distribution prior to the analysis.  
In addition, since significant portions of variation of studied traits were attributed to 
sex and hypertension status therefore general analysis was followed by sex- and 
hypertension-specific analysis to identify the candidate genes. We assumed specific 
subgroup analysis can minimize heterogeneity and helps to identify the specific genomic 
factors that would remain obscured following statistical adjustment. In general and 
hypertension specific groups, age and sex were included as covariates and in sex specific 
analysis, only age was set as covariate. 
 
2.3.3 Phenotypic correlation tests 
The generalized estimating equation (GEE) approach implemented in the GNU R 
statistical package version 2.6.1 was used to perform correlation tests which accounts for 
familial correlation via a sandwich estimator of the variance under exchangeable 
correlation. 20   
Unlike most standard statistical tests for correlation such as unpaired t-test, simple 
linear regression or the chi-square test that assume each of the subjects in a data set is 
independent of the others; GEEs use the generalized linear model to estimate more efficient 
and unbiased regression parameters relative to ordinary least squares regression in part 
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because they allow specification of a working correlation matrix that accounts for the form 
of within-subject correlation of responses on dependent variables of many different 
distributions.21 
 
2.3.4 Estimation of heritability 
Heritability estimates were done in whole cohort and next separately in males and 
females as well as hypertensives and normotensives using Sequential Oligogenic Linkage 
Analysis Routines (SOLAR) software, version 4.2.0.22 SOLAR uses likelihood ratio tests to 
evaluate heritability by comparing a purely polygenic model with a sporadic model and 
also allows for covariate adjustments. 
  
2.3.5 Genotyping 
Genotype information has been previously described.13; 18; 19 In summary, 469 
subjects genotyped with GeneChip® Human Mapping 50K Array Xba240 (Affymetrix) and 
537 subjects genotyped with 437 microsatellite markers. Altogether, 719 subjects 
genotyped using microsatellites and or GeneChip® Human Mapping 50K Array Xba240 
(Affymetrix) were analyzed in present study.  
Possible genotyping errors were detected and filtered (~ 0.2 %) using MERLIN 
package version 1.1.0.23 An exact test of Hardy-Weinberg equilibrium (HWE)24 on a 
subsample of unrelated individuals was performed using PEDSTATS program 
implemented in MERLIN package to remove genotypes that deviate from Hardy-Weinberg 
equilibrium (HWE).  Minor allele frequencies (MAF) and linkage disequilibrium (LD) 
among SNPs were calculated using PLINK software version 1.06.25 SNPs with r2 ≤ 0.8, 
HWE > 0.001 and MAF > 0.05 were included in analysis. The WGAviewr software version 
1.52Z was used to determine the nearby genes around each SNP by specifying up- and 
down-stream span of 500 kbp.26 
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2.3.6 Genetic analysis  
2.3.6.1 Linkage analysis 
Because the haplotypic relationship between stable markers (e.g. SNPs) and 
potentially unstable but highly informative markers (e.g. microsatellites) indicates that LD 
might be maintained over considerable genetic distance in non-African populations;27 
hence, to increase the power of analysis microsatellites and SNPs genotype information 
were merged within a single database and haplotype map was created by specifying r2 > 
0.4.28  
Multipoint linkage analysis was carried out on the haplotype map using MERLIN 
software package, version 0.10.2. MERLIN is based on the Lander-Green algorithm in 
which each alternative gene flow pattern in a pedigree is considered separately.23 
For the qualitative phenotypes, multipoint linkage analysis was carried out using the 
non-parametric linkage (NPL) approach implemented in MERLIN.23 which uses the 
Whittemore and Halpern NPL statistics to test for allele sharing among affected individuals 
and calculates the LOD score using the Kong and Cox linear model. 
For quantitative phenotypes, after adjustment for covariates multipoint linkage 
analysis was performed on the haplotype map using the pedigree-wide regression analysis 
approach implemented in MERLIN,29 this approach combines the simplicity and robustness 
of regression-based methods and the generality and greater power of variance-components 
models. It is based on a regression of estimated identity-by-descent (IBD) sharing between 
relative pairs on the squared sums and squared differences of trait values of the relative 
pairs 
2.3.6.2 Association tests 
The multipoint linkage analysis was followed by Family-Based Association Test 
(FBAT) implemented in the FBAT software version v2.0.2c that tests for association in the 
presence of linkage and reduces false positive associations consequently.30  
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SNPs with association P < 10 -3 were preselected for next steps. To identify specific 
genes for each trait, we selected loci that were within 1 LOD-drop interval around the 
linkage peak and had at least two identically annotated SNPs; furthermore, we corrected the 
P-values of SNPs by the number of SNPs within the area (Bonferroni correction) and 
excluded the non significant ones (P < 0.05). For commonly associated SNPs to more than 
one trait, combined P-values were calculated using Fisher's combined probability test31 and 
P-value less than 1.4×10-6 was considered significant after Bonferroni correction by the 
number of SNPs analyzed (34741). 
 
2.3.7 Functional annotations 
Molecular interaction data were extracted from Ingenuity Pathway Analysis 
database (Ingenuity® Systems, www.ingenuity.com version 8.0) in which each gene 
interaction is supported by at least one reference from the literature, textbook, or canonical 
information stored in the Ingenuity Pathways Knowledge Base.  
DAVID Functional Annotation Tool (http://david.abcc.ncifcrf.gov version 6)32; 33 
was used to identify significantly enriched KEGG pathways in the list of queried genes 
driven from genetic analysis.  
Since genes that are having function in a biological process are expected to display 
higher expression and similar expression profiles in tissues that the biological process takes 
place. We analyzed the gene expression profiles of the shared genes across 65 normal 
human tissues using data from COXPRESdb database (http://coxpresdb.hgc.jp version 
c3.1)34. Hierarchical clustering of gene expression data was done using GenePattern 
software version 3.1.135 based on the complete Linkage method and Pearson correlation 
coefficient as the measure of distances.  
The synapse databases, SynDB (http://syndb.cbi.pku.edu.cn release 2006) and 
G2Cdb (http://www.genes2cognition.org version 07) were used to query whether a gene 
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has synaptic function.36; 37 Cytoscape software version 2.6.3 was used to build and visualize 
the networks.38 
 
2.4 Results 
2.4.1 General characteristics of phenotypes 
Coffee use (79.2%) was more frequent compared to alcohol (26.5%) and tobacco 
use (26.1%); besides, while the between-sex difference was not significant in coffee use (P 
= 0.3) and smoking persistence (P = 0.4), the prevalence of habitual alcohol use, former 
smoking and current smoking were significantly higher in males compared to females (all P 
< 0.04); in addition, the prevalence of hypertension was significantly higher (P = 0.02) in 
never tobacco users as compared to former and current tobacco users (Table 1). Although 
alcohol and tobacco use decreased with aging, prevalence of habitual coffee use increased 
(all P < 0.01; Table 1).  
Analysis of both global and regional obesity-related phenotypes indicated that 
hypertensive subjects are more obese than normotensives (Table 2). The catecholamine 
levels including epinephrine and norepinephrine were not significantly different between 
hypertensives and normotensives; however, hypertensives had stronger HR (P = 0.03) and 
SBP (P = 0.02) response to mental stress than normotensives; meanwhile, hemodynamic 
traits were significantly higher in hypertensive subjects compared to normotensives (Table 
2). 
Most of the studied traits display sexual dimorphism and were significantly different 
between females and males. Females had lower BMI (kg/m2) compared to males 
(Mean±SE; 26.4±0.3 vs. 27.3±0.2, P < 0.001) and higher body fat (%) as determined by 
skinfold (Mean±SE; 37.9±0.4 vs. 25.5±0.3, P < 0.001) and bioimpedance (Mean±SE; 
34.3±0.6 vs. 23.1±0.4, P < 0.001) as well as higher skinfold in biceps, triceps, subscapular, 
suprailiac, and thigh (Table 2). While BP values were significantly higher in males, females 
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had higher HR values compared to males. Males had higher epinephrine level; however, 
norepinephrines as well as cardiovascular responses to mental stress were not significantly 
different between males and females (Table 2). 
BMI, body fat percentage determined by bioimpedance, waist circumference, waist-
hip ratio and hip-thigh proximal ratio increased with aging while thigh circumferences 
decreased, EP levels also decreased with aging; in addition, while BP related traits 
increased with aging HR changes were insignificant (Table 2).  
 
2.4.2 Phenotypic correlation results 
Alcohol and tobacco users had attenuated HR response to mental stress compared to 
non users (both P = 0.04; Table 3). Most of the global and regional measurements of 
obesity were significantly lower in current tobacco users compared to former and never 
tobacco users suggesting an invert relation between obesity and tobacco use (Table 3); 
however, the Hip to Thigh Proximal ratio was higher in tobacco users compared to non 
users (P = 0.001). This appears to be in part due to significantly reduced thigh 
circumferences in tobacco users. In fact, the most significantly correlated trait to tobacco 
use in this study was thigh circumference. All three measures of thigh circumferences were 
prominently lower in tobacco users compared to never tobacco users with P-values ranging 
from 10-4 to 5×10-7 (Table 3). Former tobacco users also had significantly reduced thigh 
circumferences than never tobacco users; however, compared to current tobacco users they 
had higher (10-2 ≤ P ≤ 10-4) thigh circumferences (Table 3). 
While the NE levels were not significantly different among tobacco use statuses,  
tobacco users had higher EP compared to former and never tobacco users; meanwhile, EP 
levels were not significantly different between former and never tobacco users suggesting 
use of tobacco increases the level of EP in the body (Table 3).  
Coffee use appears to increase mean ambulatory HR (P = 0.01). Tobacco users had 
lower mean ambulatory DBP compared to never (P = 0.02) and former tobacco users (P = 
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0.02) while the differences in mean ambulatory SBP and HR among tobacco use statuses 
were insignificant (Table 3). 
 
2.4.3 Heritability estimates 
The most heritable trait in our study was mean ambulatory HR (H2r = 64%); 
although, the between sex differences was small we found this trait to be almost completely 
attributed to genetic factors in normotensives (H2r = 99%) but not in hypertensives (H2r = 
0.0%), the heritability of average sitting HR and sleep HR also displayed similar patterns 
(Table 4).  
The heritability data indicated that both initiation (61% in former vs. never tobacco 
users)  and persistence of tobacco use (46% in current vs. former tobacco users) are highly 
attributed to genetic factors; sex-specific heritability estimates for tobacco use showed that 
genetic factors are more important in initiation (males = 81%, females = 56%) and 
persistence of tobacco use (males = 97%, females = 23%) in males compared to females; 
however, the  heritability of alcohol use in males was lower compared to females (Table 4), 
we also observed a maternal effect on alcohol use behavior that in case parents are non 
habitual alcohol users, 27% of sibs (16 users vs. 43 non users) acquire alcohol use habit and 
if father is alcohol user, 44% of sibs (20 users vs. 14 non users); however, in case mother is 
alcohol users, 75% of sibs (3 users vs. 9 non users) gain the habit. 
 
2.4.4 Genetic findings and functional annotation 
2.4.4.1 General analysis 
Table 5 lists candidate loci within 1 LOD-drop interval around the linkage peaks. In 
a common area of linkage for HR response (LOD = 2.8) and tobacco use (LOD = 2.6) on 
chromosome 12, we found SNPs inside ITPR2 gene associated to these traits as well as 
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supine NE (Figure 1 and Table 6); moreover, multivariate association analysis showed that 
these SNPs are significantly associated to all these traits (P ≤ 0.003). 
Joint linkage and association analysis also uncovered SNPs inside genes; LRP1B, 
GRID2, TLL1, PCM1, HTR2A, NETO1 and nearby AGTR1 and within intergenic regions 
between LPHN2 and TTLL7, COL24A1 and ODF2L, DAB2 and PTGER4, CHRM2 and 
MTPN, and NETO1 and CBLN2 (Table 5). Probing the protein interactions revealed that 
GRID2, HTR2A, LPHN2, LRP1B, MTPN and NETO1 are sharing interactions with 
synaptic protein, DLG4  (Figure 3) and searching the synapse databases indicated CHRM2, 
DAB2, GRID2, HTR2A, ITPR2, LPHN2, NETO1 genes have synaptic function (Table S1).  
Family based association tests identified genes commonly associated at the level of 
P < 0.05 after correction for multiple testing among substance use, obesity, stress responses 
and hemodynamic traits (Table 6). GRID2, ITPR2, LRP1B and PCM1 genes found under 
the linkage peaks were associated to other traits as well (Table 5 and 6). Functional 
annotation information showed that 44% of the shared genes are having synaptic function 
(Table S1) and the results of KEGG pathway analysis on the shared genes using David 
functional annotation tool significantly pointed to Long-Term Potentiation pathway (P = 
0.03). 
Next we checked the expression of these commonly associated genes across 65 
human tissues using data from COXPRESdb database. The gene expression results were in 
agreement with other functional annotation information. We found, identified genes are 
having higher expression in a cluster of brain-related tissues including Brain lobes, 
Cerebral cortex, Amygdala, Hippocampus and Putamen; besides, unlike other tissues, genes 
in each group tend to display similar expression profiles in these tissues (Figure 2 and 
Table 9).  
2.4.4.2 Sex-specific and hypertension-specific analysis 
Hypertension-specific genetic analysis uncovered SNP, rs4687150 (HWE P = 0.3, 
MAF = 0.3) inside IL1RAP gene associated to coffee use with negative association signal 
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(Z = -3.5, P = 0.0004) in hypertensives and positive association signal (Z = +3.8 P = 
0.0002) in normotensives. Sex-specific genetic analysis revealed SNPs, rs4888197 (HWE P 
= 1, MAF = 0.2) inside PLCG2 gene associated to thigh skinfold and rs847936 (HWE P = 
0.7, MAF = 0.8) near SCIN gene associated to tobacco use with negative association 
signals (both P ≤ 0.0009) in females and positive association signals (both P ≤ 0.0009) in 
males. Interestingly, we found, all three genes; IL1RAP, PLCG2 and SCIN share synaptic 
function (Table S1); meanwhile, SNP, rs847936 was not only positively associated to never 
smokers in males but also was positively associated to both wake HR (P = 0.00095) and 
sleep HR (P = 0.000055) in males (Table 8).  
Under a common area of linkage for body fat percentage by impedance in both 
male-specific (LOD = 2.0) and hypertension-specific analysis (LOD = 2.8), we found SNPs 
inside DNM3 gene associated to these traits (Table 7); moreover, DNM3 along 
ADAMTS3, CDH12, DTNBP1, KCNAB1, KIF5B, RGS4 and SEMA6A genes driven from 
joint linkage and association shared synaptic function (Table S1). CAMK4, CNTN4, 
CSMD1, FHIT, OLFM4, PTPRD and RORA genes driven from general analysis were also 
appeared in specific results; besides, RORA gene that was identified under the linkage peak 
associated to waist-hip ratio in normotensives was associated to standing EP in this group 
as well. Shared genes, BAI3, CNTN4, DCLK1, FHIT, INHBA, ITPR1, NLGN1, NRXN3, 
PTPRR and SCIN driven from sex-specific analysis and CAMK4, CNTN5, GLRA3, 
PTPRD, SPINK5 driven from hypertension specific analysis had synaptic function (Table 8 
and S1). 
Pathway analysis using commonly associated genes driven from sex-specific and 
hypertension-specific analysis once more significantly pointed to Long-Term Potentiation 
(P = 0.02) and GnRH signaling pathways which are interconnected pathways (P = 0.04). 
2.4.4.3 Gene expression profiles 
The gene expression data of shared genes driven from general and specific analysis 
are presented in Table 9. We found that similar to shared genes driven from general 
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analysis commonly associated genes identified through either sex-specific or hypertension-
specific analysis also have higher expression in a cluster of brain tissues including Brain 
lobes, Cerebral cortex, Amygdala, Hippocampus and Putamen (Table 9).  
2.4.4.4 Protein interactions 
Candidate genes driven from general (n = 76), sex-specific (n = 31) and 
hypertension-specific analysis (n = 38) were searched in the Ingenuity database and a 
connectivity diagram was built on the basis of interactions. Figure 3 shows an overview of 
these interactions. Although these genes were driven from different sets of analysis, we 
found numerous interactions among these genes. In the constructed network, there were 45 
(59%) genes identified through general analysis, 18 (47%) genes identified through 
hypertension specific and 20 (65%) genes identified through sex-specific analysis. 
We also checked for associations of SNPs encompassed in the missing genes of 
network (Figure 3). In this manner, we retrieved SNPs; rs6938572 (P = 0.0006) and 
rs2327017 (P = 0.0003) upstream BMP6 gene associated to average sitting DBP; 
rs2370413 (P = 0.0003) and rs2887780 (P = 0.0004) inside CACNA1C gene associated to 
skinfold subscapular in males and SBP response to mental stress respectively; rs10492133 
(P = 0.0009) inside GRIN2B associated to tobacco use; rs10491321 (P = 0.00035) upstream 
and rs7705319 (P = 0.0006) inside PPP2CA gene associated to tobacco; SNPs, rs953944 (P 
= 0.0007) rs1029819 (P = 0.0008) associated to tobacco use and rs10485912 (P = 0.00075) 
associated to overall SBP inside MAGI2 gene; SNP, rs93059 inside NFKB1 gene 
associated to average sitting HR (P = 0.00098) and DBP response to mental stress (P = 
0.0006); and SNPs inside ITPR1 gene associated to (0.0004 ≤ P ≤ 0.0007); SBP, DBP and 
SBP response to mental stress. 
 
2.5 Discussion 
In this study, we have investigated the connections among substance use, obesity, response 
to mental and physical stress and hemodynamic traits. The current research project is based 
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on French population of Saguenay-Lac-St-Jean region located in northeastern Quebec13 
which is representing one of the largest founder populations in North America with about 
300,000 inhabitants.39 14 Founder effect provides several benefits for mapping the genomic 
determinants of polygenic disorders including limited allelic and locus heterogeneity, low 
likelihood of population admixture and stratification, large size of LD blocks as well as 
good genealogical records.13; 15; 16 
Tobacco users had lower BP and obesity as well as reduced response to mental 
stress; while, hypertensive subjects were more obese and had stronger HR and SBP 
response to mental stress. These findings suggest tobacco use may decrease the BP in 
several ways. 
Since, obesity increases the risk of hypertension;7 therefore, the observed inverse 
correlation between obesity and tobacco use in our study partly explain the lower BP 
among tobacco users. In addition, stress is related to hypertension; for instance, It has been 
reported that high cardiovascular response to environmental stressors which also observed 
in this study, is a predictor of hypertension;2; 3  thus, the finding that habitual tobacco users 
showed significantly attenuated HR response to the mental stress as compared with non 
users suggest the damping effect of tobacco use on response to environmental stress may 
also account for the lowering effect of tobacco use on BP. 
In fact, the relief from stress and negative affections and enhancing the positive 
moods are among the main reasons for substance use.40; 41 Physiological studies have also 
shown that both substance use and stress influence the synaptic plasticity and substance use 
can change the sensitivity of synaptic plasticity to stressors,42; 43 for instance it has been 
reported that concurrent chronic nicotine treatment and stress prevents stress-induced 
impairment of  Long-Term Potentiation pathway. 44; 45 
Obesity and addiction also appear to share common neurological underpinnings; 
earlier studies reported that obesity and drug addiction may in part mediated by persistent 
changes in neural circuits.46; 47 In fact, similar to psychoactive drugs, palatable food can 
activate the brain reward system and pharmacological blockade of, or experimental damage 
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to forebrain dopamine systems attenuates free feeding and lever-pressing for food reward, 
as well as the rewarding effects of psychoactive substances. Synaptic plasticity also appears 
to be involved in the regulation of energy homeostasis and is acting as an important path 
through which peripheral metabolic hormones influence brain functions.48 
Hypertension is in part a centrally mediate trait, in fact central nervous system 
(CNS) is considered as initial source of blood pressure elevation (BP). For instance, once 
brain recognized a stressful stumuli, information about stress from the prefrontal cortex is 
transmitted to the hypothalamic defense area through dopaminergic neurons. An increase in 
dopaminergic neuron activity evokes the defense response. This is called synaptic 
sensitization which is an attribute of thalamocortical and memory neurons; synaptic 
sensitization has been implicated in both stress-and-salt-related hypertension and obesity 
associated hypertnesion and it ensures that repeated stimulation of the defense pathway 
makes it respond to ever milder stresses, so that hypertension eventually becomes 
permanent.7 
Consistent with these findings, genetic analysis uncovered numerous shared genes 
among substance use, obesity, response to mental and physical stress and HR and BP data 
including CAMK4, CNTN4, CSMD1, CTNNA2, DGKB, DLG2, FHIT, GRID2, ITPR2, 
LRP1B, NOVA1, NRG3, PCM1, PRKCE, RAP1B and RORA sharing synaptic function; 
furthermore, the result of gene-gene interactions indicate that these genes sharing protein 
interactions and tend to form protein network; pathways analysis also pointed to Long-
Term Potentiation pathway which is an important form of  synaptic plasticity.  
In agreement with these results; gene expression findings also revealed that these 
shared genes have higher expression in a cluster of brain related tissues including 
Temporal, Occipital, Frontal and Parietal lobes, Cerebral cortex, Amygdala and 
Hippocampus; besides, in these tissues majority of identified genes tend to display similar 
expression profiles unlike other tissues. Overall, these findings indicate that the common 
interface among these traits is likely synaptic related process. 
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The sex-specific and hypertension-specific genetic analysis uncovered IL1RAP, 
PLCG2 and SCIN genes that were significantly negatively associated to a trait in one group 
and significantly positively associated to the same trait in the contrary group. All three 
genes shared synaptic function. Consistent with the finding of SCIN gene for tobacco use, 
it is reported that nicotinic-receptor stimulation induces the redistribution of SCIN 
protein.49 
The results of pathway analysis and gene expression profiles of commonly 
associated genes driven from sex-specific and hypertension-specific analysis showed 
similar characteristics to general results; moreover, we found interactions and common 
genes among gene sets driven from general analysis and sex and hypertension-specific 
analysis, suggesting sex-specific and hypertension-specific genetic differences appear to be 
due to variations in similar biological process identified through general analysis. 
Based on these findings, we propose a model that (Figure 4) once an environmental 
stress is perceived at synapses, it can alter the efficacy of synaptic plasticity; however, other 
environmental factors as substance use can modify the sensitivity of synaptic plasticity to 
the stress. In the long term, the interaction between genetic make-up of synapses with 
environmental factors can shape individuals’s life styles and habits; in the other side, the 
taken habits and lifestyle influence the body’s systems including cardiovascular system and 
affect the cardiovascular outcomes as well as cardiovascular risk factors including body 
weight; nonetheless, similar to different routes ended to the same location, there are other 
factors that influence the cardiovascular system through other mechanisms. Our results also 
suggest that synaptic plasticity may be a common interface behind many of other complex 
disorders in which life style is a contributing factor and further support the notion of human 
disease network.50-52 
This study is limited on genomic coverage; however, the large size of LD blocks in 
this founder population reduces the number of markers for genome wide scan.13; 15; 54 Small 
sample size and lack of replication are also important potential issues in genome wide scan 
studies. Some common risk variants cannot be feasibly detected in small cohorts; moreover 
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the detected variants may not be reproducible in other cohorts which points to presence of 
locus heterogeneity.55 Considering that SNPs and genes carry out their functions through 
intricate pathways, to address this issue, we did network-based genetic analysis which aims 
to determine whether the variations that are more strongly associated to a phenotype tend to 
significantly cluster in a biological process. 
Identification of shared genetic factors among the studied traits suggests that 
complex phenotypes may not be completely unrelated and provide implications for design 
of gene-mapping studies that jointly examine complex traits, specifically those traits that 
are correlated. Current study also provides a perspective on how large human genomic data 
can be processed to implicate the role of biological processes that otherwise would be left 
unrecognized. The substantial overlap among genomic determinants of substance use, 
stress, obesity and hemodynamic traits in synaptic plasticity related processes calls for 
additional studies on plausible influence of synaptic plasticity on shaping life style habits 
and physiological outcomes. 
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Table 1. Distribution of substance use traits by sex and hypertension status and their correlations1 with sex, age2 and hypertension3 
Trait 
Females Males Sex 
(females) 
Aging 
Hypertension 
(hypertensives) 
Total Unaffected Affected Unaffected Affected 
Nor4 Hyp5 Nor Hyp Nor Hyp Nor Hyp Z P Z P Z P 
Alcohol users vs. non users 126 190 44 17 84 113 72 52 -5.6 < 1E-04 -2.7 0.004 -2.0 0.025 698 
Current vs. non tobacco users 117 174 50 36 99 125 57 39 -2.2 0.02 -3.7 0.0001 -3.4 0.0003 697 
Never vs. ever tobacco users 85 102 82 108 106 114 50 50 5.5 < 1E-04 -1.9 0.03 2.0 0.02 697 
Current vs. former tobacco users 35 66 50 36 49 75 57 39 0.3 0.4 -4.5 < 1E-04 -3.2 0.0006 407 
Current vs. never tobacco users 82 108 50 36 50 50 57 39 -4.1 < 1E-04 -0.9 0.2 -3.0 0.001 472 
Former vs. never tobacco users 82 108 35 66 50 50 49 75 -4.8 < 1E-04 3.4 0.0004 -0.6 0.3 515 
Coffee users vs. non users 41 30 127 173 33 37 120 118 0.6 0.3 3.4 0.0003 -0.2 0.4 679 
 
 
                                                            
1 Correlation test was done using GEE method. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice versa. 
2 Correlation model is substance use ~ sex + age. 
3 Correlation model is hypertension status ~ sex + age + substance use. 
4 Normotensives 
5 Hypertensives 
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Table 2. Descriptive statistics of quantitative traits distributed by sex, hypertension status and in entire cohort along their correlations1 with sex, age2 
and hypertension3 
Trait 
Females Males
Total Sex (females) 
Hypertension 
(hypertensives) 
Aging 
Normotensives Hypertensives Normotensives Hypertensives 
N Mean±SE N Mean±SE N Mean±SE N Mean±SE N Mean±SE Z P Z P Z P 
BMI (kg/m2) 175 24.7±0.4 254 27.5±0.3 162 26.3±0.4 201 28.1±0.3 792 26.8±0.2 -4.9 5.E-07 5.4 3.E-08 2.7 4.E-03
Waist Hip ratio 171 0.8±0 251 0.8±0 161 0.9±0 202 1±0 785 0.9±0 -24.4 7.E-132 4.5 3.E-06 8.8 5.E-19
Waist circumference (cm) 172 80.1±1 251 87.7±0.9 161 92.9±0.9 203 99.3±0.8 787 90.1±0.5 -16 1.E-57 4.8 1.E-06 5.3 6.E-08
Hip circumference (cm) 171 99.2±0.8 251 102.9±0.7 161 98±0.5 202 100.8±0.5 785 100.6±0.3 2.1 2.E-02 3.8 7.E-05 1 2.E-01
Hip Thigh Proximal ratio 171 1.7±0 238 1.7±0 158 1.7±0 193 1.7±0 760 1.7±0 -4 3.E-05 -0.6 3.E-01 15.5 1.E-54
Thigh proximal circumference (cm) 171 59±0.6 238 58.8±0.4 159 57.2±0.5 194 58.1±0.4 762 58.3±0.2 4.1 2.E-05 3 2.E-03 -5.5 2.E-08
Thigh mid circumference (cm) 171 52.3±0.5 241 52.8±0.4 159 52.7±0.5 195 53.4±0.4 766 52.8±0.2 -0.8 2.E-01 4.1 2.E-05 -4.6 2.E-06
Thigh distal circumference (cm) 171 39.8±0.4 239 40.6±0.3 159 40±0.3 194 40.9±0.3 763 40.4±0.2 -0.8 2.E-01 3.2 7.E-04 -1.6 6.E-02
Skinfold bicep1 (mm) 160 21.9±1.1 202 23.7±0.8 154 16.4±1 180 16.8±1 696 19.9±0.5 6.2 2.E-10 4.4 7.E-06 1.2 1.E-01
Skinfold bicep2 (mm) 160 22.1±1.1 202 23.9±0.8 154 16.7±1 180 16.9±1 696 20.1±0.5 6 1.E-09 4.3 7.E-06 1.1 1.E-01
Skinfold bicep3 (mm) 160 22.3±1.1 201 24±0.9 154 16.7±1 180 16.8±1 695 20.1±0.5 5.9 2.E-09 4 3.E-05 1 2.E-01
                                                            
1 Correlation test was performed using GEE. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice versa.  
2 Correlation model is trait ~ sex + age. 
3 Correlation model is hypertension status ~ sex + age + substance use + trait. 
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Mean skinfold biceps (mm) 160 22.1±1.1 202 23.9±0.8 154 16.6±1 180 16.8±1 696 20±0.5 6 7.E-10 4.3 1.E-05 1.1 1.E-01
Skinfold triceps1 (mm) 161 30±1 202 34.1±0.8 154 23±1 180 23.8±1 697 28±0.5 8 9.E-16 4.1 2.E-05 0.9 2.E-01
Skinfold triceps2 (mm) 161 30.2±1 202 34.5±0.8 154 23.3±1.1 179 23.6±0.9 696 28.2±0.5 7.7 6.E-15 4.2 1.E-05 1 2.E-01
Skinfold triceps3 (mm) 161 30.4±1 201 34.5±0.8 154 23.2±1.1 179 23.6±1 695 28.2±0.5 7.7 9.E-15 4.1 2.E-05 1 2.E-01
Mean skinfold triceps (mm) 161 30.2±1 202 34.4±0.8 154 23.1±1.1 180 23.8±1 697 28.2±0.5 7.7 5.E-15 4.2 1.E-05 1 2.E-01
Skinfold subscapular1 (mm) 161 24±1 201 28.1±0.8 154 22.8±0.8 177 25.9±0.8 693 25.4±0.4 2.2 2.E-02 4.1 2.E-05 1.3 1.E-01
Skinfold subscapular2 (mm) 161 24.3±1 201 28.2±0.9 154 22.7±0.8 177 25.7±0.8 693 25.5±0.4 2.3 1.E-02 4 4.E-05 1.2 1.E-01
Skinfold subscapular3 (mm) 161 24.4±1 201 28.3±0.9 154 22.9±0.9 177 25.8±0.8 693 25.5±0.5 2.3 1.E-02 4 3.E-05 1.1 1.E-01
Mean skinfold subscapular (mm) 161 24.2±1 201 28.2±0.9 154 22.8±0.8 177 25.8±0.8 693 25.5±0.4 2.2 1.E-02 4 3.E-05 1.2 1.E-01
Skinfold suprailiac1 (mm) 159 23.7±1.1 201 26.9±0.7 153 21.6±1 177 24.8±0.9 690 24.5±0.5 3.1 9.E-04 3.8 7.E-05 -1 2.E-01
Skinfold suprailiac2 (mm) 159 23.7±1.1 201 27.2±0.7 153 21.9±1 177 24.8±0.9 690 24.6±0.5 3.2 8.E-04 4.1 2.E-05 -1 2.E-01
Skinfold suprailiac3 (mm) 159 23.8±1.1 201 27.2±0.7 153 21.9±1 177 25.1±0.9 690 24.7±0.5 2.9 2.E-03 4.1 2.E-05 -0.9 2.E-01
Mean skinfold suprailiac (mm) 159 23.7±1.1 201 27.1±0.7 153 21.8±1 177 24.9±0.9 690 24.6±0.5 3 1.E-03 4 3.E-05 -0.9 2.E-01
Skinfold thigh1 (mm) 145 39.2±1.1 191 43±0.9 149 26.9±1.3 175 24.3±1.1 660 33.5±0.6 13.2 4.E-40 2.5 6.E-03 -1.1 1.E-01
Skinfold thigh2 (mm) 144 39.2±1.1 191 43.3±0.9 149 27.1±1.3 175 24.5±1.1 659 33.7±0.6 12.3 4.E-35 2.5 6.E-03 -1 2.E-01
Skinfold thigh3 (mm) 144 39.5±1.1 191 43.6±0.9 148 27±1.3 175 24.6±1.1 658 33.9±0.6 13.4 3.E-41 2.7 4.E-03 -1.2 1.E-01
Mean skinfold thigh (mm) 145 39.4±1.1 191 43.3±0.9 149 27.1±1.3 175 24.5±1.1 660 33.8±0.6 12.9 2.E-38 2.6 5.E-03 -1.1 1.E-01
Body fat percentage bioimpedance 137 30.4±0.8 177 37.4±0.8 128 21.2±0.7 158 24.6±0.6 600 28.9±0.4 18.7 5.E-78 3.5 2.E-04 9.7 1.E-22
Body fat (%) 158 36.3±0.6 201 39.1±0.4 153 25±0.5 175 26±0.4 687 32±0.3 27.7 3.E-169 4.4 5.E-06 1 2.E-01
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Supine EP (pg/ml) 66 41.9±2.1 40 40.5±2.6 57 43.3±2.3 49 46±3.2 212 42.9±1.3 -1.5 7.E-02 0 5.E-01 0.5 3.E-01
Standing EP (pg/ml) 68 50.5±3.3 37 38.6±2.4 54 57±4.7 52 54.9±3.7 211 51.2±1.9 -3.1 1.E-03 -0.7 2.E-01 -2.6 5.E-03
Response EP (pg/ml) 63 9.6±3.6 31 -1.1±2.8 54 13.8±4.6 43 6±4 191 8.2±2 -1 2.E-01 -1.2 1.E-01 -2.4 9.E-03
Supine NE (pg/ml) 73 171.7±7.1 48 167.3±9.8 57 169.4±8.6 60 160.2±9.5 238 167.4±4.3 0.7 2.E-01 -0.9 2.E-01 -0.2 4.E-01
Standing NE (pg/ml) 73 391.8±14.9 48 407.9±24.6 55 397.1±23.3 61 395.9±20.7 237 397.4±10.1 0.4 4.E-01 0.2 4.E-01 1.6 5.E-02
Response NE (pg/ml) 73 220.1±11.2 48 240.6±18.8 55 230.3±20.5 60 235.8±15.2 236 230.7±8 0 5.E-01 0.6 3.E-01 2.1 2.E-02
DBP response to mental stress (mmHg) 77 10±0.8 57 12.1±1 64 9.6±0.9 71 9.4±0.9 269 10.2±0.4 1.5 7.E-02 1.4 8.E-02 -1.3 1.E-01
SBP response to mental stress (mmHg) 77 12.1±1.3 56 18.4±1.6 64 14.9±1.4 71 19.5±1.6 268 16.1±0.7 -1.5 7.E-02 2 2.E-02 0.9 2.E-01
HR response to mental stress (beast/min) 78 7.8±1.4 57 9.4±1.1 64 7±1.1 71 8.5±1 270 8.1±0.6 0.7 2.E-01 1.8 3.E-02 -0.6 3.E-01
Average sitting DBP (mmHg) 77 69.2±0.9 57 79±1.4 64 75.1±1.1 69 86±1.3 267 77.1±0.7 -5.1 2.E-07 4.1 2.E-05 6.8 4.E-12
Average sitting SBP (mmHg) 77 109±1.3 57 136.8±2.6 64 118.1±1.3 69 136±2.1 267 124.1±1.2 -2.6 4.E-03 5.8 4.E-09 6.2 3.E-10
Average sitting HR (beast/min) 77 71.1±1.2 57 73.8±1.5 64 64.7±1.2 67 67.1±1.2 265 69.1±0.7 4.4 6.E-06 2.1 2.E-02 -1.5 6.E-02
Mean ambulatory DBP (mmHg) 61 67.4±0.8 43 79.3±1.5 48 73.3±1.1 51 84.7±1.2 203 75.6±0.7 -6.2 3.E-10 5.9 2.E-09 9.3 5.E-21
Mean ambulatory SBP (mmHg) 61 110.3±1 43 130.6±2.4 48 120.7±1.3 51 133.7±1.9 203 122.9±1 -5.3 8.E-08 5.4 3.E-08 5.6 9.E-09
Mean ambulatory HR (mmHg) 61 74.9±1 43 79.9±1.4 48 70.5±1.6 51 76.3±1.5 203 75.3±0.7 1.7 4.E-02 2.9 2.E-03 0.3 4.E-01
Sleep DBP (mmHg) 74 61.4±1 50 70.3±1.6 61 67.2±1.1 63 74.8±1.3 248 68±0.7 -5.8 3.E-09 3.8 8.E-05 5.5 2.E-08
Sleep SBP (mmHg) 74 102.5±1.1 50 117.6±2.4 61 112.6±1.2 63 122.2±2 248 113±1 -5.5 2.E-08 4.3 1.E-05 4.1 2.E-05
Sleep HR (beast/min) 74 71.2±1.2 49 74.8±1.4 60 65.8±1.3 63 67.3±1.6 246 69.6±0.7 3.4 4.E-04 1.2 1.E-01 0.3 4.E-01
Sleep MAP (mmHg) 74 75.1±1 50 86.1±1.8 61 82.3±1 63 90.6±1.4 248 83±0.7 -5.9 2.E-09 4.2 1.E-05 5 2.E-07
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Sleep PP (mmHg) 74 41.1±0.7 50 47.4±1.6 61 45.4±0.9 63 47.4±1.4 248 45±0.6 -2.5 6.E-03 3.1 9.E-04 0.7 2.E-01
Wake DBP (mmHg) 73 71±0.9 49 79.6±1.6 62 75.5±1 63 84.4±1.3 247 77.2±0.7 -5 3.E-07 3.8 8.E-05 5.5 2.E-08
Wake SBP (mmHg) 73 115.3±1.2 49 131.3±2.5 62 124.4±1.3 63 136.5±1.9 247 126.2±1 -5.4 4.E-08 4.5 4.E-06 4.7 1.E-06
Wake HR (beast/min) 73 81.6±1 49 85±1.6 62 76.6±1.4 63 81.7±1.8 247 81±0.8 2.1 2.E-02 2.2 1.E-02 0.6 3.E-01
Wake MAP (mmHg) 73 85.8±0.9 49 96.8±1.7 62 91.8±1 63 101.8±1.4 247 93.6±0.7 -5.9 2.E-09 4.5 4.E-06 5.6 1.E-08
Wake PP (mmHg) 73 44.3±0.9 49 51.8±1.7 62 48.9±1 63 52.1±1.4 247 48.9±0.6 -2.8 2.E-03 2.9 2.E-03 1.6 6.E-02
Overall PP (mmHg) 61 42.9±0.7 43 51.3±1.6 48 47.4±0.9 51 48.9±1.2 203 47.3±0.6 -2.2 1.E-02 3.2 7.E-04 0.5 3.E-01
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Table 3. Correlation1 of obesity-related traits, stress responses and HR and BP data with substance use 
Trait 
Alcohol users vs. 
non users 
Coffee users vs. 
non users 
Current vs. non 
tobacco users 
Current vs. never 
tobacco users 
Former vs. never 
tobacco users 
Current vs. former 
tobacco users 
Z P Z P Z P Z P Z P Z P
BMI (kg/m2) -0.2 4.30E-01 0.3 3.70E-01 -3.5 2.50E-04 -3.3 5.30E-04 -0.8 2.20E-01 -3.1 1.10E-03
Waist Hip ratio 0.7 2.40E-01 -0.5 3.10E-01 -0.6 2.70E-01 -0.2 4.00E-01 0.5 3.10E-01 -1.1 1.40E-01
Waist circumference (cm) -0.4 3.60E-01 -0.4 3.50E-01 -2.9 2.10E-03 -2.4 8.30E-03 -0.3 3.80E-01 -2.6 4.40E-03
Hip circumference (cm) -1.6 5.50E-02 0.4 3.30E-01 -3.4 3.10E-04 -3 1.20E-03 -0.6 2.90E-01 -3 1.50E-03
Hip Thigh Proximal ratio -0.9 2.00E-01 0.9 1.90E-01 3.1 1.10E-03 3.2 6.10E-04 2.7 3.70E-03 2 2.60E-02
Thigh proximal circumference (cm) -0.8 2.20E-01 0 4.80E-01 -4.9 4.00E-07 -4.9 5.50E-07 -2.1 1.90E-02 -3.6 1.30E-04
Thigh mid circumference (cm) 0.2 4.10E-01 -0.1 4.60E-01 -4.2 1.10E-05 -3.7 1.10E-04 -1.4 8.50E-02 -3.6 1.40E-04
Thigh distal circumference (cm) 0.6 2.90E-01 0.8 2.30E-01 -3.6 1.40E-04 -3.9 4.90E-05 -1.8 3.40E-02 -2.3 1.00E-02
Skinfold bicep1 (mm) 0.6 2.90E-01 1.4 8.80E-02 -1.3 1.00E-01 -1.5 6.40E-02 -1.3 9.40E-02 -0.8 2.10E-01
Skinfold bicep2 (mm) 0.5 2.90E-01 1.3 1.00E-01 -1.3 1.00E-01 -1.5 7.10E-02 -1.2 1.20E-01 -0.9 2.00E-01
Skinfold bicep3 (mm) 0.5 3.20E-01 1.1 1.40E-01 -1.4 8.80E-02 -1.6 5.60E-02 -1.3 1.00E-01 -0.9 1.90E-01
                                                            
1 Correlation test was performed using GEE method. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice 
versa. Correlation model is trait ~ sex + age + substance use. 
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Mean skinfold biceps (mm) 0.5 3.00E-01 1.2 1.10E-01 -1.3 9.80E-02 -1.5 6.50E-02 -1.2 1.10E-01 -0.9 2.00E-01
Skinfold triceps1 (mm) 0 4.90E-01 0.1 4.80E-01 -1.8 3.30E-02 -1.9 3.00E-02 -0.9 1.80E-01 -1 1.60E-01
Skinfold triceps2 (mm) 0 4.90E-01 0.1 4.80E-01 -1.8 3.70E-02 -1.8 3.40E-02 -0.8 2.00E-01 -1 1.60E-01
Skinfold triceps3 (mm) 0 4.80E-01 0 4.90E-01 -1.7 4.80E-02 -1.6 5.80E-02 -0.7 2.40E-01 -1.1 1.30E-01
Mean skinfold triceps (mm) 0 4.80E-01 0.1 4.50E-01 -1.9 3.00E-02 -1.9 3.10E-02 -0.8 2.20E-01 -1.1 1.40E-01
Skinfold subscapular1 (mm) -0.5 3.00E-01 0.3 3.70E-01 -1.6 5.30E-02 -1.6 5.30E-02 -0.7 2.50E-01 -0.8 2.10E-01
Skinfold subscapular2 (mm) -0.6 2.70E-01 0.4 3.60E-01 -1.4 8.30E-02 -1.4 8.10E-02 -0.6 2.80E-01 -0.7 2.50E-01
Skinfold subscapular3 (mm) -0.7 2.40E-01 0.5 3.10E-01 -1.7 4.30E-02 -1.7 4.30E-02 -0.7 2.60E-01 -0.8 2.00E-01
Mean skinfold subscapular (mm) -0.6 2.80E-01 0.4 3.50E-01 -1.6 5.50E-02 -1.6 5.40E-02 -0.7 2.50E-01 -0.8 2.20E-01
Skinfold suprailiac1 (mm) -0.8 2.20E-01 -0.2 4.30E-01 -1.8 3.40E-02 -2.3 9.50E-03 -1.6 5.80E-02 -0.7 2.30E-01
Skinfold suprailiac2 (mm) -0.8 2.10E-01 0 4.90E-01 -2 2.20E-02 -2.3 1.00E-02 -1.3 1.00E-01 -1.1 1.30E-01
Skinfold suprailiac3 (mm) -0.7 2.50E-01 -0.1 4.70E-01 -1.8 3.40E-02 -2.2 1.50E-02 -1.2 1.10E-01 -0.9 1.70E-01
Mean skinfold suprailiac (mm) -0.7 2.30E-01 -0.1 4.60E-01 -1.9 2.80E-02 -2.3 1.10E-02 -1.4 8.00E-02 -0.9 1.80E-01
Skinfold thigh1 (mm) 1.2 1.10E-01 0.9 1.70E-01 -1.8 3.40E-02 -2.2 1.30E-02 -1.7 4.10E-02 -0.6 2.90E-01
Skinfold thigh2 (mm) 1.2 1.10E-01 1 1.50E-01 -1.7 4.40E-02 -2.1 1.80E-02 -1.9 2.70E-02 -0.5 3.00E-01
Skinfold thigh3 (mm) 1 1.60E-01 1.1 1.40E-01 -1.8 3.60E-02 -2.3 1.00E-02 -2 2.00E-02 -0.4 3.40E-01
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Mean skinfold thigh (mm) 1.2 1.10E-01 1 1.60E-01 -1.8 3.50E-02 -2.3 1.20E-02 -1.9 3.20E-02 -0.5 2.90E-01
Body fat percentage bioimpedance -0.8 2.20E-01 -1.2 1.20E-01 -1.1 1.30E-01 -1.2 1.10E-01 -0.5 3.10E-01 -0.4 3.60E-01
Body fat (%) -0.2 4.00E-01 0.8 2.00E-01 -2.6 5.10E-03 -2.5 6.20E-03 -0.9 1.80E-01 -1.5 7.10E-02
Supine EP (pg/ml) 0.4 3.50E-01 -1.2 1.10E-01 1.6 5.90E-02 1.1 1.40E-01 -0.9 1.80E-01 2.3 1.20E-02
Standing EP (pg/ml) -1 1.60E-01 0.3 3.90E-01 2.5 6.50E-03 2.2 1.40E-02 -0.3 3.70E-01 2.5 6.10E-03
Response EP (pg/ml) -1.4 8.60E-02 1.1 1.40E-01 1.4 8.50E-02 1.4 7.80E-02 0.3 3.90E-01 0.9 1.70E-01
Supine NE (pg/ml) 0.1 4.70E-01 -0.5 3.10E-01 0.4 3.60E-01 0.4 3.60E-01 0 4.90E-01 0.5 3.00E-01
Standing NE (pg/ml) -0.5 3.20E-01 -0.1 4.70E-01 1.2 1.20E-01 0.8 2.10E-01 -0.5 3.20E-01 1.2 1.10E-01
Response NE (pg/ml) -0.4 3.30E-01 0.4 3.30E-01 0.9 1.70E-01 0.7 2.50E-01 -0.6 2.90E-01 0.9 1.80E-01
DBP response to mental stress (mmHg) 1.1 1.30E-01 0.6 2.70E-01 0.5 3.00E-01 0.3 3.90E-01 0 4.90E-01 1.4 7.50E-02
SBP response to mental stress (mmHg) 1.1 1.30E-01 -0.9 1.80E-01 -0.9 1.90E-01 -0.3 3.90E-01 1.3 9.90E-02 -1.4 8.40E-02
HR response to mental stress (beast/min) -1.7 4.10E-02 1.4 7.90E-02 -1.7 4.10E-02 -1.8 4.00E-02 0.5 3.10E-01 -1.2 1.10E-01
Average sitting DBP (mmHg) 1.2 1.20E-01 -1.1 1.40E-01 -2 2.10E-02 -1.7 4.20E-02 0.9 1.90E-01 -2.4 8.80E-03
Average sitting SBP (mmHg) 0.5 3.20E-01 -1.3 9.10E-02 -3.4 4.00E-04 -3.6 1.40E-04 -0.5 2.90E-01 -2.3 1.10E-02
Average sitting HR (beast/min) 0.6 2.70E-01 1.5 6.60E-02 0.5 3.10E-01 0.4 3.40E-01 -0.1 4.60E-01 0.5 3.10E-01
Mean ambulatory DBP (mmHg) -0.1 4.60E-01 -1.1 1.30E-01 -2.1 1.60E-02 -2 2.20E-02 -0.1 4.70E-01 -1.6 5.00E-02
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Mean ambulatory SBP (mmHg) -0.2 4.30E-01 -0.8 2.20E-01 -1.3 9.90E-02 -1 1.50E-01 0.2 4.30E-01 -1.5 7.10E-02
Mean ambulatory HR (mmHg) -0.3 3.90E-01 2.3 1.20E-02 -0.4 3.60E-01 -0.6 2.70E-01 -0.2 4.10E-01 0 5.00E-01
Sleep DBP (mmHg) -0.8 2.20E-01 -1 1.50E-01 -0.6 2.80E-01 -0.7 2.50E-01 -0.3 3.80E-01 0.5 3.00E-01
Sleep SBP (mmHg) -0.7 2.50E-01 -1.7 4.10E-02 0.1 4.60E-01 0 4.80E-01 0 4.90E-01 0.3 3.90E-01
Sleep HR (beast/min) 1.3 1.00E-01 1.9 2.90E-02 0.2 4.10E-01 0.3 3.70E-01 0 4.90E-01 0.1 4.60E-01
Sleep MAP (mmHg) -0.8 2.10E-01 -1.5 7.30E-02 -0.2 4.20E-01 -0.3 3.90E-01 -0.2 4.10E-01 0.5 3.20E-01
Sleep PP (mmHg) -0.5 3.10E-01 -1.5 6.10E-02 0.8 2.00E-01 0.6 2.60E-01 0 4.80E-01 0.3 4.00E-01
Wake DBP (mmHg) -0.8 2.00E-01 -0.8 2.10E-01 -0.3 3.70E-01 -0.6 2.60E-01 -0.5 3.20E-01 0 4.90E-01
Wake SBP (mmHg) -0.8 2.20E-01 0 4.80E-01 0.6 2.60E-01 0.3 3.80E-01 -0.1 4.50E-01 0.7 2.30E-01
Wake HR (beast/min) 0.8 2.00E-01 1.6 5.10E-02 1 1.50E-01 1.7 4.50E-02 0.5 3.10E-01 0.1 4.50E-01
Wake MAP (mmHg) -1 1.50E-01 -0.6 2.80E-01 0.1 4.60E-01 -0.2 4.10E-01 -0.3 3.80E-01 0.3 3.80E-01
Wake PP (mmHg) 0 4.80E-01 0.5 3.20E-01 1.1 1.30E-01 0.9 1.90E-01 0.1 4.70E-01 1 1.60E-01
Overall PP (mmHg) -0.1 4.50E-01 -0.4 3.50E-01 0.6 2.90E-01 0.7 2.40E-01 0.6 2.80E-01 -0.4 3.60E-01
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Table 4. Heritability (H2r) estimates of studied traits by sex1 and hypertension status2 and in general3 
Trait 
Females Males Normotensives Hypertensives All 
N SE H2r N SE H2r N SE H2r N SE H2r N SE H2r 
Alcohol users vs. non users 377 0.3 0.85 321 0.2 0.63 326 0.2 0.51 372 0.2 0.55 698 0.2 0.59 
Current vs. non tobacco users 377 0.2 0.39 320 0.3 0.62 323 0.2 0.26 374 0.2 0.45 697 0.1 0.39 
Current vs. never tobacco users 276 0.2 0.64 196 0.3 0.5 239 0.2 0.51 233 0.3 0.66 472 0.2 0.57 
Current vs. former tobacco users 187 0.3 0.23 220 0.3 0.97 191 0.3 0.18 216 0.3 0.62 407 0.2 0.46 
Former vs. current and never tobacco users 377 1.1 0.31 320 0.2 0.74 323 0.2 0.28 374 0.2 0.34 697 0.1 0.4 
Former vs. never tobacco users 291 0.2 0.56 224 0.4 0.81 216 0.3 0.71 299 0.3 0.43 515 0.1 0.61 
Never vs. ever tobacco users 377 0.2 0.58 320 0.2 0.35 323 0.2 0.56 374 0.2 0.36 697 0.1 0.51 
Coffee users vs. non users 371 0.2 0.61 308 0.3 0.37 321 0.2 0.66 358 0.2 0.2 679 0.1 0.45 
BMI (kg/m2) 429 0.1 0.41 363 0.1 0.22 337 0.1 0.4 455 0.1 0.36 792 0.1 0.34 
Waist Hip ratio 422 0.1 0.29 363 0.1 0.34 332 0.1 0.23 453 0.1 0.44 785 0.1 0.32 
                                                            
1 Data were adjusted for covariate age. 
2 Data were adjusted for covariates, age and sex. 
3 Data were adjusted for covariates, age and sex. 
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Waist circumference (cm) 423 0.1 0.22 364 0.1 0.31 333 0.1 0.26 454 0.1 0.34 787 0.1 0.29 
Hip circumference (cm) 422 0.1 0.28 363 0.1 0.41 332 0.1 0.36 453 0.1 0.37 785 0.1 0.33 
Hip Thigh Proximal ratio 409 0.1 0.32 351 0.1 0.24 329 0.1 0.31 431 0.1 0.25 760 0.1 0.24 
Thigh proximal circumference (cm) 409 0.1 0.42 353 0.1 0.41 330 0.1 0.42 432 0.1 0.42 762 0.1 0.38 
Thigh mid circumference (cm) 412 0.1 0.38 354 0.2 0.45 330 0.1 0.35 436 0.1 0.36 766 0.1 0.33 
Thigh distal circumference (cm) 410 0.1 0.42 353 0.1 0.35 330 0.1 0.53 433 0.1 0.36 763 0.1 0.38 
Skinfold bicep1 (mm) 362 0.1 0.38 334 0.1 0.65 314 0.1 0.4 382 0.1 0.6 696 0.1 0.46 
Skinfold bicep2 (mm) 362 0.1 0.41 334 0.1 0.67 314 0.1 0.41 382 0.1 0.63 696 0.1 0.48 
Skinfold bicep3 (mm) 361 0.1 0.43 334 0.1 0.69 314 0.1 0.39 381 0.1 0.64 695 0.1 0.47 
Mean skinfold biceps (mm) 362 0.1 0.4 334 0.1 0.67 314 0.1 0.4 382 0.1 0.62 696 0.1 0.47 
Skinfold triceps1 (mm) 363 0.1 0.39 334 0.1 0.45 315 0.1 0.26 382 0.1 0.52 697 0.1 0.35 
Skinfold triceps2 (mm) 363 0.1 0.37 333 0.1 0.44 315 0.1 0.27 381 0.1 0.48 696 0.1 0.33 
Skinfold triceps3 (mm) 362 0.1 0.38 333 0.1 0.42 315 0.1 0.27 380 0.1 0.46 695 0.1 0.33 
Mean skinfold triceps (mm) 363 0.1 0.38 334 0.1 0.47 315 0.1 0.26 382 0.1 0.52 697 0.1 0.35 
Skinfold subscapular1 (mm) 362 0.1 0.52 331 0.1 0.37 315 0.1 0.37 378 0.1 0.51 693 0.1 0.41 
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Skinfold subscapular2 (mm) 362 0.1 0.52 331 0.1 0.35 315 0.1 0.36 378 0.1 0.5 693 0.1 0.4 
Skinfold subscapular3 (mm) 362 0.1 0.48 331 0.1 0.35 315 0.1 0.36 378 0.1 0.47 693 0.1 0.39 
Mean skinfold subscapular (mm) 362 0.1 0.5 331 0.1 0.36 315 0.1 0.36 378 0.1 0.49 693 0.1 0.4 
Skinfold suprailiac1 (mm) 360 0.1 0.3 330 0.1 0.35 312 0.1 0.17 378 0.1 0.51 690 0.1 0.3 
Skinfold suprailiac2 (mm) 360 0.1 0.31 330 0.1 0.31 312 0.1 0.17 378 0.1 0.52 690 0.1 0.3 
Skinfold suprailiac3 (mm) 360 0.1 0.31 330 0.1 0.32 312 0.1 0.17 378 0.1 0.49 690 0.1 0.29 
Mean skinfold suprailiac (mm) 360 0.1 0.3 330 0.1 0.32 312 0.1 0.17 378 0.1 0.51 690 0.1 0.29 
Skinfold thigh1 (mm) 336 0.1 0.13 324 0.1 0.39 294 0.1 0.28 366 0.1 0.41 660 0.1 0.26 
Skinfold thigh2 (mm) 335 0.1 0.08 324 0.1 0.4 293 0.1 0.23 366 0.1 0.4 659 0.1 0.23 
Skinfold thigh3 (mm) 335 0.1 0.1 323 0.1 0.4 292 0.1 0.21 366 0.1 0.41 658 0.1 0.24 
Mean skinfold thigh (mm) 336 0.1 0.12 324 0.1 0.4 294 0.1 0.26 366 0.1 0.42 660 0.1 0.26 
Body fat percentage bioimpedance 314 0.1 0.19 286 0.2 0.58 265 0.2 0.24 335 0.1 0.41 600 0.1 0.32 
Body fat (%) 359 0.1 0.33 328 0.1 0.13 311 0.1 0.24 376 0.1 0.34 687 0.1 0.24 
Supine EP (pg/ml) 106 0.3 0.33 106 0.3 0.49 123 0.3 0.52 89 0.3 0.72 212 0.2 0.39 
Standing EP (pg/ml) 105 0.4 0.35 106 0.3 0.39 122 
  
89 0.3 0.67 211 0.2 0.28 
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Response EP (pg/ml) 94 0.3 0.23 97 0.3 0.09 117 0.2 0.15 74 
  
191 0.2 0.13 
Supine NE (pg/ml) 121 0.3 0.2 117 0.3 0.46 130 0.3 0.05 108 0.3 0.57 238 0.2 0.39 
Standing NE (pg/ml) 121 0.2 0.17 116 0.3 0.06 128 
  
109 0.3 0.27 237 0.1 0.18 
Response NE (pg/ml) 121 0.2 0.11 115 
  
128 
  
108 0.3 0.07 236 0.1 0.04 
DBP response to mental stress (mmHg) 134 
  
135 0.2 0.29 141 
  
128 0.2 0.17 269 0.1 0.11 
SBP response to mental stress (mmHg) 133 0.2 0.19 135 0.2 0.17 141 
  
127 
  
268 0.1 0.11 
HR response to mental stress (beast/min) 135 
 
0 135 0.3 0.18 142 0.2 0.16 128 
  
270 0.1 0.1 
Average sitting DBP (mmHg) 134 0.2 0.53 133 0.2 0.25 141 0.2 0.69 126 0.3 0.33 267 0.1 0.41 
Average sitting SBP (mmHg) 134 0.2 0.54 133 0.3 0.66 141 0.2 0.48 126 0.2 0.1 267 0.1 0.42 
Average sitting HR (beast/min) 134 0.2 0.67 131 0.2 0.76 141 0.2 0.87 124 0.3 0.34 265 0.1 0.58 
Mean ambulatory DBP (mmHg) 104 0.3 0.47 99 0.3 0.7 109 0.3 0.6 94 0.3 0.27 203 0.2 0.46 
Mean ambulatory SBP (mmHg) 104 0.2 0.49 99 0.3 0.19 109 
  
94 
  
203 0.1 0.26 
Mean ambulatory HR (mmHg) 104 0.3 0.67 99 0.3 0.81 109 0.3 0.99 94 
  
203 0.2 0.64 
Sleep DBP (mmHg) 124 0.2 0.07 124 0.2 0.47 135 0.3 0.18 113 0.2 0.47 248 0.2 0.37 
Sleep SBP (mmHg) 124 0.3 0.39 124 0.2 0.32 135 0.3 0.14 113 0.2 0.23 248 0.1 0.31 
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Sleep HR (beast/min) 123 0.3 0.33 123 0.2 0.72 134 0.2 0.74 112 0.3 0.13 246 0.2 0.54 
Sleep MAP (mmHg) 124 0.3 0.23 124 0.2 0.47 135 0.3 0.32 113 0.2 0.35 248 0.2 0.4 
Sleep PP (mmHg) 124 0.3 0.33 124 0.2 0.16 135 
  
113 0.2 0.25 248 0.1 0.14 
Wake DBP (mmHg) 122 
  
125 0.2 0.52 135 
  
112 0.2 0.27 247 0.1 0.24 
Wake SBP (mmHg) 122 0.3 0.55 125 0.2 0.35 135 0.3 0.27 112 0.2 0.3 247 0.1 0.39 
Wake HR (beast/min) 122 0.3 0.59 125 0.2 0.75 135 0.3 0.64 112 0.3 0.66 247 0.2 0.63 
Wake MAP (mmHg) 122 0.2 0.11 125 0.2 0.47 135 0.3 0.09 112 0.2 0.24 247 0.1 0.31 
Wake PP (mmHg) 122 0.2 0.68 125 0.2 0.25 135 0.2 0.36 112 0.3 0.46 247 0.1 0.28 
Overall PP (mmHg) 104 0.3 0.41 99 0.2 0.1 109 0.3 0.02 94 0.3 0.26 203 0.1 0.24 
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Table 5. Candidate loci driven by joint linkage and family-based association analysis 
Chr Trait 
Linkage Association 
Corrected P
LOD Score cM Number of SNPs1 SNP P Gene 
1 Alcohol use 2 111-119 116 rs1281590 1.1E-04 LPHN2;TTLL7 1.2E-02 
  
116 rs925076 2.0E-04 COL24A1;ODF2L 2.3E-02 
2 HR response to mental stress 2.4 144-148 114 rs10496870 3.7E-04 LRP1B 4.2E-02 
3 Average sitting HR 1.95 154-165 95 rs1492090 3.7E-04 AGTR1 3.5E-02 
4 Current tobacco use 1.75 98-106 150 rs4447825 3.0E-06 GRID2 4.5E-04 
4 Sleep MAP 2.2 165-166 36 rs954709 1.4E-04 TLL1 4.9E-03 
5 Coffee use 2.56 36-59 246 rs563972 1.8E-04 DAB2;PTGER4 4.4E-02 
7 NE standing 2.1 140-147 50 rs834767 3.7E-05 CHRM2;MTPN 1.9E-03 
                                                            
1 Numbers of SNPs that are within 1 LOD-drop interval around the linkage peak. 
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8 Never tobacco use 2 28-38 139 rs3739401 1.5E-04 PCM1 2.0E-02 
12 HR response to mental stress 2.8 46-52 91 rs4414322 3.1E-04 ITPR2 2.8E-02 
  
91 rs708156 3.2E-04 ITPR2 2.9E-02 
13 Sleep MAP 2 39-46 179 rs927544 1.5E-04 HTR2A 2.7E-02 
13 DBP response to mental stress 2.9 45.5-48 76 rs2275664 4.4E-04 PRR20 3.3E-02 
18 Skinfold biceps 2.02 99-108 152 rs10514053 3.1E-05 CBLN2;NETO1 4.7E-03 
  
rs10514055 2.2E-04 NETO1 3.4E-02 
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Table 6. Shared candidate SNPs among the studied traits driven from family based association 
analysis 
Trait Chr SNP P Gene 
Combined 
P 
Current vs. former tobacco 
users 
1 rs951908 8.8E-04 UBR4 
7.6E-08 
Body fat  1 rs1009806 4.2E-06 UBR4 
Skinfold triceps 1 rs320035 4.9E-04 AGBL4 
4.6E-08 
Never vs. ever tobacco users 1 rs679783 3.0E-05 AGBL4 
Waist circumference  1 rs679783 7.4E-05 AGBL4 
Never vs. ever tobacco users 1 rs354167 1.6E-04 AGBL4 
Never vs. ever tobacco users 1 rs1112687 1.4E-04 AGBL4 
SBP response to mental stress 1 rs1404072 4.0E-04 ELTD1 
2.3E-10 
BMI 1 rs1404072 4.5E-04 ELTD1 
Sleep SBP 1 rs10493646 3.6E-04 ELTD1 
Alcohol users vs. non users 1 rs10493646 6.6E-04 ELTD1 
Skinfold biceps 1 rs1340128 1.9E-04 KCNH1 
7.7E-07 
DBP response to mental stress 1 rs1112269 2.2E-04 KCNH1 
SBP response to mental stress 2 rs1522984 7.3E-04 PRKCE 
1.1E-07 Wake DBP 2 rs872288 9.3E-04 PRKCE 
Standing NE  2 rs951012 6.0E-04 PRKCE 
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Hip circumference  2 rs974736 5.3E-04 CTNNA2 
3.8E-10 
Hip circumference  2 rs2916484 2.4E-04 CTNNA2 
SBP response to mental stress 2 rs408144 4.7E-04 CTNNA2 
Former vs. never tobacco 
users 
2 rs10496238 8.0E-06 CTNNA2 
Response NE 2 rs1385775 6.7E-04 LRP1B 
2.5E-09 
Standing NE  2 rs10496864 7.4E-04 LRP1B 
HR response to mental stress 2 rs4133302 6.3E-04 LRP1B 
HR response to mental stress 2 rs10496870 4.8E-05 LRP1B 
Mean ambulatory DBP 2 rs1521102 2.1E-04 LRP1B 
Average sitting SBP 2 rs10497170 1.0E-05 NR4A2 
3.1E-08 
SBP response to mental stress 2 rs10497170 1.5E-04 NR4A2 
Hip Thigh Proximal ratio 2 rs10490326 1.1E-04 CPS1 
1.3E-06 Former vs. never tobacco 
users 
2 rs10490326 7.1E-04 CPS1 
Standing EP 3 rs1516391 5.0E-04 CNTN4 
4.0E-07 
Response EP 3 rs1400205 9.6E-04 CNTN4 
Never vs. ever tobacco users 3 rs339287 3.9E-04 CNTN4 
Never vs. ever tobacco users 3 rs339286 4.3E-05 CNTN4 
Mean ambulatory HR 3 rs10510314 3.9E-05 EDEM1 
9.4E-08 
HR response to mental stress 3 rs10510314 1.2E-04 EDEM1 
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Hip Thigh Proximal ratio 3 rs3905330 1.7E-04 DAG1 
7.5E-07 
DBP response to mental stress 3 rs3905330 2.5E-04 DAG1 
Skinfold subscapular 3 rs1882898 3.1E-04 FHIT 
6.0E-07 
Skinfold subscapular 3 rs1882899 1.3E-04 FHIT 
Skinfold subscapular 3 rs963685 4.5E-05 FHIT 
Mean ambulatory DBP 3 rs953480 7.3E-04 FHIT 
Mean ambulatory DBP 3 rs953479 7.3E-04 FHIT 
Thigh proximal circumference  3 rs6767186 3.1E-05 PHLDB2 
5.5E-07 
Average sitting DBP 3 rs6767186 9.6E-04 PHLDB2 
Waist circumference  4 rs6532079 2.6E-04 FAM13A1 
1.2E-06 
HR response to mental stress 4 rs6532079 2.6E-04 FAM13A1 
DBP response to mental stress 4 rs720327 4.7E-04 FAM190A 
7.1E-08 Response EP 4 rs10516878 6.6E-04 FAM190A 
Thigh mid circumference  4 rs1919224 8.7E-04 FAM190A 
Skinfold thigh 4 rs7663835 9.8E-04 GRID2 
5.2E-08 
Current vs. never tobacco 
users 
4 rs1369169 4.2E-05 GRID2 
Current vs. former tobacco 
users 
4 rs2085364 2.6E-06 GRID2 
Wake SBP 4 rs1533875 1.0E-04 ODZ3 4.2E-07 
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Response NE 4 rs1533875 2.2E-04 ODZ3 
Never vs. ever tobacco users 5 rs410112 2.1E-05 MYO10;FAM134B 
2.7E-07 
Waist circumference  5 rs410112 7.4E-04 MYO10;FAM134B 
Never vs. ever tobacco users 5 rs2434517 1.5E-04 MYO10;FAM134B 
Waist circumference  5 rs2434517 9.6E-04 MYO10;FAM134B 
Never vs. ever tobacco users 5 rs588367 2.7E-04 MYO10;FAM134B 
Waist circumference  5 rs588367 7.2E-04 MYO10;FAM134B 
Never vs. ever tobacco users 5 rs876095 5.3E-05 MYO10;FAM134B 
Waist circumference  5 rs876095 6.9E-04 MYO10;FAM134B 
Coffee users vs. non users 5 rs32441 1.3E-04 ST8SIA4;FAM174A 
1.1E-06 
Sleep PP 5 rs32441 4.9E-04 ST8SIA4;FAM174A 
Body fat percentage 
bioimpedance 
5 rs10515313 1.6E-04 ST8SIA4;SLCO4C1 
1.2E-06 
Mean ambulatory HR 5 rs10515313 4.1E-04 ST8SIA4;SLCO4C1 
Coffee users vs. non users 5 rs960452 7.3E-05 CAMK4 
1.1E-06 
Supine EP 5 rs9326835 8.8E-04 CAMK4 
Coffee users vs. non users 5 rs4835804 6.1E-05 SNX2;SNCAIP 
7.5E-07 
Standing NE  5 rs4835804 6.9E-04 SNX2;SNCAIP 
Thigh mid circumference  5 rs6881950 1.1E-04 ODZ2 
7.9E-07 
SBP response to mental stress 5 rs1472356 4.2E-04 ODZ2 
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Average sitting DBP 6 rs1364557 6.3E-05 FARS2 
7.5E-07 
Thigh distal circumference  6 rs10484311 6.6E-04 FARS2 
Coffee users vs. non users 6 rs9321180 8.9E-05 
ARHGAP18;C6orf1
91 
5.3E-07 
Former vs. never tobacco 
users 
6 rs9321180 3.3E-04 
ARHGAP18;C6orf1
91 
Never vs. ever tobacco users 7 rs7800027 2.5E-05 DGKB 
4.2E-07 
Skinfold subscapular 7 rs7810871 9.0E-04 DGKB 
Standing EP 8 rs1499682 9.0E-04 CSMD1 
1.5E-12 
Standing EP 8 rs2100119 5.7E-04 CSMD1 
Coffee users vs. non users 8 rs810437 4.7E-04 CSMD1 
Never vs. ever tobacco users 8 rs810437 4.9E-04 CSMD1 
Wake DBP 8 rs1350307 2.2E-04 CSMD1 
Body fat percentage 
bioimpedance 
8 rs1350307 5.1E-04 CSMD1 
Wake DBP 8 rs1673243 2.4E-04 CSMD1 
Body fat percentage 
bioimpedance 
8 rs1673243 5.9E-04 CSMD1 
Waist Hip ratio 8 rs10503296 6.5E-04 CSMD1 
Wake HR 8 rs10503484 7.0E-04 SGCZ 
3.0E-10 Current vs. never tobacco 
users 
8 rs1381418 7.8E-04 SGCZ 
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Hip Thigh Proximal ratio 8 rs2035141 1.3E-06 SGCZ 
Supine EP 8 rs2299594 8.9E-04 PCM1 
2.3E-10 
Coffee users vs. non users 8 rs2299594 9.9E-04 PCM1 
Never vs. ever tobacco users 8 rs208756 3.2E-04 PCM1 
Never vs. ever tobacco users 8 rs3739401 1.5E-04 PCM1 
Skinfold suprailiac 8 rs3739401 3.4E-04 PCM1 
Hip circumference  8 rs10503607 4.1E-04 PCM1 
Never vs. ever tobacco users 8 rs10503607 8.4E-04 PCM1 
Thigh mid circumference  8 rs10503649 5.0E-04 CSGALNACT1 
1.2E-06 Current vs. never tobacco 
users 
8 rs10503658 1.4E-04 CSGALNACT1 
Skinfold biceps 8 rs421501 5.7E-05 PXMP3;PKIA 
6.0E-07 
Mean ambulatory DBP 8 rs421501 5.8E-04 PXMP3;PKIA 
Sleep PP 9 rs1434276 3.4E-04 PTPRD 
3.0E-12 
Skinfold thigh 9 rs867980 2.0E-04 PTPRD 
Supine EP 9 rs664921 4.1E-05 PTPRD 
Never vs. ever tobacco users 9 rs725262 1.3E-04 PTPRD 
Sleep HR 9 rs2378665 3.0E-05 SLC28A3;RMI1 
2.3E-07 
Average sitting DBP 9 rs2378665 3.9E-04 SLC28A3;RMI1 
Hip Thigh Proximal ratio 10 rs4933268 7.5E-04 NRG3 7.0E-08 
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Hip Thigh Proximal ratio 10 rs7069222 9.8E-04 NRG3 
Former vs. never tobacco 
users 
10 rs1336274 4.6E-06 NRG3 
Hip Thigh Proximal ratio 11 rs3905300 7.9E-04 ODZ4 
2.9E-09 Response NE 11 rs10501444 3.2E-05 ODZ4 
SBP response to mental stress 11 rs10501444 3.2E-04 ODZ4 
Thigh distal circumference  11 rs4143314 9.1E-04 DLG2 
7.5E-13 
Wake MAP 11 rs1384753 2.7E-05 DLG2 
Hip circumference  11 rs1384754 4.4E-04 DLG2 
DBP response to mental stress 11 rs10501570 1.6E-05 DLG2 
Response EP 11 rs651661 9.5E-04 DLG2 
Skinfold thigh 11 rs473968 9.0E-04 DLG2 
Skinfold thigh 11 rs1213257 2.0E-04 DLG2 
Coffee users vs. non users 11 rs16915547 6.2E-06 CHORDC1 
8.1E-08 Former vs. never tobacco 
users 
11 rs16915547 6.4E-04 CHORDC1 
HR response to mental stress 12 rs4414322 3.1E-04 ITPR2 
7.7E-09 
HR response to mental stress 12 rs708156 1.0E-03 ITPR2 
Supine NE  12 rs10506006 1.4E-04 ITPR2 
Current vs. former tobacco 
users 
12 rs728009 5.3E-04 ITPR2 
Current vs. former tobacco 12 rs10506011 9.0E-04 ITPR2 
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users 
Mean ambulatory HR 12 rs10492303 4.4E-05 MDM1;RAP1B 
5.1E-07 
Mean ambulatory DBP 12 rs10492303 6.3E-04 MDM1;RAP1B 
Coffee users vs. non users 12 rs4762559 2.3E-05 ANKS1B 
4.5E-08 
Never vs. ever tobacco users 12 rs4762559 3.4E-04 ANKS1B 
Coffee users vs. non users 12 rs10507107 4.2E-05 ANKS1B 
Never vs. ever tobacco users 12 rs10507107 9.3E-05 ANKS1B 
Hip circumference  13 rs3803261 4.6E-04 OLFM4 
2.0E-12 
Waist circumference  13 rs3803260 7.5E-05 OLFM4 
Never vs. ever tobacco users 13 rs3803260 8.2E-04 OLFM4 
Alcohol users vs. non users 13 rs7997432 9.8E-05 OLFM4 
Coffee users vs. non users 13 rs7997432 3.4E-04 OLFM4 
Coffee users vs. non users 13 rs9285197 4.0E-05 OLFM4 
Skinfold biceps 13 rs10507651 8.1E-05 TDRD3 
9.2E-07 
Sleep MAP 13 rs10507651 6.4E-04 TDRD3 
Coffee users vs. non users 13 rs7981910 5.5E-05 GPC6 
1.8E-12 
Hip Thigh Proximal ratio 13 rs4412846 7.0E-04 GPC6 
Hip Thigh Proximal ratio 13 rs920956 1.7E-04 GPC6 
Mean ambulatory SBP 13 rs1584147 5.5E-04 GPC6 
Hip Thigh Proximal ratio 13 rs1933146 1.2E-04 GPC6 
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Hip Thigh Proximal ratio 13 rs9284276 1.1E-04 GPC6 
Supine NE  13 rs9284276 8.9E-04 GPC6 
Hip Thigh Proximal ratio 13 rs6650320 4.4E-05 GPC6 
Supine NE  13 rs6650320 1.6E-04 GPC6 
Hip Thigh Proximal ratio 13 rs6650321 6.6E-05 GPC6 
Sleep HR 14 rs1954668 5.7E-04 NOVA1 
5.0E-08 Alcohol users vs. non users 14 rs1954673 3.7E-04 NOVA1 
Coffee users vs. non users 14 rs1954673 8.7E-04 NOVA1 
Average sitting HR 15 rs10519074 4.2E-04 RORA 
2.2E-09 
Skinfold subscapular 15 rs10519076 3.1E-04 RORA 
Skinfold thigh 15 rs10519095 3.6E-04 RORA 
Wake MAP 15 rs726914 9.1E-05 RORA 
Wake MAP 15 rs726913 4.8E-05 RORA 
Skinfold subscapular 16 rs9302844 3.6E-05 A2BP1 
9.7E-08 Supine EP 16 rs740676 1.4E-04 A2BP1 
Supine EP 16 rs763650 1.3E-04 A2BP1 
Coffee users vs. non users 17 rs2469828 1.1E-04 TMEM99;KRT12 
3.6E-07 
Never vs. ever tobacco users 17 rs2469828 1.8E-04 TMEM99;KRT12 
Coffee users vs. non users 18 rs10502334 1.4E-04 L3MBTL4;EPB41L3 
9.4E-07 
Hip Thigh Proximal ratio 18 rs10502334 3.9E-04 L3MBTL4;EPB41L3 
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Coffee users vs. non users 18 rs640128 4.7E-04 PTPRM 
2.1E-08 
SBP response to mental stress 18 rs4798593 2.1E-06 PTPRM 
SBP response to mental stress 18 rs4890429 6.2E-05 RIT2;SYT4 
3.2E-07 
BMI 18 rs4890429 2.8E-04 RIT2;SYT4 
Coffee users vs. non users 20 rs6135159 7.0E-05 MACROD2 
1.1E-07 
Current vs. non tobacco users 20 rs10485518 7.7E-05 MACROD2 
Current vs. former tobacco 
users 
20 rs10485531 5.6E-04 MACROD2 
Current vs. former tobacco 
users 
20 rs2023385 7.5E-04 MACROD2 
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Table 7. Hypertension-specific and sex-specific candidate loci driven by joint linkage and family-based association analysis 
Status Chr Trait 
Linkage
 
Association
Corrected 
P LOD 
Score 
cM 
Number of 
SNPs1 
  SNP P Gene 
Hypertensives 1 Body fat percentage bioimpedance 2.8 188-192 113
 
rs7526653 4.4E-05 DNM3 5.0E-03
   
113
 
rs9286842 3.1E-04 DNM3 3.5E-02
   
113
 
rs2861812 6.4E-05 PAPPA2 7.2E-03
Hypertensives 1 Hip circumference  2.65 184-189 64
 
rs593479 1.7E-04 PRRX1 1.1E-02
Hypertensives 1 Thigh distal circumference 2.83 166-176 92
 
rs2841979 1.3E-05 RGS4;C1orf110 1.2E-03
Hypertensives 1 Thigh proximal circumference 2.9 187-191 76
 
rs593479 8.6E-05 PRRX1 6.5E-03
Hypertensives 3 Hip circumference  2.5 170-172 57
 
rs1874952 6.1E-04 KCNAB1 3.5E-02
Normotensives 4 Sleep HR 2.3 80-88 126
 
rs7700235 1.7E-04 ADAMTS3 2.1E-02
   
126
 
rs788910 2.7E-04 ADAMTS3 3.4E-02
                                                            
1 Numbers of SNPs that are within 1 LOD-drop interval around the linkage peak. 
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Hypertensives 5 Skinfold subscapular 3.1 36-40 51
 
rs10520888 4.4E-04 PRDM9;CDH12 2.3E-02
Normotensives 5 Standing EP 2 120-127 77
 
rs254150 1.6E-04 COMMD10;SEMA6A 1.2E-02
Hypertensives 6 Hip circumference  3.8 27-29 5
 
rs4486015 3.3E-04 DTNBP1;MYLIP 1.6E-03
Hypertensives 10 Hip circumference  2.8 59-61 18
 
rs2065443 1.4E-04 ARHGAP12 2.4E-03
   
18
 
rs1775715 2.2E-04 KIF5B 4.0E-03
Normotensives 11 HR response to mental stress 3.9 18-25 114
 
rs4757397 2.9E-04 SOX6 3.3E-02
Normotensives 15 Waist Hip ratio 2 49-56 90
 
rs10519116 9.7E-05 RORA 8.7E-03
Hypertensives 16 Hip Thigh Proximal ratio 3.3 28-36 51
 
rs2023763 2.3E-04 SYT17;TMC5 1.2E-02
Hypertensives 21 Skinfold biceps 2.46 34-45 104
 
rs2249248 1.4E-04 DSCAM;BACE2 1.5E-02
Males 1 Body fat percentage bioimpedance 2.02 186-206 320
 
rs4471302 1.4E-04 DNM3 4.5E-02
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Females 13 Mean skinfold suprailiac 2.1 44-45.5 14
 
rs3803261 2.8E-04 OLFM4 4.0E-03
Females 17 Wake PP 2.03 90-102 101
 
rs10512596 6.0E-06 CD300LB 6.0E-04
  
 
    rs783250 5.3E-05 CD300LB 5.4E-03
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Table 8. Hypertension-specific and sex-specific shared candidate SNPs among the studied traits driven from family based association analysis 
Status Trait Chr SNP P Gene Combined P 
Normotensives Supine EP 4 rs6855889 5.7E-04 CPE 
2.3E-08 
Normotensives Skinfold thigh 4 rs7692208 3.0E-04 CPE 
Normotensives Alcohol users vs. non users 4 rs10517848 9.6E-04 CPE 
Normotensives Skinfold thigh 4 rs10517848 9.4E-04 CPE 
Normotensives Alcohol users vs. non users 4 rs4481204 4.6E-04 CPE 
Normotensives Supine EP 4 rs1898593 6.8E-04 CPE 
Normotensives Wake MAP 4 rs4128165 1.7E-04 GLRA3 
9.8E-07 Normotensives Skinfold biceps 4 rs1352055 7.0E-04 GLRA3 
Normotensives Skinfold biceps 4 rs1385832 3.3E-04 GLRA3 
Normotensives Overall PP 5 rs4913079 2.4E-04 PFDN1;HBEGF 
4.9E-07 
Normotensives Waist circumference  5 rs4913079 1.1E-04 PFDN1;HBEGF 
Normotensives Waist circumference  7 rs1880610 7.9E-04 SDK1 1.1E-08 
118 
 
 
Normotensives Thigh distal circumference  7 rs10499327 1.4E-04 SDK1 
Normotensives Coffee users vs. non users 7 rs956393 4.0E-04 SDK1 
Normotensives Coffee users vs. non users 7 rs10485876 3.4E-04 SDK1 
Normotensives HR response to mental stress 7 rs10485873 7.4E-04 SDK1 
Normotensives Standing EP 15 rs7166370 3.4E-05 RORA 
6.8E-08 
Normotensives Waist Hip ratio 15 rs10519116 9.7E-05 RORA 
Hypertensives Coffee users vs. non users 5 rs10515427 3.0E-04 CAMK4 
8.0E-07 
Hypertensives Coffee users vs. non users 5 rs306079 6.0E-04 CAMK4 
Hypertensives Skinfold subscapular 5 rs306079 4.2E-04 CAMK4 
Hypertensives Coffee users vs. non users 5 rs10491334 3.4E-04 CAMK4 
Hypertensives Coffee users vs. non users 5 rs9326835 1.1E-04 CAMK4 
Hypertensives Hip circumference  5 rs10515597 3.4E-04 SPINK5 
2.1E-07 Hypertensives DBP response to mental stress 5 rs10515597 1.3E-04 SPINK5 
Hypertensives Hip circumference  5 rs10515599 8.6E-05 SPINK5 
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Hypertensives DBP response to mental stress 5 rs10515599 3.2E-04 SPINK5 
Hypertensives Sleep SBP 6 rs6905827 7.0E-04 MAN1A1 
6.2E-07 
Hypertensives Never vs. ever tobacco users 6 rs6905827 4.9E-05 MAN1A1 
Hypertensives Current vs. never tobacco users 6 rs1028571 8.9E-04 NKAIN2 
4.7E-08 
Hypertensives Current vs. non tobacco users 6 rs1028572 2.2E-04 NKAIN2 
Hypertensives Supine EP 6 rs2552085 8.6E-04 NKAIN2 
Hypertensives Overall PP 6 rs1842129 9.3E-04 NKAIN2 
Hypertensives Skinfold triceps 8 rs17079530 5.7E-04 CSMD1 
1.2E-06 
Hypertensives Sleep PP 8 rs10503263 1.2E-04 CSMD1 
Hypertensives Skinfold triceps 9 rs10511522 2.9E-04 PTPRD 
9.3E-09 Hypertensives Never vs. ever tobacco users 9 rs768224 1.0E-04 PTPRD 
Hypertensives Mean ambulatory HR 9 rs7023147 9.6E-04 PTPRD 
Hypertensives Mean ambulatory HR 10 rs10509265 7.5E-04 CTNNA3 7.4E-07 
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Hypertensives Coffee users vs. non users 10 rs2894028 5.5E-05 CTNNA3 
Hypertensives Wake MAP 11 rs726533 4.1E-04 CNTN5 
5.0E-07 
Hypertensives Waist circumference  11 rs726533 6.6E-05 CNTN5 
Hypertensives Hip circumference  13 rs1927762 9.4E-07 FAM155A 
2.5E-09 
Hypertensives Former vs. current and never tobacco users 13 rs3905075 1.1E-04 FAM155A 
Hypertensives Coffee users vs. non users 14 rs1955639 4.1E-04 C14orf37 
1.1E-06 
Hypertensives Thigh proximal circumference  14 rs178493 1.6E-04 C14orf37 
Hypertensives Hip circumference  18 rs8091206 1.4E-04 ZNF532 
1.0E-06 
Hypertensives Former vs. current and never tobacco users 18 rs8091206 4.3E-04 ZNF532 
Females Never vs. ever tobacco users 3 rs339287 3.9E-05 CNTN4 
4.0E-07 
Females Waist Hip ratio 3 rs339286 5.6E-04 CNTN4 
Females Wake HR 3 rs304039 6.5E-04 ITPR1 1.8E-09 
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Females Average sitting DBP 3 rs3804992 3.7E-05 ITPR1 
Females Skinfold subscapular 3 rs4685834 2.0E-04 ITPR1 
Females Skinfold subscapular 3 rs9284900 2.5E-04 FHIT 
1.9E-08 
Females Average sitting HR 3 rs213342 8.9E-04 FHIT 
Females Waist circumference  3 rs1882898 2.4E-04 FHIT 
Females Waist circumference  3 rs1882899 9.1E-05 FHIT 
Females Waist circumference  3 rs963685 8.1E-05 FHIT 
Females Response NE 3 rs7631068 8.8E-04 FHIT 
Females Coffee users vs. non users 3 rs2089352 3.1E-04 CADPS 
3.7E-07 
Females Mean ambulatory HR 3 rs523320 6.4E-05 CADPS 
Females SBP response to mental stress 3 rs583911 5.5E-05 IL12A 
6.7E-07 
Females Current vs. never tobacco users 3 rs583911 6.7E-04 IL12A 
Females Alcohol users vs. non users 4 rs10519407 5.2E-04 PCDH18 6.8E-11 
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Females Alcohol users vs. non users 4 rs1011403 1.1E-04 PCDH18 
Females Alcohol users vs. non users 4 rs1517945 1.1E-04 PCDH18 
Females Alcohol users vs. non users 4 rs1517946 1.1E-04 PCDH18 
Females HR response to mental stress 4 rs633403 2.9E-04 PCDH18 
Females HR response to mental stress 4 rs536520 3.6E-04 PCDH18 
Females Thigh mid circumference  4 rs534612 4.5E-04 PCDH18 
Females Alcohol users vs. non users 4 rs10519412 1.4E-04 PCDH18 
Females Response NE 4 rs1816176 7.5E-04 PCDH18 
Females Thigh distal circumference  4 rs1816176 8.6E-04 PCDH18 
Females Coffee users vs. non users 5 rs1392452 6.8E-05 CDH6 
2.3E-07 
Females Waist Hip ratio 5 rs1392452 1.7E-04 CDH6 
Females Skinfold thigh 6 rs9294628 9.3E-04 EYS 
3.8E-09 Females Waist Hip ratio 6 rs10485054 7.1E-05 EYS 
Females Current vs. former tobacco users 6 rs10485054 3.6E-04 EYS 
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Females Current vs. never tobacco users 6 rs974110 2.6E-04 EYS 
Females Current vs. former tobacco users 6 rs354362 8.1E-04 EYS 
Females Mean ambulatory SBP 6 rs10484935 5.9E-04 EYS 
Females BMI 6 rs9294806 1.4E-04 BAI3 
9.4E-07 Females Waist Hip ratio 6 rs10485434 2.0E-04 BAI3 
Females Never vs. ever tobacco users 6 rs10485433 3.8E-04 BAI3 
Females Mean ambulatory SBP 7 rs4385381 8.7E-04 INHBA 
9.1E-08 
Females Thigh distal circumference  7 rs4385381 7.2E-04 INHBA 
Females BMI 7 rs1014106 7.8E-04 INHBA 
Females Former vs. never tobacco users 7 rs1014106 5.6E-04 INHBA 
Females Waist Hip ratio 12 rs816203 1.9E-04 KSR2 
9.6E-07 
Females Response NE 12 rs1878419 2.9E-04 KSR2 
Females BMI 13 rs10507433 4.3E-05 DCLK1 8.1E-08 
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Females Current vs. non tobacco users 13 rs7334245 9.3E-05 DCLK1 
Females Current vs. never tobacco users 13 rs9315383 8.1E-04 DCLK1 
Females Coffee users vs. non users 14 rs766146 2.3E-04 STRN3 
4.1E-10 
Females Waist Hip ratio 14 rs766146 9.7E-05 STRN3 
Females Coffee users vs. non users 14 rs9322866 6.2E-05 STRN3 
Females Waist Hip ratio 14 rs9322866 1.8E-05 STRN3 
Females DBP response to mental stress 14 rs9322866 9.0E-04 STRN3 
Females Coffee users vs. non users 14 rs1179966 7.2E-05 SLC25A21 
1.2E-06 
Females Skinfold subscapular 14 rs1956425 9.5E-04 SLC25A21 
Females Waist circumference  14 rs10483492 8.5E-04 C14orf25 
1.3E-06 Females Wake PP 14 rs728087 9.0E-05 C14orf25 
Females Wake SBP 14 rs6571820 5.5E-04 C14orf25 
Females Coffee users vs. non users 14 rs7150974 5.3E-04 NRXN3 4.3E-07 
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Females Wake HR 14 rs7141526 4.4E-05 NRXN3 
Males Skinfold thigh 3 rs1873038 5.4E-04 NLGN1 
2.5E-08 
Males Sleep HR 3 rs725802 8.1E-04 NLGN1 
Males Sleep HR 3 rs725800 7.6E-04 NLGN1 
Males DBP response to mental stress 3 rs4894664 2.0E-04 NLGN1 
Males Sleep HR 7 rs847936 5.5E-05 VWDE;SCIN 
8.8E-07 
Males Never vs. ever tobacco users 7 rs847936 9.0E-04 VWDE;SCIN 
Males Waist Hip ratio 8 rs10504932 4.4E-04 CDH17;PDP1 
2.7E-07 
Males Former vs. current and never tobacco users 8 rs10504932 3.3E-05 CDH17;PDP1 
Males Coffee users vs. non users 8 rs10505508 1.7E-04 PVT1 
1.1E-06 
Males Former vs. current and never tobacco users 8 rs10505508 3.6E-04 PVT1 
Males Sleep HR 8 rs10505551 7.7E-04 ADCY8;ASAP1 
8.6E-07 
Males Skinfold subscapular 8 rs10505551 6.3E-05 ADCY8;ASAP1 
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Males Waist circumference  12 rs958644 8.2E-04 PTPRR 
6.0E-07 
Males Mean skinfold subscapular 12 rs10506604 6.1E-05 PTPRR 
Males Sleep DBP 12 rs2458439 5.4E-04 PTPRR 
Males Sleep DBP 12 rs2458437 7.1E-04 PTPRR 
Males Alcohol users vs. non users 12 rs10506912 3.2E-04 LRRIQ1 
5.9E-07 
Males Coffee users vs. non users 12 rs10506912 1.0E-04 LRRIQ1 
Males Coffee users vs. non users 12 rs2404772 8.8E-04 LRRIQ1 
Males Alcohol users vs. non users 12 rs1159869 5.8E-04 LRRIQ1 
Males Coffee users vs. non users 12 rs1159869 2.1E-04 LRRIQ1 
Males Current vs. non tobacco users 13 rs596425 1.4E-04 SGCG 
7.7E-07 Males Current vs. non tobacco users 13 rs512444 3.1E-04 SGCG 
Males Standing NE  13 rs1359978 3.1E-04 SGCG 
Males Waist circumference  13 rs10507737 4.0E-05 PCDH9 6.6E-07 
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Males HR response to mental stress 13 rs10507737 9.1E-04 PCDH9 
Males Waist Hip ratio 13 rs10507739 5.5E-04 PCDH9 
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Table 9. Comparing the gene expression profiles among the shared genes driven from general analysis, sex-specific and hypertension-specific analysis 
General Sex-specific Hypertension-specific 
Tissue N Mean SE Tissue N Mean SE Tissue N Mean SE 
Temporal lobe 60 0.33 0.1 Cerebellum 27 0.31 0.2 Cerebellum 16 0.62 0.3 
Occipital lobe 60 0.32 0.1 Accumbens 27 0.31 0.1 Temporal lobe 16 0.56 0.3 
Accumbens 60 0.32 0.1 Occipital lobe 27 0.30 0.2 Amygdala 16 0.52 0.2 
Frontal lobe 60 0.32 0.1 Parietal lobe 27 0.30 0.2 Accumbens 16 0.52 0.3 
Parietal lobe 60 0.32 0.1 Frontal lobe 27 0.29 0.1 Parietal lobe 16 0.52 0.3 
Amygdala 60 0.29 0.1 Putamen 27 0.29 0.1 Cerebral cortex 16 0.50 0.3 
Cerebral cortex 60 0.29 0.1 Temporal lobe 27 0.27 0.1 Putamen 16 0.50 0.3 
Dorsal root ganglia 60 0.28 0.1 Amygdala 27 0.27 0.1 Frontal lobe 16 0.50 0.2 
Putamen 60 0.27 0.1 Cerebral cortex 27 0.27 0.1 Occipital lobe 16 0.49 0.3 
Hippocampus 60 0.26 0.1 Hippocampus 27 0.25 0.1 Hippocampus 16 0.49 0.2 
Thalamus 60 0.24 0.1 Spinal cord 27 0.23 0.2 Medulla 16 0.44 0.3 
Hypothalamus 60 0.23 0.1 
 
Ventral tegmental 
area 
27 0.22 0.1 
 
Nodose nucleus 16 0.43 0.3 
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Cerebellum 60 0.23 0.1 Vestibular nuclei sup 27 0.21 0.1 Corpus callosum 16 0.43 0.3 
Vestibular nuclei sup 60 0.22 0.1 Thalamus 27 0.21 0.1 Spinal cord 16 0.41 0.3 
Trigeminal ganglia 60 0.20 0.1 Medulla 27 0.20 0.1 Midbrain 16 0.39 0.3 
Medulla 60 0.19 0.1 Substantia nigra 27 0.16 0.1 Substantia nigra 16 0.38 0.2 
Ventral tegmental area 60 0.16 0.1 Midbrain 27 0.16 0.1 Hypothalamus 16 0.38 0.2 
Spinal cord 60 0.16 0.1 Heart atrium 27 0.11 0.2 Thalamus 16 0.38 0.2 
Midbrain 60 0.15 0.1 Hypothalamus 27 0.10 0.1 Vestibular nuclei sup 16 0.38 0.2 
Substantia nigra 60 0.10 0.1 Saphenous vein 27 0.10 0.1 Subthalamic nucleus 16 0.37 0.3 
Heart atrium 60 0.09 0.1 Colon cecum 27 0.09 0.1 Ventral tegmental area 16 0.36 0.2 
Corpus callosum 60 0.05 0.1 Dorsal root ganglia 27 0.07 0.1 Cervix 16 0.13 0.2 
Pituitary gland 60 0.04 0.1 Heart ventricle 27 0.07 0.2 Vagina 16 0.11 0.2 
Vagina 60 0.03 0.1 Subthalamic nucleus 27 0.06 0.1 Dorsal root ganglia 16 0.05 0.2 
Heart ventricle 60 0.03 0.1 Nodose nucleus 27 0.05 0.1 Trigeminal ganglia 16 0.01 0.2 
Cervix 60 0.03 0.1 Coronary artery 27 0.03 0.1 Esophagus 16 -0.04 0.4 
Nodose nucleus 60 0.02 0.1 Trigeminal ganglia 27 0.03 0.1 Tongue main corpus 16 -0.07 0.3 
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Adipose omental 60 0.02 0.1 Cervix 27 0.03 0.1 Saphenous vein 16 -0.09 0.2 
Testes 60 0.01 0.1 Pituitary gland 27 0.02 0.1 Pharyngeal mucosa 16 -0.09 0.4 
Subthalamic nucleus 60 0.00 0.1 Corpus callosum 27 0.02 0.1 Pituitary gland 16 -0.09 0.1 
Urethra 60 -0.01 0.2 Tongue main corpus 27 0.01 0.2 Coronary artery 16 -0.10 0.1 
Skeletal muscle 60 -0.01 0.1 Trachea 27 0.01 0.1 Urethra 16 -0.11 0.2 
Kidney cortex 60 -0.03 0.1 Urethra 27 -0.01 0.1 Vulva 16 -0.11 0.4 
Colon cecum 60 -0.05 0.1 Myometrium 27 -0.02 0.1 Adipose omental 16 -0.12 0.1 
Prostate gland 60 -0.06 0.1 Adipose omental 27 -0.03 0.1 Prostate gland 16 -0.13 0.2 
Thyroid gland 60 -0.07 0.1 Esophagus 27 -0.04 0.1 Ovary 16 -0.14 0.2 
Tongue main corpus 60 -0.08 0.1 Vagina 27 -0.05 0.1 Myometrium 16 -0.16 0.1 
Coronary artery 60 -0.09 0.1 Stomach fundus 27 -0.06 0.1 Tonsil 16 -0.16 0.3 
Kidney medulla 60 -0.10 0.1 Mammary gland 27 -0.06 0.1 Oral mucosa 16 -0.18 0.5 
Adrenal gland cortex 60 -0.10 0.1 
 
Adipose 
subcutaneous 
27 -0.06 0.1 
 
Adipose 16 -0.19 0.1 
Ovary 60 -0.11 0.1 Stomach cardiac 27 -0.07 0.1 Nipple cross.Section 16 -0.19 0.3 
Mammary gland 60 -0.12 0.1 Pharyngeal mucosa 27 -0.08 0.1 Colon cecum 16 -0.20 0.1 
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Lung 60 -0.12 0.1 
 
Tongue superior 
part 
27 -0.08 0.1 
 
Tongue superior part 16 -0.21 0.3 
Stomach cardiac 60 -0.14 0.1 Bronchus 27 -0.10 0.1 Endometrium 16 -0.21 0.2 
Stomach fundus 60 -0.15 0.1 Skeletal muscle 27 -0.10 0.2 Mammary gland 16 -0.25 0.2 
Adipose 60 -0.15 0.1 Kidney cortex 27 -0.13 0.2 Bronchus 16 -0.25 0.1 
Bone marrow 60 -0.16 0.2 Nipple cross.Section 27 -0.13 0.1 Adipose subcutaneous 16 -0.27 0.1 
Bronchus 60 -0.16 0.1 Kidney medulla 27 -0.14 0.2 Heart atrium 16 -0.27 0.1 
Adipose subcutaneous 60 -0.16 0.1 Salivary gland 27 -0.14 0.1 Stomach fundus 16 -0.27 0.1 
Oral mucosa 60 -0.17 0.1 Ovary 27 -0.14 0.1 Thyroid gland 16 -0.27 0.2 
Esophagus 60 -0.17 0.1 Lung 27 -0.15 0.1 Kidney medulla 16 -0.28 0.1 
Trachea 60 -0.18 0.1 Endometrium 27 -0.16 0.1 Trachea 16 -0.28 0.1 
Lymph nodes 60 -0.18 0.1 Adipose 27 -0.17 0.1 Kidney cortex 16 -0.29 0.3 
Tongue superior part 60 -0.19 0.1 Oral mucosa 27 -0.17 0.1 Heart ventricle 16 -0.31 0.1 
Myometrium 60 -0.19 0.1 Adrenal gland cortex 27 -0.19 0.1 Lymph nodes 16 -0.33 0.2 
Stomach pyloric 60 -0.19 0.1 Stomach pyloric 27 -0.19 0.1 Lung 16 -0.33 0.1 
Endometrium 60 -0.19 0.1 Prostate gland 27 -0.21 0.1 Stomach cardiac 16 -0.34 0.1 
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Vulva 60 -0.20 0.1 Lymph nodes 27 -0.21 0.1 Skeletal muscle 16 -0.36 0.2 
Pharyngeal mucosa 60 -0.21 0.1 Thyroid gland 27 -0.22 0.1 Adrenal gland cortex 16 -0.36 0.1 
Spleen 60 -0.21 0.1 Spleen 27 -0.24 0.1 Stomach pyloric 16 -0.37 0.2 
Nipple cross.Section 60 -0.21 0.1 Vulva 27 -0.27 0.1 Testes 16 -0.39 0.1 
Liver 60 -0.22 0.1 Testes 27 -0.30 0.1 Salivary gland 16 -0.46 0.1 
Salivary gland 60 -0.23 0.1 Bone marrow 27 -0.31 0.1 Spleen 16 -0.49 0.3 
Saphenous vein 60 -0.24 0.1 Tonsil 27 -0.33 0.1 Liver 16 -0.55 0.3 
Tonsil 60 -0.34 0.1 Liver 27 -0.45 0.1 Bone marrow 16 -0.57 0.3 
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Figure 1. Joint linkage and 
association analysis identified 
SNPs inside ITPR2 gene 
associated to tobacco use and 
HR response within a common 
area of linkage for these traits 
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Figure 2. Gene expression heat map for commonly 
associated genes driven from general analysis 
across 65 human tissues 
The largest gene expression values are displayed in 
red, the smallest values in blue and intermediate 
values in shades of red (pink) or blue. Unlike other 
tissues, the identified genes tend to display similar 
expression profiles in cluster of brain tissues 
including Brain lobes, Cerebral cortex, Amygdala, 
Hippocampus and Putamen (marked with dashed 
black box). 
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Figure 3. Overview of protein 
interactions among genes 
driven from general, sex-
specific and hypertension-
specific analysis 
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Figure 4. Hypothetical model of interaction among stress, synaptic plasticity, substance use obesity and related-cardiovascular outcomes
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3.1 Abstract 
To gain an understanding of interactions between tobacco use with obesity, 
hypertension and stress, we investigated the phenotypic and genotypic relatedness of 
smoking initiation and persistence with obesity, hemodynamic and stress related traits in a 
cohort of 119 multigenerational French Canadian families from founder population of 
Saguenay–Lac St-Jean region.  
Obesity-related anthropometric traits, 24-hour heart rate (HR) and blood pressure 
(BP) data including response to and recovery from mental stress of mathematical test as 
well as changes in plasma catecholamine levels after orthostatic test were assessed and 
combined with smoking data collected during clinical interviews. Following analysis of 
phenotypic correlations, tobacco use and significantly correlated obesity, hemodynamic and 
stress related traits with tobacco use (P < 0.05) were subjected to univariate and bivariate 
general, sex- and hypertension-specific family-based genome wide scan using 50K array 
Affymetrix GeneChip in order to identify the significantly shared loci.  
Our findings indicate that the degree and direction of relatedness of tobacco 
smoking with obesity, hemodynamic and stress related traits vary according to sex and 
hypertension status; for instance, while in males, current tobacco users were slender 
compared to never or former tobacco users, there were no such differences in females; 
moreover, we found several obesity related traits that their correlations with smoking 
behavior seemingly root in genetic factors rather than smoking effect itself. Shared SNPs 
reached genome-wide significance (P < 1.4×10-6) were identified between tobacco use with 
hemodynamic, obesity and stress related traits including SNP, rs679783 inside AGBL4 
(Combined P = 2.3×10-7) identified through general analysis; and SNPs, rs947084 inside 
OBSCN (Combined P = 1.2×10-6) as well as rs36950 inside KCNN2 gene (Combined P = 
8.1×10-8) identified through subgroup analysis; in addition, bivariate association analysis 
further supports the significance of these findings; moreover, rs679783 was significantly 
associated to both smoking initiation and persistence, rs947084 was significantly associated 
to smoking initiation and rs36950 was significantly associated to smoking persistence 
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which point to presence of genetic similarities and differences between current and former 
tobacco users. In summary, consistent with phenotypic relatedness we identified shared 
SNPs between tobacco use and significantly correlated obesity, hemodynamic and stress 
related traits; moreover, our findings underline the importance of subgroup analysis and 
emphasize the shortcoming of satirical adjustments.  
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3.2 Introduction 
Although tobacco use and stress are related traits but the identity of this relation 
appears to be complex and paradoxical. Enhancing the positive moods and relief from 
stress and negative affections are among the main reasons for smoking,1; 2 it is also reported 
that concurrent chronic nicotine treatment and stress prevents stress-induced impairment of 
Long-Term Potentiation pathway (LTP);3 however, other studies reported that smoking 
does not reduce, and in some cases enhances the physiological effects of stress.4; 5 
Tobacco use is also related to hypertension; tobacco smoking temporarily raises 
blood pressure (BP) and heart rate (HR); nonetheless, the relationship between chronic 
smoking and development of high blood pressure is unclear and controversial while some 
studies reported no effect or positive correlation, other studies pointed that smokers have 
lower BP compare to former and non smokers.6-8 
Due to numerous health benefits, smoking cession is highly recommended but it is 
also accompanied with weight gain which indicates an invert relationship between tobacco 
use and body weight; smokers weight less than nonsmokers of the same age and gender.9-11 
In fact, nicotine administration alters food intake and body weight in both animals and 
humans and nicotinic receptors have been found in hypothalamic appetite-regulating areas 
suggesting that centrally mediated actions of nicotine may contribute to the reduced 
appetite and body weight loss;12 in contrast, number of studies found that heavy smokers 
tend to have greater body weight than light smokers or non smokers and smoking is 
conducive to greater accumulation of visceral fat and increase in waist circumferences.10; 13; 
14 
Phenotypic correlations particularly among complex disorders can be in part due to 
genotypic relatedness.15; 16 therefore, the relatedness of obesity, stress and hemodynamic 
traits with tobacco use may be in part due to genotypic overlaps. In this context, former 
smoking and current smoking data may help to further investigate whether the observed 
correlation between tobacco use and obesity, hemodynamic and stress related traits roots in 
environmental effect (smoking effect) and/or the influence of genetic determinants. 
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Hence, to investigate the interaction between tobacco use with hypertension, obesity 
and stress, we probed the phenotypic relatedness of smoking initiation and persistence with 
hemodynamic, obesity and stress related traits in cohort of families from Saguenay-Lac-
Saint-Jean (SLSJ) region.17 Next, tobacco use and significantly correlated traits (P < 0.05) 
with tobacco use were subjected to univariate and bivariate family-based genome wide scan 
in order to identify the significantly shared loci.  
 
3.3 Methodology 
3.3.1 Family cohort 
Families were selected from the population of SLSJ region located in northeastern 
Quebec17 which is representing one of the largest founder populations in North America 
with about 300,000 inhabitants.18 19 
The founder effect observed in the SLSJ region provides several advantages for 
gene finding studies for instance, allelic and locus heterogeneity, a key feature of common 
complex diseases that can obscure the association signal within disease-associated genomic 
regions is lower in founder population compared to general populations, the likelihood of 
population stratification that introduces errors and bias the results is also low in a founder 
population and the large size of LD blocks in these populations reduces the number of 
markers for whole genome scan studies.17; 20; 21 
SLSJ population has been already the site of many genetic studies leading to the 
identification of genes for several monogenomic disorders. A single homozygous mutation 
was identified in 80% of patients with hereditary tyrosinemia type I,22 and only three 
mutations were found in 94% of patients with cystic fibrosis pointing to the reduced genetic 
heterogeneity in this population.23 It is also reported that large blocks of ancestral DNA 
flank the disease mutations in this population;24; 25 furthermore, the availability of extensive 
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genealogical records of this population who has computerized genealogical records dating 
to the original 17th-century settlers provides additional benefits for genetic studies.17 
Details about families and extensive phenotyping have been described previously.17; 
26-28 Among numerous phenotypes monitored in this cohort, those that are investigated in 
this study are described. 
In summary, families with catholic French Canadian origin were ascertained by the 
presence of at least one sib pair with hypertension and dyslipidemia. The exclusion criteria 
included body mass index (BMI) ≥ 35 kg/m2, secondary hypertension, diastolic blood 
pressure (DBP) >110 mmHg and the use of medication, diabetes mellitus, renal or liver 
dysfunction, malignancy, pregnancy, and substance abuse. Following the selection of 
affected sibs, all first- and second-degree relatives aged > 18 years were invited to 
participate in the study. The recruited population included 119 families (average 
generations of 2.58) comprising 897 subjects. The study was reviewed and approved by 
institutional ethics committees of Complexe Hospitalier de la Sagamie, Université du 
Québec à Chicoutimi, as well as the Centre hospitalier de l’Université de Montréal.  
 
3.3.2 Phenotypes 
In the first day of phenotyping, sitting blood pressure was measured and blood 
samples were obtained to extract DNA from leukocytes for genotyping and measuring other 
blood factors. Phenotyping for obesity consisted of 3 global and 11 regional measurements 
of obesity. The global measures included BMI as well as total body fat derived from 
bioimpedance (RJL Systems Inc) and skinfold measurements. The regional measures 
included 6 extremity circumferences in upper arm, waist, hip; and proximal, middle and 
distal thigh; as well as 5 skinfold measurements in biceps, triceps, subscapular, suprailiac 
and thigh. 
Phenotyping for habitual substance use was carried out using questionnaires in 
about 700 subjects during clinical interviews. Those smokes regularly were grouped as 
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current tobacco users and non smokers who used to smoke regularly in the past were 
considered as former tobacco users; in addition, subjects who never or occasionally smoke 
were grouped as unaffected. 
294 subjects without any contraindications were invited for extensive phenotyping 
and had their antihypertensive drugs withdrawn for 1 week and lipid-lowering agents 
withdrawn for 1 month. Full phenotyping was performed in a group of 159 normotensive 
and 135 hypertensive subjects. 
In a quiet room with minimal patient interruptions, a postural test was conducted 
and the plasma epinephrine (EP) and norepinephrine (NE) levels were monitored in blood 
samples taken from subjects during 60 minutes (min) supine and 10 min standing position, 
these data were used as biomarkers of response to physical stress.  
HR and BP changes to the mental stress of mathematical tests were used as markers 
of response to and recovery from mental stress. Subjects were asked to sit for 10 min before 
the test; next, they pass a 2 min arithmetic test. In parallel, HR, DBP and systolic blood 
pressure (SBP) were measured every 5 min before the test (3 times), every 2 min during the 
test (2 times) and every 2 min after the test (6 times). Stress response was defined as the 
differences in the first HR and BP values of math test and the average values of baseline, 
before the test. Stress recovery was defined as the differences in the first HR and BP values 
of math test and the average values of resting position, after the test; moreover, the 
differences between recovery from and response to mental stress was considered as delta 
stress reactivity. 
The mental arithmetic test29 which was a sequence of simple arithmetic problems 
were presented to the subjects by a slide projector. Each problem had two components, a 
simple addition or subtraction followed by a simple multiplication or division. The 
difficulty level increased and was adjusted to assure some failure for all subjects.  
In addition, beginning on the second day of phenotyping, BP and HR were 
measured every 20 min during the day and every 45 min during the night with an 
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Accutracker II monitor (Sun Tech Medical Instruments, Inc.) for 24 hours.17 Using these 
data, the pulse pressure (PP) was defined as the difference between SBP and DBP and 
mean arterial pressure (MAP) was defined as one third SBP plus two third DBP.  
The inverse normal transformation subsequently was used on quantitative 
phenotype data to ensure a normal distribution prior to the analysis. 
 
3.3.3 Phenotypic correlations and statistical adjustments 
The GEE approach implemented in the GNU R statistical package version 2.6.1 was 
utilized to perform correlation tests which accounts for familial correlation via a sandwich 
estimator of the variance under exchangeable correlation.30 31   
GEEs use the generalized linear model to estimate more efficient and unbiased 
regression parameters relative to ordinary least squares regression in part because they 
permit specification of a working correlation matrix that accounts for the form of within-
subject correlation of responses on dependent variables of many different distributions.30 31 
Correlation tests were performed in whole cohort and next separately in males and 
females as well as in hypertensive and normotensive subjects. In entire sample and 
hypertensive and normotensive groups, sex, age, alcohol and coffee use were set as 
covariates in correlation tests and in male and female groups, age, alcohol and coffee use 
were included as covariates. 
 
3.3.4 Genotypes 
Genotyping information has been previously described.17; 27; 28 In summary, 469 
subjects were genotyped with GeneChip® Human Mapping 50K Array Xba240 
(Affymetrix) were analyzed in present study. Possible genotyping errors were detected and 
filtered (~ 0.2 %) using MERLIN package version 1.1.0.32 An exact test of Hardy-
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Weinberg equilibrium (HWE)33 was performed to remove genotypes that significantly 
deviate from HWE using PEDSTATS program implemented in MERLIN package.  
Linkage disequilibrium (LD) among SNPs were calculated using PLINK software version 
1.06.34 SNPs with r2 ≤ 0.8, HWE P-value > 0.001 and MAF > 0.05 were used through the 
analysis. The WGAviewr software version 1.52Z was used to determine the nearby genes 
around each SNP by specifying up- and down-stream span of 500 kbp.35 
 
3.3.5 Genetic analysis 
The degree of correlation between tobacco use initiation and persistence with 
cardiovascular, obesity and stress related traits were calculated. Tobacco use and 
significantly correlated traits (P < 0.05) were subjected to univariate genome wide family-
based association tests. SNPs associated to smoking initiation and persistence with P-value 
< 10-3 were preselected. Next we investigated whether these SNPs are associated to at least 
one significantly correlated trait with tobacco use and achieve the overall association P-
value < 1.4×10-6, after Bonferroni correction by the number of SNPs analyzed (34741); 
furthermore, the detected SNPs were subjected to bivariate family based association tests to 
investigate association between a SNP and two phenotypes concomitantly. 
Since the large portions of variations of these traits are attributed to sex and 
hypertension status therefore in addition to general, sex- and hypertension-specific family 
based association tests were also performed. In general and hypertension specific 
association analysis, age and sex were included as covariates and in sex specific association 
analysis, only age was used as covariate. 
Univariate family-based association tests were performed using the FBAT software 
version v2.0.2c.36 Family-based association analysis compared to case-control design is 
appealing since it tests for association in presence of linkage; hence, findings always imply 
both linkage and association; beside, family-based association analysis avoids confounding 
due to model misspecification as well as admixture or population stratification.37 
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To quantify the overall evidence of association of a SNP, Fisher's method was used 
to combine the individual P-values obtained for each SNP associated to different traits. The 
method, also known as Fisher's combined probability test, is a technique for meta-analysis 
or data fusion. Using this method, it is possible to combines P-values from several studies 
into one test statistic that has a chi-square distribution. The P-value for the X2 statistic can 
be inferred from a chi-square table using 2k “degree of freedom”, where k corresponds to 
the number of tests being combined.38 
Bivariate association analysis was performed using FBAT-GEE implemented in 
FBAT software version v2.0.2c. FBAT-GEE which is based on GEE approach generalizes 
univariate family-based association analysis to multivariate scenarios. It can produce a 
X2FBAT-GEE statistic, which follows a chi-square distribution. The test can be applied to 
multiple phenotypes that have different distributions and its degree of freedom corresponds 
to the number of phenotypes that are tested .39 
 
3.4 Results 
3.4.1 General characteristics of phenotypes and phenotypic correlations 
Former smoking and current smoking were more frequent in males than in females 
(P < 10-4); meanwhile, the prevalence of tobacco use decreased with aging (Table 1 and 2). 
Descriptive statistics of cardiovascular, obesity and stress related traits distributed by sex, 
hypertension and tobacco use status along with their correlations with sex, age and 
hypertension are presented in Table 3 and S1.  
None of the studied cardiovascular, obesity and stress related traits were 
significantly lower in hypertensives than in normotensives (Table S1). Analysis of global 
and regional obesity-related phenotypes indicated that hypertensive subjects are more obese 
than normotensives (Table S1) and tobacco users are slender compared to former and never 
tobacco users (Table 4); moreover, sex specific correlation tests showed that the invert 
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correlation between tobacco use and obesity measures only exists in males and not in 
females (Table 5).  
Among the overall measurements of obesity, BMI and body fat percentage 
determined by skinfold were lower in current tobacco users compared to non users (Table 
4). Males had higher BMI but lower body fat compared to females (P < 0.001) indicating 
that these traits are sex dependent (Table S1); Following this with sex-specific analysis, we 
found that , all three global measures of obesity, BMI (Mean±SE; 25.8±0.5 vs 28.2±0.5), 
body fat percentage derived from skinfold (Mean±SE; 23.8±0.7 vs 27.7±0.5) and body fat 
percentage determined by bioimpedance (Mean±SE; 21.1±0.9 vs 23.3±0.7) were 
significantly lower in male smokers than in male non smokers; meanwhile, these traits were 
not significantly different between current, former and never tobacco users in females 
(Table 3 and 5). BMI was also lower in tobacco users compared to non tobacco users in 
both hypertensive and normotensive groups. Body fat percentage determined by 
bioimpedance was significantly higher in hypertensive smokers compared to hypertensive 
former smokers (Z= 3.1, P = 0.001); however, it was lower in normotensive smokers (Z = -
1.7, P = 0.04) than in normotensive former smokers (Table 6). 
Tobacco users had lower skinfold in their ticpes, superailiac and thigh as compared 
to non users (Table 4); assessing the correlation between skinfold measures and sex status 
indicated that these traits significantly display sexual dimorphism in which females had 
higher values compared to males (Table S1). Female smokers had higher subscapular 
skinfold than female non smokers (Mean±SE; 27.9±1.7 vs 24.9±1, P = 0.01) while on the 
other side, male smokers had lower subscapular skinfold compared to (Mean±SE; 21.4±1.3 
vs 28.2±1.1, P < 0.001) male non smokers. Other skinfold measures including tricpes 
biccpes, superailiac and thigh skinfold were also significantly lower in male smokers 
compared to male non smokers (Table 3 and 5). In normotensives, superailiac skinfold (P = 
0.004) and thigh skinfold (P = 0.02) were significantly lower in current tobacco users 
compared to non users and similar to hypertensive group, the rest of skinfold measures 
were insignificant among different statuses of tobacco use in this group (Table 6).  
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Extremity circumferences were significantly different between males and females 
and between hypertensives and normotensives (Table S1). In entire sample and among 
males, extremity circumferences including waist, hip, proximal thigh, middle thigh, and 
distal thigh were significantly lower in current tobacco users compared to never and former 
tobacco users; however, these measures were not significant among different statuses of 
tobacco use in females (Table 4 and 5). In both hypertensive and normotensive groups, 
tobacco users had lower hip and thigh circumferences and higher hip-to-thigh proximal 
ratio compared to non users (Table 6).  
The higher hip-to-thigh proximal ratio appeared to be in part due to significantly 
reduced thigh circumferences in tobacco users. In fact, the most significantly correlated 
trait with tobacco use in this study was thigh circumference. All three measures of thigh 
circumferences were prominently lower in tobacco users compared to never tobacco users 
with P-values ranging from 10-4 to 5×10-7. Former tobacco users also had significantly 
reduced thigh circumferences than never tobacco users; however, compared to current 
tobacco users they had higher (10-2 ≤ P ≤ 10-4) thigh circumferences (Table 4). Similar 
patterns were also observed in males, hypertensives and normotensives groups; meanwhile, 
there were not significant differences among tobacco use statuses in females (Table 5 and 
6). 
Waist-hip ratio, a commonly used index of upper-body obesity, was not 
significantly different among tobacco use statuses in females, hypertensives, normotensives 
as well as in entire sample; however, in males, smokers had significantly lower waist-hip 
ratio compared to former (P = 0.02) and never tobacco users (P = 0.02); in addition, there 
was not major difference between former and never smokers (P = 0.3) suggesting use of 
tobacco is a contributing factor to lower waits-hip ratio in males (Table 4, 5 and 6). 
While NE levels were not significantly different among current, former and never 
tobacco users either in entire sample or specific sub groups (Table 4, 5 and 6). In all, female 
and normotensive subjects, use of tobacco appeared to increase the EP levels (Table 4, 5 
and 6). 
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Tobacco users had significantly attenuated HR response to mental stress (P = 0.04) 
and brief difference (P = 0.02) between their SBP response and recovery from mental stress 
(Delta SBP) as compared to subjects with no history of tobacco use; in addition, tobacco 
users had shorter HR and SBP recovery from mental stress than former tobacco users (both 
P = 0.03; Table 4). Delta SBP was also significantly lower in current smokers compared to 
never tobacco users in females and in normotensives; meanwhile, in normotensives, former 
smokers had higher SBP response to mental stress compared to non users (Table 3, 5 and 
6). DBP recovery from mental stress and response to mental stress were significantly higher 
in smokers compared to former smokers in hypertensives and also in males (Table 5 and 6); 
besides, SBP recovery from mental stress (18.9±2.3 vs 24.6±1.8, P = 0.046) as well as 
response to mental stress (11.5±2.3 vs 15±1.7, P = 0.03) were significantly lower in female 
smokers compared to former female smokers (Table 5). 
Average sitting blood pressures were significantly lower in tobacco users compared 
to former and non tobacco users in entire sample and among females while in male group 
only average sitting SBP was significantly lower (121.3±2.8 vs 126.6±2.6, P = 0.04) in 
current tobacco users than non users (Table 4 and 5). Ambulatory DBP were significantly 
lower in tobacco users compared to former and non tobacco users in all and among males; 
meanwhile, male smokers had lower ambulatory HR compared to male non smokers and 
male former smokers had significantly higher (Mean±SE; 131.7±2.8 vs. 123.5±1.4, P = 
0.03) ambulatory SBP compared to male non smokers (Table 4 and 5). In normotensives, 
use of tobacco appeared to be negatively correlated with mean ambulatory blood pressure 
(DBP; Z = -2.1 P = 0.02 and SBP; Z = -1.8 P = 0.04); however, hypertensive tobacco users 
had higher blood pressure (DBP; Z = 1.6 P = 0.06 and SBP; Z = 4 P < 0.001) compared to 
non users (Table 3 and 6).  
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3.4.2 Genetic results 
Consistent with the observed phenotypic correlations, we identified shared SNPs 
between tobacco use and significantly correlated obesity, stress and hemodynamic related 
traits (Table 7). 
SNP, rs679783 (HWE P = 0.2, MAF = 0.3) inside AGBL4 gene was significantly 
associated to current (P = 6.0×10-4) and former tobacco (P = 1.6×10-4) use as compared to 
subjects with no history of tobacco use; however, the genotypic difference was insignificant 
between current and former tobacco users (P = 0.7) which indicates genetic similarity 
between current and former tobacco users and points that this SNP contributes to smoking 
behavior. Univariate association analysis showed that SNP, rs679783 is also significantly 
associated to both global and regional measurements of obesity including body mass index, 
thigh circumferences in proximal, middle and distal as well as waist and hip circumferences 
(3.3×10-3 ≤ P ≤ 7.4×10-5). The overall evidence of association for this SNP calculated using 
Fisher's combined probability test (Combined P = 2.3×10-7) surpassed the Bonferroni 
threshold (P = 1.4×10-6) for genome wide significance (Table 7). To further investigate the 
relevance of association of this SNP to smoking and obesity-related traits, we followed the 
univariate association analysis with bivariate analysis. The resulted bivariate association 
signals between tobacco use and each of the obesity related traits were all significant for 
this SNP (P < 0.01;Table 8) which further supports the likely pleiotropic effect of this gene 
in tobacco use and obesity. 
SNP, rs947084 (HWE P = 0.5, MAF= 0.4) inside OBSCN gene was associated to 
former smokers as compared to current (P = 5.1×10-4) and never tobacco users (P = 5.8×10-
5); moreover, the difference between current and never tobacco use (P = 0.5) was 
insignificant which suggests this SNP is important in smoking initiation but not in smoking 
persistence and indicates genetic difference between current and former tobacco users; 
besides, this SNP was trivially associated to each different statuses of tobacco use in 
females (P ≥ 0.1) which furthermore points to male specific effect of this marker. SNP, 
rs947084 was also significantly associated to hip to thigh proximal ratio (P = 3.2×10-3) in 
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males but not in females (P = 0.3) and combined effects of association of this SNP to 
tobacco use and hip to thigh proximal ratio was P = 1.2×10-6 (Table 7); besides, bivariate 
association analysis further supports univariate analysis findings (Table 8). 
The most significant association signals were obtained for marker, rs36950 located 
inside KCNN2 gene. This SNP was significantly associated to current tobacco use 
compared to former (P = 2.7×10-5) and never tobacco use (P = 2.7×10-5) in hypertensives; 
moreover, the difference between former and never tobacco users was insignificant (P = 
0.7) which indicates this SNP contribute to smoking persistence and not smoking initiation; 
besides, this marker was insignificantly associated to each different statuses of tobacco use 
in normotensive subjects (P ≥ 0. 8) that points to hypertensive effect of this SNP.  We also 
found that this SNP is significantly associated to SBP recovery from mental stress (P = 
1.3×10-3 in hypertensives and P = 0.5 in normotensives) as well as mean ambulatory SBP 
(P = 8.8×10-3 in hypertensives and P = 0.9 in normotensives) in hypertensives but not in 
normotensives (Table 7). The overall evidence of association for this SNP (Combined P = 
8.1×10-8) exceeds our genome-wide significance level (P = 1.4×10-6); moreover, bivariate 
association signals as presented in Table 8 were highly significant for this SNP (2.5×10-5 ≤ 
P ≤ 2.4×10-6) which further point the possible pleiotropic effect of this SNP in tobacco use, 
mental stress and blood pressure. Interestingly, checking the protein interactions showed 
that both KCNN2 and OBSCN are sharing interactions with CALM1 protein.  
 
3.5 Discussion 
In this study, we investigated the phenotypic and genotypic relatedness of tobacco 
use initiation and persistence with hemodynamic, obesity and stress related traits in cohort 
of French Canadian families from founder population of SLSJ that provides several 
advantages over general population, including reduced heterogeneity; longer linkage 
disequilibrium intervals, as estimated by genetic clock; and importantly, access to their 
genealogical records.17; 20; 21 
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The short and long-term hemodynamic effect of tobacco smoking has been the 
subject of many studies; although BP and HR rise immediately after smoking, results from 
epidemiological studies have generally shown that smokers have lower BP compare to 
nonsmokers; meanwhile, former smokers have BP similar to those of nonsmokers.6-8  
Wake HR was significantly higher in tobacco users compared to former and never 
tobacco users in entire sample and among females and hypertensives which is consistent 
with previous findings;8 moreover, in agreement with studies that reported smoking have 
damping effect on BP; average sitting BP as well as ambulatory DBP were significantly 
lower in tobacco users compared to former and non tobacco users in entire sample; while, 
the differences between former and never tobacco users were insignificant pointing to the 
lowering effect of smoking on BP, similar trends were also observed in males, females and 
normotensives; however, in hypertensive group, tobacco users had higher DBP as well as 
SBP compared to non users which suggest there might be hypertension specific factors (e.g.  
genetic factors) that modify effect of tobacco smoking on blood pressure.6; 7 For instance, 
as it is also observed in our cohort, smoking increases the epinephrine level in the body; 40; 
41 however, it has been documented that compared to normotensives, the elevated level of 
epinephrine significantly enhances the cardiac response in hypertensives.42  
Overall, analysis of both global and regional measurements of obesity indicated that 
current tobacco users are slender compared to never or former tobacco users; these findings 
are consistent with numerous studies that indicated smokers tend to have lower body 
weight than do non-smokers.10; 11; 43; 44Apart from thigh circumferences and thigh skinfold, 
other obesity measures were insignificant between former and never tobacco users which 
furthermore support the notion that smoking cession is associated with body weight gain.45; 
46 Thigh circumferences were significantly lower in current tobacco users compared to 
former and never tobacco users; moreover, former tobacco users had lower thigh 
circumferences than non users. These findings suggest the observed differences in thigh 
circumference may have tobacco related roots as well as genetic underpinnings that are 
shared among current and former tobacco user. 
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Similar trends were observed in males and normotensives; however, in females 
obesity related measures were not significantly different among tobacco use statues and 
even female smokers had higher subscapular skinfold than female non smokers, the fact 
that smoking cession or initiation is not associated to weight gain in females is interesting 
since studies have shown that compared to men, women are more concern about unwanted 
weight gain as a result of smoking cession and among female smokers, many smoke to 
control their weight; in addition, they are more likely to resume smoking to lose weight. 47; 
48 Nevertheless, our result supports previous findings in which weight gain did not 
necessarily follow smoking cessation in females. 13; 49  
It has been suggested that waist circumference or waist-to-hip ratio, predictors of 
intra-abdominal visceral fat is higher in smokers than in nonsmokers;10; 13; 14 however, we 
found that tobacco users have lower waist and hip circumferences compared to former and 
never tobacco users, these differences were not significant between former and never 
tobacco users suggesting use of tobacco decreases waist and hip circumferences, besides; 
the waist-hip ratio, a commonly used index of upper-body obesity, was not significantly 
different among tobacco use statuses, similar trends were also observed in normotensives 
and hypertensives. In male group, smokers had even significantly lower waist-hip ratio 
compared to former and never tobacco users; in addition, there was no significant 
difference between former and never smokers suggesting use of tobacco is contributing to 
lower waits-hip ratio in males. Relative to hypertension, these findings are interesting, since 
central obesity is positively correlated with hypertension 50; 51; therefore, the observed 
lower blood pressure among tobacco users in our cohort can be also due to lower intra-
abdominal visceral fat in tobacco users compared to non tobacco users.  
The effect of smoking on hemodynamic reactions to psychological stress exposures 
is not clear. While some studies have found smoking has additive effect on hemodynamic 
reactivity to mental stress, 52-54 others reported attenuated response to mental stress in 
smokers compared to non smokers or no significant differences;8; 55-57 meanwhile, studies 
have found sex-smoking interaction on response to mental stress.58; 59 
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Overall, we found that, tobacco users have significantly attenuated HR response to 
mental stress and brief difference between their SBP response and recovery from mental 
stress as compared to subjects with no history of tobacco use; in addition, tobacco users had 
shorter HR and SBP recovery from mental stress than former tobacco users. 
Our findings are in agreement with the growing body of literature showing that 
smokers have blunted reactivity to mental stress.8; 55; 56 These results also suggest in 
addition to response to mental stress which is usually used by most of the studies that 
compare hemodynamic reactivity in smokers and non-smokers, assessment of recovery 
from mental stress and the difference between response and recovery can provide additional 
insights into influence of smoking on hemodynamic reactions to psychological stress.  
Subgroup analysis indicated that there are hypertension and sex differences in 
hemodynamic reactivity to psychological and physiological stressors; for instance, in 
hypertensive and in male groups, DBP recovery from as well as response to mental stress 
were significantly higher in smokers compared to former smokers but not in females and 
normotensives, our findings are consistent with those that reported male smokers are more 
reactive than male non-smokers in their diastolic blood pressure response to mental 
arithmetic test; 58; 60 in addition, we found that in male group, SBP recovery from and 
response to mental stress were significantly higher in former smokers compared to never 
smokers while this trend was opposite in females; moreover, in agreement with previous 
findings,61 these measurements were significantly lower in female smokers compared to 
former smokers. 
While NE levels were not significantly different among tobacco use statuses either 
in entire sample or specific sub groups. In all, females and normotensives use of tobacco 
appeared to increase the EP levels. This is consistent with those studies that reported 
tobacco use increases the level of EP.40; 62 In fact, nicotine binds to ganglion type nicotinic 
receptors in the adrenal medulla and increases flow of epinephrine and this appears to be in 
part responsible for stimulating effects of tobacco use.40; 41; 62; 63 
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In present study, no account was taken of the extent of smoking. Although smoking 
is sometimes underestimated in self-reports, particularly among former smokers,64 several 
studies found that smoking information collected using questionnaires can be reasonably 
reliable and agree to biochemical assessments.65; 66 Nonetheless, it would have strengthened 
our study if additional detailed information regarding duration and intensity of smoking 
behavior as well as biochemical measures to verify smoking behavior were available. 
Phenotypic correlation particularly among complex disorders appears to be in part 
due to genotypic relatedness;15; 16; 67; 68 therefore, the observed correlation between tobacco 
use with obesity, hemodynamic and stress related traits may be partly due to genetic 
overlaps.15; 16 Identification of such pleiotropic genes can provide several benefits for health 
programs,16; 69-71 such as providing additional insights into mechanisms of comorbidity of 
these phenotypes, cross-utilization of drugs and therefore expanding application of current 
medications, reducing the possible drug side effects and eventually development of more 
rational therapeutic approaches. 
Using both univariatre and bivariat family-based association analysis, we searched 
for common loci between tobacco use and significantly correlated obesity, hemodynamic 
and stress related traits with tobacco use. We found three commonly associated SNPs to 
tobacco use and significantly correlated traits with tobacco use inside KCNN2, OBSCN 
and AGBL4 genes, findings which were further supported by bivairaie association analysis. 
KCNN2 gene was shared among tobacco use, mean ambulatory SBP as well as SBP 
response to and recovery from mental stress; while, AGBL4 and OBSCN genes were 
shared between obesity-related traits and tobacco use.  
The most significant association signal was obtained for KCNN2 gene which is a 
member of the calcium-activated potassium channel family and appears to regulate 
neuronal excitability by contributing to the slow component of synaptic after hyper 
polarization. Interestingly, this gene has been already implicated in stress related traits; for 
instance, over-expression of this gene in the basolateral amygdala reduces anxiety and 
stress-induced corticosterone secretion at a systemic level.72 It has also been reported that 
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KCNN2 negatively regulates the excitation of enteric neurons via functional interactions 
with nicotinic acetylcholine receptors;73 moreover, this gene is involved in cardiac 
repolarization in atrial myocytes74; 75 which further support pleiotropic characteristic 
identified in present study for this gene. OBSCN encoded protein belongs to the family of 
giant sacromeric signaling proteins and have role in the organization of myofibrils during 
assembly, it mediates interactions between the sarcoplasmic reticulum and myofibrils and It 
has been implicated in hypertrophic cardiomyopathy.76 Interestingly both KCNN2 and 
OBSCN have been earlier shown to interact with CALM1 protein suggesting these proteins 
may have function in similar physiological processes.77-79 AGBL4 has been already 
implicated in substance use;80; 81 however, little is known about AGBL4 function and it 
may play a role in the processing of tubulin.  
SNP inside KCNN2 gene was significantly associated to tobacco use, stress and 
blood pressure in hypertensives and not in normotensives; additionally, SNP inside 
OBSCN gene was commonly associated to tobacco use and hip thigh proximal ratio in 
males and not in females. Detection of such specific loci may be due to their sex- and 
hypertension-specific effects or co-segregation with epistatic sex- and hypertension specific 
genetic factors that modify their effects;28; 51; 82; 83 consistently, we found that large portions 
of variations of studied traits are attributed to sex and hypertension status; moreover, we 
have already reported sex- and hypertension-differences in the heritabilities of many of 
these traits.28; 82 Therefore, by increasing genetic homogeneity, subgroup analysis can 
uncover genetic factors that otherwise would remain obscured.  
Inclusion of former smokers in this study allows us to determine whether smoking 
cession is associated with a similar magnitude of change to that typical of non smokers and 
also if the shared genetic factors between former and current tobacco users contribute to the 
differences. In this regard we found several obesity related traits that their relatedness with 
smoking behavior seemingly are mediated by genetic factors. Thigh skinfold in whole 
cohort subscapular skinfold in females, superaialic skinfold and body fat percentage in 
normotensives along with hip thigh proximal ratio in both normotensives and hypertensives 
157 
 
 
were significantly correlated with current and former tobacco users as compared to subjects 
with no history of tobacco use; moreover, the differences between current and former 
tobacco users were not significant for these traits suggesting that the observed correlations 
probably roots in genetic factors that are shared between former and current tobacco users 
rather than smoking effect itself. 
Moreover, our genetic findings highlight the presence of genetic similarities and 
differences between current and former tobacco users. SNP, rs679783 was significantly 
associated to both former and current tobacco use while rs947084 was significantly 
associated to smoking initiation and SNP, rs36950 was significantly associated to smoking 
persistence. Consistent with these findings it is also reported that genetic factors differently 
contribute to the determination of smoking initiation and persistence;84 moreover, we have 
also previously reported that genetic factors account for 61% variability of smoking 
initiation and 46% variability of smoking persistence.  
In summary consistent with phenotypic relatedness we identified shared SNPs 
between tobacco use and significantly correlated obesity, hemodynamic and stress related 
traits; moreover, our findings underline the importance of subgroup analysis and emphasize 
the shortcoming of satirical adjustments. 
Although in some gene-environment studies, tobacco use is considered as an 
environmental factor, we found several obesity related traits that their correlations with 
smoking behavior appear to root in genetic factors rather than smoking effect itself; in 
addition, consistent with phenotypic relatedness we identified shared SNPs between 
tobacco use and significantly correlated obesity, hemodynamic and stress related traits. 
These findings point that tobacco use as an environmental factor has its own genetic 
underpinnings and phenotypic correlation may be an indicator of genotypic relatedness; in 
addition, this study raises implications for gene environment studies that include tobacco 
use as an environmental factor and points to considering subgroup analysis in genetic 
studies and personalized medicine programs. 
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Table 1. Characteristics of tobacco use statuses 
Characteristic 
Never tobacco 
users 
Former tobacco 
users 
Current tobacco 
users 
All 
Age (Mean±SE; N) 48.5±0.9; 290 54.4±0.8; 225 46.9±1; 182 50±0.6; 697 
Females (N) 190 101 86 377 
Males (N) 100 124 96 320 
Hypertensives (N) 158 141 75 374 
Normotensives (N) 132 84 107 323 
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Table 2. Distribution of tobacco use1 traits by sex and hypertension status along with their correlations2 with sex, age3 and hypertension4 
Trait 
Females Males Sex 
(females) 
Aging 
Hypertension 
(hypertensives) 
Total Unaffected Affected Unaffected Affected
Nor5 Hyp6 Nor Hyp Nor Hyp Nor Hyp Z P Z P Z P
Current vs. never tobacco users 17.4 22.9 10.6 7.6 10.6 10.6 12.1 8.3 -4.1 < 1E-04 -0.9 0.2 -3.0 0.001 472 
Current vs. former tobacco users 8.6 16.2 12.3 8.8 12.0 18.4 14.0 9.6 0.3 0.4 -4.5 < 1E-04 -3.2 0.0006 407 
Former vs. never tobacco users 15.9 21.0 6.8 12.8 9.7 9.7 9.5 14.6 -4.8 < 1E-04 3.4 0.0004 -0.6 0.3 515 
 
 
 
 
 
 
                                                            
1 Data are in percentage. 
2 Correlation test was done using GEE method. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice versa. 
3 Correlation model is substance use ~ sex + age. 
4 Correlation model is hypertension status ~ sex + age + substance use. 
5 Normotensives 
6 Hypertensives 
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Table 3. Descriptive statistics of obesity, stress and hemodynamic related traits distributed by sex, hypertension and tobacco use statuses 
Trait 
Males Females
All 
Normotensives Hypertensives Normotensives Hypertensives
Never 
tobacco 
users 
Former 
tobacco 
users 
Current 
tobacco 
users 
Never 
tobacco 
users 
Former 
tobacco 
users 
Current 
tobacco 
users 
Never 
tobacco 
users 
Former 
tobacco 
users 
Current 
tobacco 
users 
Never 
tobacco 
users 
Former 
tobacco 
users 
Current 
tobacco 
users 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
Mean±SE 
(N) 
BMI (kg/m2) 
28.1±0.8 
(49) 
26.4±0.6 
(49) 
24.7±0.6 
(54) 
28.3±0.6 
(48) 
28.7±0.5 
(73) 
27.3±0.8 
(39) 
24.3±0.5 
(80) 
25±0.7 
(35) 
25.4±0.7 
(50) 
27.2±0.5 
(104) 
27.5±0.7 
(63) 
27.1±0.9 
(35) 
26.7±0.2 
(679) 
Waist Hip ratio 0.9±0 (48) 1±0 (47) 0.9±0 (56) 1±0 (50) 1±0 (75) 1±0 (37) 0.8±0 (78) 0.8±0 (35) 0.8±0 (48) 
0.8±0 
(100) 0.9±0 (63) 
0.8±0 
(36) 
0.9±0 
(673) 
Waist circumference (cm) 
95.6±1.4 
(48) 
95.9±1.4 
(47) 
88.4±1.7 
(56) 
99.2±1.6 
(50) 
100.7±1.4 
(75) 
97.7±2.2 
(37) 
79.5±1.5 
(79) 
79±2.3 
(35) 
81.7±1.7 
(48) 
86±1.4 
(100) 
87.8±1.9 
(63) 
86.6±2.5 
(36) 
89.6±0.6 
(674) 
Hip circumference (cm) 
100.8±0.8 
(48) 
99.4±0.9 
(47) 
94.8±1 
(56) 
101.9±1.1 
(50) 
101±0.9 
(75) 
100±1.5 
(37) 
98.8±1.2 
(78) 
99.5±1.4 
(35) 
99.5±1.5 
(48) 
101.6±1.1 
(100) 
102.9±1.4 
(63) 
102.5±1.
9 (36) 
100.3±0.4 
(673) 
Hip Thigh Proximal ratio 1.7±0 (48) 1.8±0 (46) 1.7±0 (54) 1.7±0 (47) 1.8±0 (71) 1.8±0 (35) 1.7±0 (78) 1.7±0 (35) 1.7±0 (48) 1.7±0 (96) 1.7±0 (58) 
1.7±0 
(32) 
1.7±0 
(648) 
Thigh proximal 
circumference (cm) 
60.6±0.8 
(48) 
57±0.7 
(46) 
54.6±0.8 
(55) 
60.7±1 
(47) 
57.2±0.6 
(71) 
57.4±1.2 
(35) 
59.2±0.9 
(78) 58±1 (35) 
59.7±1.2 
(48) 
58.4±0.6 
(96) 
58.6±0.8 
(58) 
57.6±1.1 
(32) 
58.3±0.3 
(649) 
Thigh mid circumference 
(cm) 
55.2±0.8 
(48) 
52.2±0.7 
(47) 
51.4±0.9 
(54) 
55±0.8 
(47) 
52.8±0.6 
(71) 
52.4±1 
(36) 
52.1±0.7 
(78) 
52.1±0.9 
(35) 
52.9±0.9 
(48) 
52.6±0.6 
(98) 
52.8±0.8 
(59) 
51.1±1.2 
(32) 
52.7±0.2 
(653) 
Thigh distal circumference 
(cm) 
41.5±0.5 
(48) 
40.3±0.7 
(46) 
38.6±0.5 
(55) 
41.6±0.5 
(47) 
40.4±0.5 
(71) 
40.5±0.8 
(35) 
39.8±0.5 
(78) 
39.6±0.7 
(35) 
40±0.7 
(48) 
40.5±0.5 
(97) 
40.3±0.6 
(58) 
39.8±0.9 
(32) 
40.2±0.2 
(650) 
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Skinfold bicep1 (mm) 
18.2±1.7 
(47) 
18.5±2 
(44) 
14.9±1.5 
(53) 
20.2±1.8 
(43) 
18.1±1.7 
(65) 
18.8±2.9 
(31) 
21±1.4 
(76) 
21±2.1 
(30) 
25±2.4 
(44) 
23.9±1.3 
(81) 
26.5±2 
(47) 
22.3±2.7 
(23) 
20.7±0.5 
(584) 
Skinfold bicep2 (mm) 
18.8±1.7 
(47) 
18.7±2.1 
(44) 
15.1±1.6 
(53) 
20.1±1.8 
(43) 
18.3±1.7 
(65) 
19.1±2.9 
(31) 
21.3±1.5 
(76) 
21±2.1 
(30) 
25.4±2.4 
(44) 
23.9±1.3 
(81) 
27.4±2.1 
(47) 
22.5±2.8 
(23) 
21±0.6 
(584) 
Skinfold bicep3 (mm) 
18.8±1.8 
(47) 
18.9±2.1 
(44) 
15.1±1.6 
(53) 
20.1±1.8 
(43) 
18.1±1.6 
(65) 
18.7±2.9 
(31) 
21.6±1.5 
(76) 
21.4±2.2 
(30) 
25.1±2.4 
(44) 
24.2±1.3 
(81) 
27.2±2.1 
(46) 
23.1±2.9 
(23) 
21±0.6 
(583) 
Mean skinfold biceps (mm) 
18.6±1.7 
(47) 
18.7±2.1 
(44) 
15.1±1.5 
(53) 
20.1±1.8 
(43) 
18.1±1.7 
(65) 
18.9±2.9 
(31) 
21.3±1.5 
(76) 
21.1±2.1 
(30) 
25.2±2.4 
(44) 
24±1.3 
(81) 
27.1±2 
(47) 
22.6±2.8 
(23) 
20.9±0.5 
(584) 
Skinfold triceps1 (mm) 
26.3±1.8 
(47) 
24.8±2.1 
(44) 
20.7±1.8 
(53) 
27.7±1.8 
(43) 
24.4±1.6 
(65) 
25.3±3 
(31) 
29.1±1.2 
(76) 
30.7±2 
(31) 
31.6±2.2 
(44) 
34.1±1.2 
(81) 
34.5±1.8 
(47) 
33±2.8 
(23) 
28.5±0.5 
(585) 
Skinfold triceps2 (mm) 
26.5±1.8 
(47) 
25.2±2.2 
(44) 
21±1.8 
(53) 
27.6±1.8 
(43) 
24.2±1.5 
(64) 
25.3±3 
(31) 
29.4±1.3 
(76) 
30.9±2 
(31) 
31.8±2.2 
(44) 
34.4±1.2 
(81) 
35.3±1.8 
(47) 
33.2±2.8 
(23) 
28.7±0.5 
(584) 
Skinfold triceps3 (mm) 
26.7±1.8 
(47) 
25.2±2.2 
(44) 
20.7±1.7 
(53) 
27.8±1.8 
(43) 
24.1±1.5 
(64) 
25.2±3 
(31) 
29.4±1.3 
(76) 
31.1±2 
(31) 
32.1±2.2 
(44) 
34.3±1.2 
(80) 
35.6±1.8 
(47) 
33.5±2.8 
(23) 
28.8±0.5 
(583) 
Mean skinfold triceps (mm) 
26.5±1.8 
(47) 
25±2.1 
(44) 
20.8±1.7 
(53) 
27.7±1.8 
(43) 
24.7±1.6 
(65) 
25.3±3 
(31) 
29.3±1.3 
(76) 
30.9±2 
(31) 
31.8±2.2 
(44) 
34.4±1.2 
(81) 
35.1±1.8 
(47) 
33.2±2.8 
(23) 
28.7±0.5 
(585) 
Skinfold subscapular1 
(mm) 
27.1±1.4 
(47) 
22.8±1.5 
(44) 
19.6±1.5 
(53) 
29.3±1.8 
(43) 
25.5±1.2 
(63) 
24.4±2.2 
(30) 
23.5±1.5 
(76) 
22±1.7 
(31) 
27.2±2.3 
(44) 
25.9±1.2 
(80) 
30.8±2 
(47) 
28.4±2.4 
(23) 
25.4±0.5 
(581) 
Skinfold subscapular2 
(mm) 
26.9±1.4 
(47) 
23±1.5 
(44) 
19.6±1.5 
(53) 
29.1±1.8 
(43) 
25.5±1.1 
(63) 
24.7±2.3 
(30) 
23.7±1.5 
(76) 
22.4±1.7 
(31) 
27.7±2.3 
(44) 
25.9±1.2 
(80) 
31.1±2.1 
(47) 
28.8±2.5 
(23) 
25.5±0.5 
(581) 
Skinfold subscapular3 
(mm) 
27.3±1.4 
(47) 
23.1±1.5 
(44) 
19.7±1.5 
(53) 
29.5±1.8 
(43) 
25.6±1.2 
(63) 
24.5±2.3 
(30) 
23.9±1.5 
(76) 
22.4±1.7 
(31) 
27.6±2.3 
(44) 
26.1±1.3 
(80) 
31.2±2.1 
(47) 
28.8±2.5 
(23) 
25.6±0.5 
(581) 
Mean skinfold subscapular 
(mm) 
27.1±1.4 
(47) 
23±1.5 
(44) 
19.6±1.5 
(53) 
29.3±1.8 
(43) 
25.6±1.2 
(63) 
24.5±2.3 
(30) 
23.7±1.5 
(76) 
22.2±1.7 
(31) 
27.5±2.3 
(44) 
26±1.2 
(80) 31±2 (47) 
28.7±2.5 
(23) 
25.5±0.5 
(581) 
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Skinfold suprailiac1 (mm) 
27.6±1.9 
(46) 
19.1±1.6 
(44) 
18.5±1.8 
(53) 
26.7±2.3 
(42) 
21.4±1.5 
(64) 
22±2.2 
(30) 
23.9±1.6 
(76) 23±2 (31) 
24.6±2.4 
(42) 
24.9±1 
(80) 
28.6±1.7 
(47) 
27.6±2.2 
(23) 
23.8±0.5 
(578) 
Skinfold suprailiac2 (mm) 
27.6±1.9 
(46) 
19.6±1.6 
(44) 
18.7±1.9 
(53) 
26.8±2.3 
(42) 
21.7±1.5 
(64) 
22.1±2.2 
(30) 
23.8±1.6 
(76) 
23.4±1.9 
(31) 
24.4±2.4 
(42) 
25.3±1.1 
(80) 
29±1.7 
(47) 
27.8±2.2 
(23) 
24±0.5 
(578) 
Skinfold suprailiac3 (mm) 
27.5±1.9 
(46) 
19.6±1.6 
(44) 
19±1.9 
(53) 
27±2.2 
(42) 
21.8±1.5 
(64) 
22.3±2.2 
(30) 
23.7±1.6 
(76) 
23.4±2 
(31) 
25±2.5 
(42) 
25.5±1.1 
(80) 
29.1±1.7 
(47) 
28±2.2 
(23) 
24.2±0.5 
(578) 
Mean skinfold suprailiac 
(mm) 
27.6±1.9 
(46) 
19.4±1.6 
(44) 
18.7±1.9 
(53) 
26.8±2.3 
(42) 
21.6±1.5 
(64) 
22.1±2.2 
(30) 
23.8±1.6 
(76) 
23.3±2 
(31) 
24.7±2.4 
(42) 
25.2±1.1 
(80) 
28.9±1.7 
(47) 
27.8±2.2 
(23) 
24±0.5 
(578) 
Skinfold thigh1 (mm) 
31.8±2.1 
(45) 
28.5±2.6 
(43) 
23.9±2.1 
(51) 
29.1±2.5 
(42) 
23.8±1.6 
(62) 
26.3±2.9 
(30) 
38.3±1.5 
(69) 
39.2±2.1 
(29) 
40.4±2.3 
(37) 
43±1.4 
(73) 
43.5±1.9 
(45) 
40.8±2.9 
(22) 
34±0.7 
(548) 
Skinfold thigh2 (mm) 
32±2.1 
(45) 
28.9±2.7 
(43) 
24.1±2.1 
(51) 
29.6±2.5 
(42) 
24±1.6 
(62) 
26.5±2.9 
(30) 
38.6±1.5 
(69) 
38.9±2.2 
(29) 
40±2.4 
(36) 
43.3±1.4 
(73) 
43.6±1.9 
(45) 
41.1±3 
(22) 
34.2±0.7 
(547) 
Skinfold thigh3 (mm) 
32.4±2.2 
(45) 
27.9±2.6 
(42) 
24.4±2.1 
(51) 
29.7±2.6 
(42) 
24.1±1.7 
(62) 
26.4±3 
(30) 
39.1±1.5 
(69) 
39.1±2.2 
(29) 
40.1±2.4 
(36) 
43.8±1.4 
(73) 
44±1.9 
(45) 
41.4±3 
(22) 
34.4±0.7 
(546) 
Mean skinfold thigh (mm) 
32.1±2.1 
(45) 
28.7±2.7 
(43) 
24.1±2.1 
(51) 
29.5±2.5 
(42) 
24±1.6 
(62) 
26.4±2.9 
(30) 
38.7±1.5 
(69) 
39.1±2.2 
(29) 
40.6±2.4 
(37) 
43.4±1.4 
(73) 
43.7±1.9 
(45) 
41.1±3 
(22) 
34.2±0.7 
(548) 
Body fat percentage 
bioimpedance 
21.8±1.1 
(41) 
25.1±1.4 
(34) 
18.5±1.1 
(44) 
24.9±1 
(36) 
25.6±1.1 
(57) 
25.4±1.3 
(26) 
30.2±1.2 
(66) 
31±1.8 
(25) 
30.8±1.4 
(36) 
36.8±1.2 
(69) 
37.4±1.8 
(41) 
36.4±2.7 
(16) 
28.7±0.5 
(491) 
Body fat (%) 
27.6±0.8 
(46) 
25.2±0.9 
(44) 
23.2±0.9 
(53) 
27.9±0.8 
(42) 
25.8±0.6 
(63) 
24.9±1.1 
(29) 
36.2±0.9 
(76) 
36.6±1.2 
(30) 
36.9±1.2 
(42) 
38.6±0.6 
(80) 
40.1±1 
(47) 
38.9±1.2 
(23) 
32±0.4 
(575) 
Supine EP (pg/ml) 
45.2±3.4 
(19) 
41.9±6.3 
(17) 
43.2±2.6 
(20) 
46.2±6.5 
(13) 
39.8±3.8 
(15) 
44.8±8 
(10) 
44.4±3.3 
(35) 
37.1±4.3 
(10) 
43.3±3.6 
(16) 
37.9±3 
(22) 
40.8±4.1 
(12) 
58.8±22.
2 (3) 
42.7±1.3 
(192) 
Standing EP (pg/ml) 
59.3±9.2 
(18) 
48.3±7.5 
(15) 
61.8±7.7 
(20) 
55.1±7.2 
(13) 
50.1±5.5 
(15) 
50.6±7.2 
(8) 
47.9±4.1 
(34) 
42.5±8.4 
(9) 
62.6±7.8 
(19) 
36.6±3.1 
(22) 
38.1±3.8 
(9) 
51.3±11.
7 (3) 
50.8±2 
(185) 
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Response EP (pg/ml) 
14.5±9.6 
(18) 
6.1±6.9 
(15) 
18.6±7.6 
(20) 
6.3±8.8 
(12) 
10.2±4.7 
(12) 
3.3±6.8 
(8) 
4.8±4.4 
(33) 
3.6±5.7 
(9) 
23.1±9.7 
(16) 
0.3±2.9 
(18) 
0.1±7.2 
(9) 
-7.5±10.5 
(3) 
8.6±2.2 
(173) 
Supine NE (pg/ml) 
177.5±19 
(19) 
152.8±13.
5 (17) 
176.8±12 
(20) 
170.5±22 
(16) 
167.4±17.
3 (18) 
162.9±24.
4 (10) 
170.2±11.
1 (36) 
185.2±15.
5 (11) 
164.6±12.
5 (20) 
164.8±11.
2 (26) 
161.4±22.
6 (12) 
226.6±74
.1 (3) 
169.4±4.7 
(208) 
Standing NE (pg/ml) 
355.3±27.
4 (18) 
381.7±47.
8 (16) 
442.8±44.
3 (20) 
418.4±45 
(16) 
398.7±41.
4 (19) 
438.9±57.
4 (10) 
395.1±23.
1 (36) 
412.9±39.
1 (11) 
372.5±26.
1 (20) 
412.3±33.
5 (26) 
382.2±58.
6 (12) 
504±74.3 
(3) 
401.2±11.2 
(207) 
Response NE (pg/ml) 
180.4±22.
3 (18) 
235.4±40 
(16) 
266±40.9 
(20) 
247.9±32.
5 (16) 
231.9±33.
1 (18) 
276.1±35 
(10) 
224.9±17.
3 (36) 
227.7±28.
7 (11) 
207.8±21.
9 (20) 
247.5±27.
5 (26) 
220.8±40.
7 (12) 
277.4±8.
9 (3) 
232.6±8.9 
(206) 
DBP recovery to mental 
stress (mmHg) 
10.6±1.4 
(22) 
9.7±1.8 
(18) 
11.1±1.5 
(23) 
9.9±1.7 
(19) 
7.3±1.1 
(23) 
11.4±2.3 
(13) 
11±1.2 
(37) 
9.7±1.7 
(15) 
10.6±1.4 
(19) 
13.1±1.4 
(27) 
14.7±1.3 
(19) 
11.9±4.1 
(4) 
10.9±0.4 
(239) 
Delta DBP (mmHg) 
0.6±0.5 
(22) 
0.6±1.1 
(18) 
1.4±0.7 
(23) 
0.8±1.1 
(19) 
0.8±0.7 
(23) 
-0.7±1.2 
(13) 
0.9±0.7 
(37) 
-0.1±1.2 
(15) 0±0.6 (19) 1.1±1 (27) 
1.9±1.1 
(19) 
2.8±0.6 
(4) 
0.8±0.3 
(239) 
DBP response to mental 
stress (mmHg) 
10±1.5 
(22) 
9.1±2.2 
(18) 
9.7±1.5 
(23) 
9.2±1.7 
(19) 
6.5±1.3 
(23) 
12.2±2.3 
(13) 
10.1±1.3 
(37) 
9.8±1.8 
(15) 
10.6±1.2 
(19) 
12±1.3 
(27) 
12.8±1.5 
(19) 
9.1±4.6 
(4) 
10.1±0.5 
(239) 
SBP recovery from mental 
stress (mmHg) 
21.1±2.3 
(22) 
24.8±2.9 
(18) 
20.6±2.5 
(23) 
23±2.4 
(19) 
30.6±2.8 
(23) 
26.1±2.6 
(13) 
19.9±2 
(37) 
18.9±2.9 
(15) 
17.9±2.5 
(19) 
31±2.3 
(27) 
29±1.6 
(19) 
24.9±4.5 
(3) 
23.9±0.8 
(238) 
Delta SBP (mmHg) 
7.2±1.1 
(22) 
8.4±1.6 
(18) 6.1±1 (23) 
10±2.3 
(19) 
9.1±1.2 
(23) 
7.9±1.9 
(13) 
8.3±0.9 
(37) 
5.4±1.2 
(15) 
6.6±0.9 
(19) 11±1 (27) 
12.9±2.5 
(19) 
12.2±3.2 
(3) 
8.6±0.4 
(238) 
SBP response to mental 
stress (mmHg) 
13.9±2 
(22) 
16.4±3 
(18) 
14.4±2.4 
(23) 
13±2.5 
(19) 
21.5±2.4 
(23) 
18.3±3.2 
(13) 
11.6±1.9 
(37) 
13.5±3.1 
(15) 
11.3±2.6 
(19) 
20±2.5 
(27) 
16.1±2 
(19) 
12.8±6.7 
(3) 
15.3±0.8 
(238) 
HR recovery to mental 
stress (beast/min) 
6.7±2.2 
(22) 
7.3±1.6 
(18) 
5.9±2.2 
(23) 
6.2±1.4 
(19) 
9.1±2.1 
(23) 
8.1±2.7 
(13) 
8.3±1.7 
(37) 
13±5.3 
(16) 
5.9±0.9 
(19) 
11.9±1.7 
(27) 
9.6±1.7 
(19) 
10±4.8 
(4) 
8.4±0.7 
(240) 
Delta HR (beast/min) 
-0.8±0.5 
(22) 0±0.8 (18) 
-0.1±0.7 
(23) 
-1.3±1 
(19) 
0.6±0.8 
(23) 
0.2±1.4 
(13) 
1.6±0.8 
(37) 
0.7±0.8 
(16) 
0.1±0.9 
(19) 
1.6±0.8 
(27) 
-0.2±0.9 
(19) 
0.4±1.1 
(4) 
0.3±0.3 
(240) 
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HR response to mental 
stress (beast/min) 
7.5±2.1 
(22) 
7.3±1.6 
(18) 6±2 (23) 
7.5±1.4 
(19) 
8.5±1.8 
(23) 
7.9±2.4 
(13) 
6.7±1.5 
(37) 
12.3±5.4 
(16) 
5.9±1.1 
(19) 
10.3±1.6 
(27) 
9.8±1.6 
(19) 
9.6±4.4 
(4) 
8.1±0.6 
(240) 
Average sitting DBP 
(mmHg) 
74.2±1.8 
(21) 
79.3±2.1 
(19) 
72.4±1.7 
(23) 
83.9±2.2 
(19) 
88.4±2.3 
(23) 
82.7±3.4 
(13) 
70±1.5 
(35) 
70.3±1.6 
(16) 
66.8±2 
(20) 
77.3±1.8 
(27) 
80.1±2.7 
(18) 
78.2±2.4 
(5) 
76.4±0.7 
(239) 
Average sitting SBP 
(mmHg) 
119.6±2.1 
(21) 
122.2±2.7 
(19) 
113.6±1.8 
(23) 
134.3±4.3 
(19) 
139.2±3.6 
(23) 
134.9±5.4 
(13) 
110.8±1.9 
(35) 
108.5±2 
(16) 
105.6±2.7 
(20) 
133.7±3.3 
(27) 
135.4±4.9 
(18) 
139.5±7.
1 (5) 
123.1±1.2 
(239) 
Average sitting HR 
(beast/min) 
61.5±2.2 
(21) 
68.8±1.7 
(19) 
64.5±1.9 
(23) 
68.8±2.6 
(19) 
64.2±2.1 
(22) 
68.7±3.1 
(12) 
70.9±1.6 
(35) 
70.3±2.8 
(16) 
72.7±2.6 
(20) 
74±2.1 
(27) 
72.3±2.3 
(18) 
74.4±3.7 
(5) 
69±0.7 
(237) 
Mean ambulatory DBP 
(mmHg) 
73.7±1.5 
(16) 
77.7±2 
(13) 
69.9±1.6 
(19) 
80.5±1.4 
(13) 
86.6±2.7 
(17) 
82.9±3.7 
(7) 
68.4±1.3 
(26) 
66±2.1 
(11) 
66.2±1.4 
(18) 
78.9±1.8 
(20) 
79.7±2.8 
(14) 
86.6±3.7 
(2) 
74.9±0.8 
(176) 
Mean ambulatory SBP 
(mmHg) 
122.2±2.1 
(16) 
123.1±2 
(13) 
117.7±2.2 
(19) 
125.1±1.8 
(13) 
138.3±4 
(17) 
137±4.7 
(7) 
111.7±1.6 
(26) 
107.5±1.9 
(11) 
109±1.5 
(18) 
129±3.5 
(20) 
129.4±3.6 
(14) 
149.6±4.
1 (2) 
122±1.1 
(176) 
Mean ambulatory HR 
(mmHg) 
68.7±2.7 
(16) 
73±2.4 
(13) 
70.2±2.8 
(19) 
76.9±3.6 
(13) 
75±2.6 
(17) 
77.4±4.3 
(7) 
75.1±1.5 
(26) 
74.2±2.2 
(11) 
75.5±2.2 
(18) 
79.6±2.2 
(20) 79±2 (14) 
82.6±8.6 
(2) 
75±0.8 
(176) 
Sleep DBP (mmHg) 
68.5±1.9 
(19) 
68.3±2 
(18) 
66±1.8 
(23) 
72.9±2.2 
(16) 
75.7±2.5 
(22) 
72.5±3.3 
(11) 
61.4±1.4 
(36) 
59.6±2.5 
(12) 
62±1.9 
(19) 
70.4±1.9 
(22) 
68.9±2.7 
(16) 
79±6.2 
(4) 
67.6±0.7 
(218) 
Sleep SBP (mmHg) 
114.8±2.2 
(19) 
112.1±1.8 
(18) 
111.8±2.1 
(23) 
120.1±3.7 
(16) 
124.9±3.9 
(22) 
122.2±4.3 
(11) 
102.1±1.5 
(36) 
99.2±2.2 
(12) 
103.4±2.5 
(19) 
117±3.9 
(22) 
115.1±3 
(16) 
134±10.9 
(4) 
112.7±1 
(218) 
Sleep HR (beast/min) 
64.9±2.2 
(18) 
67.6±1.6 
(18) 
64.9±2.5 
(23) 
64.4±2.3 
(16) 
66±3.1 
(22) 
68.5±3.7 
(11) 
71.4±1.6 
(36) 
71.1±2.7 
(12) 
71.8±2.6 
(19) 
74.7±2.1 
(21) 
72.9±2.6 
(16) 
76.8±7 
(4) 
69.2±0.8 
(216) 
Sleep MAP (mmHg) 
83.9±1.9 
(19) 
82.9±1.8 
(18) 
81.2±1.7 
(23) 
88.6±2.6 
(16) 
92.1±2.8 
(22) 
89.1±3.3 
(11) 
75±1.3 
(36) 
72.8±2.3 
(12) 
75.8±2 
(19) 
85.9±2.4 
(22) 
84.3±2.7 
(16) 
97.3±7.7 
(4) 
82.7±0.8 
(218) 
Sleep PP (mmHg) 
46.3±1.6 
(19) 
43.8±1.5 
(18) 
45.9±1.5 
(23) 
47.2±2.1 
(16) 
49.2±2.7 
(22) 
49.6±3.2 
(11) 
40.8±1.1 
(36) 
39.6±0.9 
(12) 
41.4±1.5 
(19) 
46.6±2.9 
(22) 
46.2±1.4 
(16) 
55±5.1 
(4) 
45±0.6 
(218) 
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Wake DBP (mmHg) 
75.8±1.5 
(20) 
76.6±2 
(18) 
74.3±1.8 
(23) 
83.7±2.3 
(16) 
83.3±2.4 
(22) 
84.1±3.4 
(11) 
70.7±1.3 
(35) 
70±2.2 
(12) 
71.2±2.2 
(19) 
80.4±2 
(21) 
78±2.2 
(16) 
84.8±5.2 
(4) 
76.7±0.7 
(217) 
Wake SBP (mmHg) 
125.3±2.3 
(20) 
124.2±2.2 
(18) 
124.1±2.2 
(23) 
132.5±3.3 
(16) 
137.6±3.9 
(22) 
138.3±4.8 
(11) 
114.9±1.6 
(35) 
111.2±1.7 
(12) 
117±3.2 
(19) 
130.7±4.1 
(21) 
128.6±3.2 
(16) 
145.8±10
.6 (4) 
125.5±1.1 
(217) 
Wake HR (beast/min) 
74.6±2.9 
(20) 
79.8±1.7 
(18) 
75.6±2.5 
(23) 
77±3.1 
(16) 
81±3.7 
(22) 
81.6±3.6 
(11) 
80.1±1.4 
(35) 
79.6±2.3 
(12) 
84.3±2.3 
(19) 
84.8±2.6 
(21) 
82.6±2.7 
(16) 
85.3±5.2 
(4) 
80.1±0.8 
(217) 
Wake MAP (mmHg) 
92.3±1.6 
(20) 
92.5±1.9 
(18) 
90.9±1.7 
(23) 
100±2.6 
(16) 
101.4±2.8 
(22) 
102.2±3.4 
(11) 
85.4±1.3 
(35) 
83.7±2 
(12) 
86.5±2.4 
(19) 
97.2±2.5 
(21) 
94.9±2.4 
(16) 
105.1±6.
9 (4) 
93±0.8 
(217) 
Wake PP (mmHg) 
49.5±1.7 
(20) 
47.6±1.7 
(18) 
49.8±1.7 
(23) 
48.8±1.6 
(16) 
54.3±2.5 
(22) 
54.2±4 
(11) 
44.2±1.4 
(35) 
41.2±1.1 
(12) 
45.8±1.9 
(19) 
50.3±3 
(21) 
50.6±1.9 
(16) 
61±6.2 
(4) 
48.8±0.7 
(217) 
Overall PP (mmHg) 
48.6±1.7 
(16) 
45.4±1 
(13) 
47.9±1.5 
(19) 
44.6±1.3 
(13) 
51.7±2.2 
(17) 
54.1±4.1 
(7) 
43.3±1.2 
(26) 
41.5±1.2 
(11) 
42.8±1.2 
(18) 
50.1±2.6 
(20) 
49.7±1.8 
(14) 
63±0.4 
(2) 
47.1±0.6 
(176) 
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Table 4. Correlation1 of obesity, stress and hemodynamic related traits with tobacco use 
Trait 
Current vs. never 
tobacco users 
Current vs. former 
tobacco users 
Former vs. never 
tobacco users 
Z P Z P Z P 
BMI (kg/m2) -3.3 5.E-04 -3.1 1.E-03 -0.8 2.E-01 
Waist Hip ratio -0.2 4.E-01 -1.1 1.E-01 0.5 3.E-01 
Waist circumference (cm) -2.4 8.E-03 -2.6 4.E-03 -0.3 4.E-01 
Hip circumference (cm) -3 1.E-03 -3 1.E-03 -0.6 3.E-01 
Hip Thigh Proximal ratio 3.2 6.E-04 2 3.E-02 2.7 4.E-03 
Thigh proximal circumference (cm) -4.9 5.E-07 -3.6 1.E-04 -2.1 2.E-02 
Thigh mid circumference (cm) -3.7 1.E-04 -3.6 1.E-04 -1.4 9.E-02 
Thigh distal circumference (cm) -3.9 5.E-05 -2.3 1.E-02 -1.8 3.E-02 
Skinfold bicep1 (mm) -1.5 6.E-02 -0.8 2.E-01 -1.3 9.E-02 
Skinfold bicep2 (mm) -1.5 7.E-02 -0.9 2.E-01 -1.2 1.E-01 
                                                            
1 Correlation test was performed using GEE method. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice 
versa. Correlation model is trait ~ sex + age + substance use. 
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Skinfold bicep3 (mm) -1.6 6.E-02 -0.9 2.E-01 -1.3 1.E-01 
Mean skinfold biceps (mm) -1.5 7.E-02 -0.9 2.E-01 -1.2 1.E-01 
Skinfold triceps1 (mm) -1.9 3.E-02 -1 2.E-01 -0.9 2.E-01 
Skinfold triceps2 (mm) -1.8 3.E-02 -1 2.E-01 -0.8 2.E-01 
Skinfold triceps3 (mm) -1.6 6.E-02 -1.1 1.E-01 -0.7 2.E-01 
Mean skinfold triceps (mm) -1.9 3.E-02 -1.1 1.E-01 -0.8 2.E-01 
Skinfold subscapular1 (mm) -1.6 5.E-02 -0.8 2.E-01 -0.7 2.E-01 
Skinfold subscapular2 (mm) -1.4 8.E-02 -0.7 3.E-01 -0.6 3.E-01 
Skinfold subscapular3 (mm) -1.7 4.E-02 -0.8 2.E-01 -0.7 3.E-01 
Mean skinfold subscapular (mm) -1.6 5.E-02 -0.8 2.E-01 -0.7 3.E-01 
Skinfold suprailiac1 (mm) -2.3 9.E-03 -0.7 2.E-01 -1.6 6.E-02 
Skinfold suprailiac2 (mm) -2.3 1.E-02 -1.1 1.E-01 -1.3 1.E-01 
Skinfold suprailiac3 (mm) -2.2 1.E-02 -0.9 2.E-01 -1.2 1.E-01 
Mean skinfold suprailiac (mm) -2.3 1.E-02 -0.9 2.E-01 -1.4 8.E-02 
Skinfold thigh1 (mm) -2.2 1.E-02 -0.6 3.E-01 -1.7 4.E-02 
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Skinfold thigh2 (mm) -2.1 2.E-02 -0.5 3.E-01 -1.9 3.E-02 
Skinfold thigh3 (mm) -2.3 1.E-02 -0.4 3.E-01 -2 2.E-02 
Mean skinfold thigh (mm) -2.3 1.E-02 -0.5 3.E-01 -1.9 3.E-02 
Body fat percentage bioimpedance -1.2 1.E-01 -0.4 4.E-01 -0.5 3.E-01 
Body fat (%) -2.5 6.E-03 -1.5 7.E-02 -0.9 2.E-01 
Supine EP (pg/ml) 1.1 1.E-01 2.3 1.E-02 -0.9 2.E-01 
Standing EP (pg/ml) 2.2 1.E-02 2.5 6.E-03 -0.3 4.E-01 
Response EP (pg/ml) 1.4 8.E-02 0.9 2.E-01 0.3 4.E-01 
Supine NE (pg/ml) 0.4 4.E-01 0.5 3.E-01 0 5.E-01 
Standing NE (pg/ml) 0.8 2.E-01 1.2 1.E-01 -0.5 3.E-01 
Response NE (pg/ml) 0.7 2.E-01 0.9 2.E-01 -0.6 3.E-01 
DBP response to mental stress (mmHg) 0.3 4.E-01 1.4 7.E-02 0 5.E-01 
DBP recovery mental stress (mmHg) -0.2 4.E-01 1.4 7.E-02 -0.1 4.E-01 
Delta DBP (mmHg) -0.6 3.E-01 0.4 3.E-01 -0.3 4.E-01 
SBP response to mental stress (mmHg) -0.3 4.E-01 -1.4 8.E-02 1.3 1.E-01 
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SBP recovery from mental stress 
(mmHg) -1.5 7.E-02 -1.8 3.E-02 0.9 2.E-01 
Delta SBP (mmHg) -2.1 2.E-02 -1.1 1.E-01 -0.6 3.E-01 
HR response to mental stress 
(beast/min) -1.8 4.E-02 -1.2 1.E-01 0.5 3.E-01 
HR recovery from mental stress 
(beast/min) -1.5 7.E-02 -1.9 3.E-02 0.9 2.E-01 
Delta HR (beast/min) 0.3 4.E-01 -0.6 3.E-01 0.6 3.E-01 
Average sitting DBP (mmHg) -1.7 4.E-02 -2.4 9.E-03 0.9 2.E-01 
Average sitting SBP (mmHg) -3.6 1.E-04 -2.3 1.E-02 -0.5 3.E-01 
Average sitting HR (beast/min) 0.4 3.E-01 0.5 3.E-01 -0.1 5.E-01 
Mean ambulatory DBP (mmHg) -2 2.E-02 -1.6 5.E-02 -0.1 5.E-01 
Mean ambulatory SBP (mmHg) -1 1.E-01 -1.5 7.E-02 0.2 4.E-01 
Mean ambulatory HR (mmHg) -0.6 3.E-01 0 5.E-01 -0.2 4.E-01 
Sleep DBP (mmHg) -0.7 3.E-01 0.5 3.E-01 -0.3 4.E-01 
Sleep SBP (mmHg) 0 5.E-01 0.3 4.E-01 0 5.E-01 
Sleep HR (beast/min) 0.3 4.E-01 0.1 5.E-01 0 5.E-01 
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Sleep MAP (mmHg) -0.3 4.E-01 0.5 3.E-01 -0.2 4.E-01 
Sleep PP (mmHg) 0.6 3.E-01 0.3 4.E-01 0 5.E-01 
Wake DBP (mmHg) -0.6 3.E-01 0 5.E-01 -0.5 3.E-01 
Wake SBP (mmHg) 0.3 4.E-01 0.7 2.E-01 -0.1 5.E-01 
Wake HR (beast/min) 1.7 4.E-02 0.1 4.E-01 0.5 3.E-01 
Wake MAP (mmHg) -0.2 4.E-01 0.3 4.E-01 -0.3 4.E-01 
Wake PP (mmHg) 0.9 2.E-01 1 2.E-01 0.1 5.E-01 
Overall PP (mmHg) 0.7 2.E-01 -0.4 4.E-01 0.6 3.E-01 
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Table 5. Correlation of obesity, stress and hemodynamic related traits with tobacco use in females and males 
Trait 
Females Males 
Current vs. never 
tobacco users 
Current vs. 
former tobacco 
users 
Former vs. never 
tobacco users 
Current vs. never 
tobacco users 
Current vs. 
former tobacco 
users 
Former vs. never 
tobacco users 
Z P Z P Z P Z P Z P Z P 
Hypertension status -2.4 8.E-03 -3.0 2.E-03 0.9 2.E-01 -1.8 4.E-02 -2.0 3.E-02 -0.2 4.E-01 
BMI (kg/m2) 0.0 5.E-01 -1.2 1.E-01 0.7 2.E-01 -4.1 2.E-05 -3.9 5.E-05 0.3 4.E-01 
Waist Hip ratio 1.2 1.E-01 0.2 4.E-01 1.1 1.E-01 -2.0 3.E-02 -1.9 3.E-02 0.4 3.E-01 
Waist circumference (cm) 0.0 5.E-01 -0.5 3.E-01 0.4 3.E-01 -3.4 4.E-04 -3.3 5.E-04 0.4 3.E-01 
Hip circumference (cm) -0.4 3.E-01 -0.7 2.E-01 0.2 4.E-01 -3.8 8.E-05 -4.1 2.E-05 0.4 3.E-01 
Hip Thigh Proximal ratio 0.2 4.E-01 -0.5 3.E-01 1.0 2.E-01 3.9 5.E-05 3.5 3.E-04 1.0 1.E-01 
Thigh proximal circumference 
(cm) -0.9 2.E-01 -0.6 3.E-01 -0.3 4.E-01 -5.0 2.E-07 -4.4 5.E-06 -0.6 3.E-01 
Thigh mid circumference (cm) -0.8 2.E-01 -1.3 1.E-01 0.3 4.E-01 -3.4 3.E-04 -3.9 5.E-05 0.1 5.E-01 
Thigh distal circumference (cm) -1.2 1.E-01 -0.6 3.E-01 -0.4 3.E-01 -4.2 1.E-05 -3.0 2.E-03 -0.2 4.E-01 
Skinfold bicep1 (mm) 1.2 1.E-01 0.5 3.E-01 0.5 3.E-01 -2.2 1.E-02 -0.8 2.E-01 -0.6 3.E-01 
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Skinfold bicep2 (mm) 1.2 1.E-01 0.2 4.E-01 0.7 2.E-01 -2.3 1.E-02 -0.7 2.E-01 -0.8 2.E-01 
Skinfold bicep3 (mm) 1.0 1.E-01 0.2 4.E-01 0.7 2.E-01 -2.4 7.E-03 -0.7 2.E-01 -0.9 2.E-01 
Mean skinfold biceps (mm) 1.1 1.E-01 0.3 4.E-01 0.7 3.E-01 -2.3 1.E-02 -0.7 2.E-01 -0.8 2.E-01 
Skinfold triceps1 (mm) 0.9 2.E-01 0.2 4.E-01 0.6 3.E-01 -2.6 5.E-03 -1.2 1.E-01 0.1 5.E-01 
Skinfold triceps2 (mm) 0.8 2.E-01 0.1 5.E-01 0.8 2.E-01 -2.3 1.E-02 -1.0 2.E-01 -0.2 4.E-01 
Skinfold triceps3 (mm) 1.2 1.E-01 0.1 5.E-01 1.2 1.E-01 -2.3 1.E-02 -1.1 1.E-01 -0.3 4.E-01 
Mean skinfold triceps (mm) 0.9 2.E-01 0.1 5.E-01 0.7 2.E-01 -2.4 8.E-03 -1.2 1.E-01 0.0 5.E-01 
Skinfold subscapular1 (mm) 2.3 1.E-02 1.0 1.E-01 1.7 5.E-02 -3.7 1.E-04 -2.1 2.E-02 -1.5 7.E-02 
Skinfold subscapular2 (mm) 2.4 7.E-03 1.2 1.E-01 1.7 5.E-02 -3.8 8.E-05 -2.2 1.E-02 -1.4 8.E-02 
Skinfold subscapular3 (mm) 2.3 1.E-02 1.0 2.E-01 1.7 4.E-02 -4.2 2.E-05 -2.2 1.E-02 -1.4 8.E-02 
Mean skinfold subscapular (mm) 2.3 1.E-02 1.1 1.E-01 1.7 5.E-02 -3.9 5.E-05 -2.2 1.E-02 -1.5 7.E-02 
Skinfold suprailiac1 (mm) 1.0 2.E-01 0.8 2.E-01 1.2 1.E-01 -3.7 1.E-04 -1.9 3.E-02 -1.0 2.E-01 
Skinfold suprailiac2 (mm) 0.9 2.E-01 0.4 3.E-01 1.6 5.E-02 -3.4 3.E-04 -2.1 2.E-02 -0.7 2.E-01 
Skinfold suprailiac3 (mm) 1.1 1.E-01 0.7 2.E-01 1.6 5.E-02 -3.3 4.E-04 -2.1 2.E-02 -0.8 2.E-01 
Mean skinfold suprailiac (mm) 1.0 2.E-01 0.7 3.E-01 1.5 7.E-02 -3.5 2.E-04 -2.0 2.E-02 -0.9 2.E-01 
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Skinfold thigh1 (mm) 0.3 4.E-01 0.6 3.E-01 0.2 4.E-01 -2.6 5.E-03 -0.9 2.E-01 -0.4 3.E-01 
Skinfold thigh2 (mm) 0.2 4.E-01 0.5 3.E-01 0.1 5.E-01 -2.6 4.E-03 -0.9 2.E-01 -0.7 2.E-01 
Skinfold thigh3 (mm) -0.1 4.E-01 0.5 3.E-01 0.0 5.E-01 -2.7 3.E-03 -0.8 2.E-01 -0.7 3.E-01 
Mean skinfold thigh (mm) 0.2 4.E-01 0.7 2.E-01 0.1 5.E-01 -2.6 4.E-03 -0.9 2.E-01 -0.5 3.E-01 
Body fat percentage 
bioimpedance 0.8 2.E-01 0.7 2.E-01 1.0 2.E-01 -2.1 2.E-02 -1.1 1.E-01 -0.3 4.E-01 
Body fat (%) 1.1 1.E-01 0.4 3.E-01 1.6 6.E-02 -4.9 4.E-07 -2.7 4.E-03 -1.1 1.E-01 
Supine EP (pg/ml) 1.1 1.E-01 1.2 1.E-01 -0.4 4.E-01 0.6 3.E-01 1.6 6.E-02 -0.5 3.E-01 
Standing EP (pg/ml) 2.7 3.E-03 3.3 6.E-04 -0.5 3.E-01 0.3 4.E-01 1.1 1.E-01 -0.1 5.E-01 
Response EP (pg/ml) 1.9 3.E-02 1.8 4.E-02 -0.3 4.E-01 0.2 4.E-01 -0.1 5.E-01 0.1 5.E-01 
Supine NE (pg/ml) 0.4 3.E-01 -0.2 4.E-01 0.7 2.E-01 0.4 3.E-01 0.8 2.E-01 0.0 5.E-01 
Standing NE (pg/ml) 0.0 5.E-01 0.4 4.E-01 -0.1 4.E-01 1.2 1.E-01 1.1 1.E-01 -0.3 4.E-01 
Response NE (pg/ml) -0.3 4.E-01 0.6 3.E-01 -0.5 3.E-01 1.1 1.E-01 0.8 2.E-01 -0.5 3.E-01 
DBP recovery mental stress 
(mmHg) -0.7 2.E-01 -1.0 2.E-01 2.4 9.E-03 0.5 3.E-01 2.7 3.E-03 -0.7 3.E-01 
DBP response to mental stress 
(mmHg) -0.4 3.E-01 -1.0 2.E-01 -0.4 3.E-01 1.0 2.E-01 2.2 1.E-02 0.2 4.E-01 
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Delta DBP (mmHg) -0.4 3.E-01 -0.4 3.E-01 0.5 3.E-01 -0.4 4.E-01 0.6 3.E-01 -0.6 3.E-01 
SBP recovery from mental stress 
(mmHg) -1.9 3.E-02 -1.7 5.E-02 -2.3 1.E-02 -0.3 4.E-01 -0.9 2.E-01 1.7 4.E-02 
SBP response to mental stress 
(mmHg) -1.3 9.E-02 -1.8 3.E-02 -1.4 7.E-02 0.5 3.E-01 -0.5 3.E-01 2.2 2.E-02 
Delta SBP (mmHg) -2.0 3.E-02 -0.4 3.E-01 -0.3 4.E-01 -1.2 1.E-01 -1.2 1.E-01 -0.3 4.E-01 
HR recovery from mental stress 
(beast/min) -0.6 3.E-01 -1.4 9.E-02 0.3 4.E-01 -0.5 3.E-01 -0.9 2.E-01 1.5 7.E-02 
HR response to mental stress 
(beast/min) -0.3 4.E-01 -1.1 1.E-01 0.4 3.E-01 -1.0 2.E-01 -0.4 4.E-01 2.7 4.E-03 
Delta HR (beast/min) -1.3 9.E-02 0.0 5.E-01 -0.6 3.E-01 1.1 1.E-01 -0.4 4.E-01 1.1 1.E-01 
Average sitting DBP (mmHg) -1.7 4.E-02 -3.3 5.E-04 0.9 2.E-01 -1.5 7.E-02 -1.5 6.E-02 -0.2 4.E-01 
Average sitting SBP (mmHg) -3.7 9.E-05 -2.6 5.E-03 -0.5 3.E-01 -1.8 4.E-02 -1.4 8.E-02 -0.3 4.E-01 
Average sitting HR (beast/min) 0.3 4.E-01 0.4 4.E-01 0.2 4.E-01 0.2 4.E-01 -0.1 5.E-01 -0.1 5.E-01 
Mean ambulatory DBP (mmHg) -0.9 2.E-01 -0.1 4.E-01 -1.8 4.E-02 -1.9 3.E-02 -3.4 4.E-04 1.4 8.E-02 
Mean ambulatory SBP (mmHg) -0.8 2.E-01 -0.2 4.E-01 -1.1 1.E-01 -0.4 4.E-01 -2.1 2.E-02 1.9 3.E-02 
Mean ambulatory HR (mmHg) 0.0 5.E-01 -0.2 4.E-01 -0.1 5.E-01 -2.9 2.E-03 -0.3 4.E-01 -0.5 3.E-01 
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Sleep DBP (mmHg) 0.5 3.E-01 0.7 2.E-01 -0.7 2.E-01 -1.3 1.E-01 -0.5 3.E-01 0.2 4.E-01 
Sleep SBP (mmHg) 0.7 2.E-01 0.9 2.E-01 -0.5 3.E-01 -0.5 3.E-01 -0.7 3.E-01 0.4 4.E-01 
Sleep HR (beast/min) 0.1 5.E-01 1.1 1.E-01 -0.3 4.E-01 0.5 3.E-01 0.0 5.E-01 0.0 5.E-01 
Sleep MAP (mmHg) 0.7 3.E-01 0.8 2.E-01 -0.8 2.E-01 -0.9 2.E-01 -0.5 3.E-01 0.3 4.E-01 
Sleep PP (mmHg) 0.9 2.E-01 0.6 3.E-01 0.5 3.E-01 0.3 4.E-01 -0.1 5.E-01 0.2 4.E-01 
Wake DBP (mmHg) 0.4 3.E-01 -0.1 5.E-01 -0.8 2.E-01 -1.0 2.E-01 -0.2 4.E-01 -0.3 4.E-01 
Wake SBP (mmHg) 0.7 3.E-01 1.1 1.E-01 -0.7 2.E-01 0.0 5.E-01 -0.2 4.E-01 0.7 2.E-01 
Wake HR (beast/min) 2.9 2.E-03 1.8 4.E-02 -0.1 5.E-01 0.3 4.E-01 -0.6 3.E-01 0.5 3.E-01 
Wake MAP (mmHg) 0.4 3.E-01 0.1 5.E-01 -0.9 2.E-01 -0.5 3.E-01 -0.3 4.E-01 0.2 4.E-01 
Wake PP (mmHg) 0.9 2.E-01 1.8 4.E-02 -0.5 3.E-01 0.6 3.E-01 0.0 5.E-01 1.0 2.E-01 
Overall PP (mmHg) 0.0 5.E-01 -0.4 4.E-01 -0.1 5.E-01 1.9 3.E-02 -0.2 4.E-01 1.5 7.E-02 
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Table 6. Correlation of obesity, stress and hemodynamic related traits with tobacco use in hypertensives and normotensives 
Trait 
Hypertensives Normotensives
Current vs. never 
tobacco users 
Current vs. 
former tobacco 
users 
Former vs. never 
tobacco users 
Current vs. never 
tobacco users 
Current vs. 
former tobacco 
users 
Former vs. never 
tobacco users 
Z P Z P Z P Z P Z P Z P
BMI (kg/m2) -2.3 1.E-02 -1.9 3.E-02 0.0 5.E-01 -1.8 4.E-02 -1.4 9.E-02 -1.4 8.E-02
Waist Hip ratio -0.4 3.E-01 -1.2 1.E-01 0.8 2.E-01 0.6 3.E-01 0.2 4.E-01 -0.2 4.E-01
Waist circumference (cm) -1.4 7.E-02 -1.1 1.E-01 0.0 5.E-01 -1.5 6.E-02 -1.4 8.E-02 -1.0 2.E-01
Hip circumference (cm) -2.2 1.E-02 -1.0 2.E-01 -0.5 3.E-01 -2.3 1.E-02 -2.6 4.E-03 -0.7 2.E-01
Hip Thigh Proximal ratio 2.9 2.E-03 1.6 6.E-02 2.4 8.E-03 2.7 3.E-03 0.7 2.E-01 1.9 3.E-02
Thigh proximal circumference (cm) -2.9 2.E-03 -1.7 4.E-02 -1.6 6.E-02 -3.7 9.E-05 -2.4 8.E-03 -1.6 6.E-02
Thigh mid circumference (cm) -2.6 5.E-03 -2.0 2.E-02 -1.1 1.E-01 -1.4 8.E-02 -1.9 3.E-02 -0.7 3.E-01
Thigh distal circumference (cm) -2.7 3.E-03 -0.9 2.E-01 -1.4 8.E-02 -2.7 3.E-03 -2.3 1.E-02 -1.5 7.E-02
Skinfold bicep1 (mm) -1.0 2.E-01 -0.3 4.E-01 -1.0 2.E-01 0.0 5.E-01 -0.3 4.E-01 -0.4 3.E-01
Skinfold bicep2 (mm) -0.8 2.E-01 -0.4 4.E-01 -0.5 3.E-01 -0.1 4.E-01 -0.1 5.E-01 -0.5 3.E-01
Skinfold bicep3 (mm) -0.8 2.E-01 -0.2 4.E-01 -0.7 2.E-01 -0.4 4.E-01 -0.3 4.E-01 -0.5 3.E-01
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Mean skinfold biceps (mm) -0.9 2.E-01 -0.3 4.E-01 -0.7 2.E-01 -0.2 4.E-01 -0.3 4.E-01 -0.4 3.E-01
Skinfold triceps1 (mm) -0.5 3.E-01 0.3 4.E-01 -1.0 2.E-01 -1.2 1.E-01 -1.0 1.E-01 0.0 5.E-01
Skinfold triceps2 (mm) -0.5 3.E-01 0.2 4.E-01 -0.9 2.E-01 -1.1 1.E-01 -1.0 2.E-01 0.0 5.E-01
Skinfold triceps3 (mm) -0.4 3.E-01 0.1 4.E-01 -0.7 2.E-01 -1.0 2.E-01 -1.0 1.E-01 0.1 4.E-01
Mean skinfold triceps (mm) -0.5 3.E-01 0.1 4.E-01 -0.8 2.E-01 -1.1 1.E-01 -1.0 2.E-01 0.0 5.E-01
Skinfold subscapular1 (mm) -1.4 9.E-02 -0.6 3.E-01 0.6 3.E-01 -1.0 2.E-01 0.1 5.E-01 -2.3 1.E-02
Skinfold subscapular2 (mm) -1.0 2.E-01 -0.5 3.E-01 0.7 2.E-01 -0.9 2.E-01 0.0 5.E-01 -2.2 1.E-02
Skinfold subscapular3 (mm) -1.3 1.E-01 -0.6 3.E-01 0.6 3.E-01 -1.1 1.E-01 -0.1 5.E-01 -2.3 1.E-02
Mean skinfold subscapular (mm) -1.2 1.E-01 -0.6 3.E-01 0.6 3.E-01 -1.0 1.E-01 0.0 5.E-01 -2.3 1.E-02
Skinfold suprailiac1 (mm) -0.6 3.E-01 0.5 3.E-01 -0.1 5.E-01 -2.8 3.E-03 -0.6 3.E-01 -2.8 3.E-03
Skinfold suprailiac2 (mm) -0.7 3.E-01 0.3 4.E-01 0.0 5.E-01 -2.7 4.E-03 -1.0 2.E-01 -2.5 7.E-03
Skinfold suprailiac3 (mm) -0.7 2.E-01 0.3 4.E-01 0.0 5.E-01 -2.4 8.E-03 -0.8 2.E-01 -2.3 1.E-02
Mean skinfold suprailiac (mm) -0.7 3.E-01 0.4 3.E-01 -0.1 5.E-01 -2.7 4.E-03 -0.8 2.E-01 -2.6 5.E-03
Skinfold thigh1 (mm) -0.6 3.E-01 0.8 2.E-01 -1.3 9.E-02 -2.0 2.E-02 -1.7 5.E-02 -0.4 3.E-01
Skinfold thigh2 (mm) -0.7 3.E-01 0.8 2.E-01 -1.4 9.E-02 -1.9 3.E-02 -1.6 6.E-02 -0.7 2.E-01
Skinfold thigh3 (mm) -0.8 2.E-01 0.7 3.E-01 -1.4 8.E-02 -2.0 2.E-02 -1.4 9.E-02 -0.9 2.E-01
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Mean skinfold thigh (mm) -0.7 2.E-01 0.7 2.E-01 -1.3 9.E-02 -2.0 2.E-02 -1.5 6.E-02 -0.6 3.E-01
Body fat percentage bioimpedance 0.0 5.E-01 3.1 8.E-04 -0.8 2.E-01 -1.3 1.E-01 -1.7 4.E-02 0.3 4.E-01
Body fat (%) -1.2 1.E-01 -0.5 3.E-01 -0.1 5.E-01 -2.3 1.E-02 -1.0 2.E-01 -1.7 5.E-02
Supine EP (pg/ml) 0.5 3.E-01 1.2 1.E-01 0.0 5.E-01 0.3 4.E-01 2.2 1.E-02 -1.5 6.E-02
Standing EP (pg/ml) 0.9 2.E-01 0.1 4.E-01 0.5 3.E-01 1.6 5.E-02 3.6 2.E-04 -1.2 1.E-01
Response EP (pg/ml) -0.8 2.E-01 -0.7 2.E-01 0.7 3.E-01 1.9 3.E-02 2.4 9.E-03 -0.2 4.E-01
Supine NE (pg/ml) 0.6 3.E-01 0.2 4.E-01 -0.2 4.E-01 0.4 3.E-01 0.3 4.E-01 1.1 1.E-01
Standing NE (pg/ml) 0.9 2.E-01 0.5 3.E-01 -0.7 2.E-01 0.8 2.E-01 0.7 2.E-01 0.6 3.E-01
Response NE (pg/ml) 0.5 3.E-01 1.1 1.E-01 -1.1 1.E-01 0.8 2.E-01 0.4 4.E-01 0.5 3.E-01
DBP recovery mental stress (mmHg) 0.8 2.E-01 1.8 4.E-02 0.0 5.E-01 0.0 5.E-01 1.1 1.E-01 -0.1 5.E-01
DBP response to mental stress (mmHg) 1.0 2.E-01 1.7 4.E-02 0.1 5.E-01 0.4 3.E-01 0.7 2.E-01 0.6 3.E-01
Delta DBP (mmHg) -0.3 4.E-01 -0.6 3.E-01 0.5 3.E-01 -0.7 2.E-01 1.2 1.E-01 -1.1 1.E-01
SBP recovery from mental stress (mmHg) -0.6 3.E-01 -1.1 1.E-01 0.8 2.E-01 -0.1 4.E-01 -0.3 4.E-01 0.7 2.E-01
SBP response to mental stress (mmHg) 0.2 4.E-01 -0.1 5.E-01 0.9 2.E-01 0.6 3.E-01 -0.3 4.E-01 1.8 4.E-02
Delta SBP (mmHg) -0.9 2.E-01 -0.7 3.E-01 0.0 5.E-01 -2.2 1.E-02 0.0 5.E-01 -1.5 6.E-02
HR recovery from mental stress (beast/min) -0.4 4.E-01 -0.6 3.E-01 -0.2 4.E-01 -1.0 2.E-01 -1.6 6.E-02 0.9 2.E-01
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HR response to mental stress (beast/min) -0.4 3.E-01 0.3 4.E-01 -0.2 4.E-01 -1.5 7.E-02 -1.0 1.E-01 0.5 3.E-01
Delta HR (beast/min) -0.4 3.E-01 -0.9 2.E-01 -0.5 3.E-01 0.4 3.E-01 -0.5 3.E-01 1.2 1.E-01
Average sitting DBP (mmHg) -0.5 3.E-01 -0.5 3.E-01 0.8 2.E-01 -1.6 6.E-02 -2.5 7.E-03 0.7 2.E-01
Average sitting SBP (mmHg) 0.3 4.E-01 0.2 4.E-01 -0.3 4.E-01 -3.9 4.E-05 -1.7 5.E-02 -1.2 1.E-01
Average sitting HR (beast/min) 0.4 3.E-01 1.9 3.E-02 -1.6 5.E-02 1.0 2.E-01 -0.5 3.E-01 1.8 4.E-02
Mean ambulatory DBP (mmHg) 1.6 6.E-02 -0.4 4.E-01 0.9 2.E-01 -2.1 2.E-02 -1.2 1.E-01 -0.1 5.E-01
Mean ambulatory SBP (mmHg) 4.0 4.E-05 1.5 7.E-02 0.8 2.E-01 -1.8 4.E-02 -0.6 3.E-01 -1.0 2.E-01
Mean ambulatory HR (mmHg) 0.7 2.E-01 0.5 3.E-01 0.3 4.E-01 -0.3 4.E-01 -0.2 4.E-01 -0.1 4.E-01
Sleep DBP (mmHg) 0.9 2.E-01 2.8 3.E-03 -0.2 4.E-01 -0.7 2.E-01 1.0 2.E-01 -0.4 3.E-01
Sleep SBP (mmHg) 1.8 4.E-02 2.3 1.E-02 0.2 4.E-01 0.0 5.E-01 1.1 1.E-01 -0.8 2.E-01
Sleep HR (beast/min) 1.1 1.E-01 1.6 6.E-02 -0.3 4.E-01 -0.5 3.E-01 -0.3 4.E-01 -0.6 3.E-01
Sleep MAP (mmHg) 1.4 8.E-02 2.6 5.E-03 -0.1 5.E-01 -0.3 4.E-01 1.0 1.E-01 -0.6 3.E-01
Sleep PP (mmHg) 1.6 5.E-02 1.1 1.E-01 0.3 4.E-01 0.7 3.E-01 1.2 1.E-01 -1.3 1.E-01
Wake DBP (mmHg) 1.1 1.E-01 1.6 5.E-02 -0.5 3.E-01 -0.4 4.E-01 0.0 5.E-01 0.5 3.E-01
Wake SBP (mmHg) 2.7 3.E-03 2.8 2.E-03 -0.1 5.E-01 -0.1 5.E-01 1.3 9.E-02 -1.1 1.E-01
Wake HR (beast/min) 1.8 3.E-02 4.3 1.E-05 -0.2 4.E-01 1.1 1.E-01 -0.2 4.E-01 1.1 1.E-01
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Wake MAP (mmHg) 2.0 2.E-02 1.9 3.E-02 -0.4 3.E-01 -0.6 3.E-01 0.4 3.E-01 -0.1 5.E-01
Wake PP (mmHg) 3.7 9.E-05 0.5 3.E-01 0.7 3.E-01 0.2 4.E-01 1.7 5.E-02 -0.9 2.E-01
Overall PP (mmHg) 4.7 1.E-06 2.7 4.E-03 1.0 2.E-01 -0.5 3.E-01 1.0 2.E-01 -1.8 3.E-02
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Table 7. Significantly shared SNPs between tobacco use and correlated obesity, stress and 
hemodynamic related traits 
Status Trait SNP Univariate P Gene Combined P
G
e
n
e
ra
l 
Waist circumference rs679783 7.40E-05
AGBL4 2.30E-07 
Former vs. never tobacco users rs679783 1.60E-04
Current vs. never tobacco users rs679783 6.00E-04
Hip circumference  rs679783 8.40E-04
Thigh mid circumference rs679783 1.90E-03
Thigh distal circumference rs679783 2.50E-03
BMI rs679783 2.50E-03
Thigh proximal circumference rs679783 3.30E-03
 
   
M
a
le
s 
Former vs. never tobacco users rs947084 2.20E-05
OBSCN 1.20E-06 Current vs. former tobacco users rs947084 5.10E-04
Hip Thigh Proximal ratio rs947084 3.20E-03
 
   
H
yp
e
rt
e
n
si
ve
s 
Current vs. former tobacco users rs36950 2.70E-05
KCNN2 1.54E-08 
Current vs. never tobacco users rs36950 2.70E-05
SBP recovery from mental stress rs36950 1.30E-03
Mean ambulatory SBP rs36950 8.80E-03
 
  
192 
 
 
Table 8. Bivariate association analysis on significantly shared SNPs 
Status Tobacco use Correlated trait SNP Bivariate P Gene 
G
e
n
e
ra
l 
Former vs. never tobacco users Hip circumference  rs679783 1.2E-03 
AGBL4 
Current vs. never tobacco users Hip circumference  rs679783 1.9E-04 
Former vs. never tobacco users Thigh mid circumference  rs679783 9.2E-04 
Current vs. never tobacco users Thigh mid circumference  rs679783 7.3E-04 
Former vs. never tobacco users Thigh distal circumference  rs679783 1.5E-03 
Current vs. never tobacco users Thigh distal circumference  rs679783 1.3E-03 
Former vs. never tobacco users BMI rs679783 2.2E-03 
Current vs. never tobacco users BMI rs679783 8.0E-04 
Former vs. never tobacco users Thigh proximal circumference  rs679783 2.7E-03 
Current vs. never tobacco users Thigh proximal circumference  rs679783 1.0E-03 
Former vs. never tobacco users Waist circumference  rs679783 1.2E-04 
Current vs. never tobacco users Waist circumference  rs679783 3.0E-05 
M
a
le
s Former vs. never tobacco users Hip Thigh Proximal ratio rs947084 5.2E-06 
OBSCN 
Current vs. former tobacco users Hip Thigh Proximal ratio rs947084 3.9E-03 
H
yp
e
rt
e
n
si
ve
s 
Current vs. never tobacco users SBP recovery from mental stress rs36956 2.4E-06 
KCNN2 
Current vs. former tobacco users SBP recovery from mental stress rs36956 2.4E-06 
Current vs. former tobacco users SBP recovery from mental stress rs36950 8.1E-06 
Current vs. never tobacco users SBP recovery from mental stress rs36950 8.1E-06 
Current vs. former tobacco users Mean ambulatory SBP rs36950 2.5E-05 
Current vs. never tobacco users Mean ambulatory SBP rs36950 2.5E-05 
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 Discussion 
 
 
 
 
4.1 Shared genetic factors among polygenic disorders  
Earlier large-scale clinical studies indicated that many patients suffer from several 
complex disorders simultaneously. For instance, metabolic syndrome is characterized by a 
group of risk factors including central obesity, dyslipidemia, hypertension, and impaired 
glucose/insulin homeostasis. Among patients diagnosed with cardiovascular disorders, only 
20–25% of patients have only one concomitant disease; while, the remainders suffer from 
two or more disorders. It is also reported that 40% of patients with type 2 diabetes have 
three or more concomitant diseases.1-4  
Growing number of studies pointed that apart from environmental factors genetic 
determinants are also involved in these phenotypic correlations. Williams et al5 investigated 
the correlation between hypertension, migraine, Raynaud's phenomenon and coronary 
artery disease in a sample of 2204 individuals that included 525 monozygous twins and 577 
dizygous twins and calculated genetic correlations among these traits, they reported 
significant genetic contribution to all four traits with heritabilities ranging from 0.34 to 0.64 
and found that a shared genetic componet explains the phenotypic correlations among these 
vascular conditions.  
Rzhetzky et al6 analyzed 1.5 million medical records involving 161 diseases 
represent a broad spectrum of disorders affecting diverse physiological systems and 
estimate pairwise correlations of disease co-occurrences as well as the extent of genetic 
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overlap among them. They noted that disease phenotypes form a highly connected network 
of strong pairwise correlations and found that multifactorial disease phenotypes are highly 
genetically correlated traits and recommend the design of gene-mapping studies that 
analyze multiple disorders jointly. 
In another study using data from Mendelian Inheritance in Man (OMIM) database 
that represents and up-to-date repository of all known disease genes and the disorders, Goh 
et al7 constructed a network of human diseases in which two disorders are connected to 
each other if they share at least one gene. Although they found clustering among the disease 
of the same class but the resulted network did not fall into many single nodes 
corresponding to specific disorders or grouped into small clusters of a few closely related 
disorders; instead it form a large network of human diseases. Of 1,284 disorders in OMIM 
database, 867 had at least one link to other disorders, and 516 disorders form a giant 
component, suggesting that the genetic origins of most diseases, to some extent, are shared 
with other diseases. 
In a more recent study, Torkamani et al8 compared the results of GWAS of bipolar 
disorder, coronary artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 
1 diabetes, and type 2 diabetes performed in Wellcome Trust Case Control Consortium 
(WTCCC) GWAS dataset. They found a large number of significantly shared SNPs not 
only among the related ones but also among seemingly unrelated traits e.g. among bipolar 
disorder with the metabolic disorders, coronary artery disease and type 2 diabetes or 
between hypertension and Crohn’s disease.  
Despite numerous evidences suggest pleiotropic genes are not rare among polygenic 
disorders, current genome-wide scan studies are normally analyze different phenotypes in 
isolation and ignores genes that are showing pleiotropic effect and important to the 
pathogenesis of correlated disorders and can provide several benefits.7; 9-11  
Motivated by these lines of evidences, we aimed to investigate for shared genomic 
factors of habitual alcohol, tobacco and coffee use, response to mental and physical stress, 
obesity-related anthropometric traits and heart rate (HR) and blood pressure (BP) 
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measurements. Alcohol, tobacco and coffee are the most commonly consumed 
psychoactive substances in the world. Their concurrent use has been consistently shown 
across a wide variety of populations.15 Stress has been found both in experimental and 
clinical research to relate to initiation, intensification and relapse to substance use;16 
besides, both stress and substance use are considered as contributing factors to development 
of cardiovascular disease and cardiovascular risk factors including obesity.12-14; 59   
HPA axis, the main component of body’s response to stressors has been implicated 
in substance use,  obesity and regulation of cardiovascular system;17-21 moreover, number of 
genes involved in HPA axis were found to connect these traits; for instance, variations in 
mu opioid receptor (OPRM1) have been reported to influence response to stressors, food 
intake and substance use;12; 17; 21 nonetheless, similar to other polygenic traits, substance use, 
obesity, stress, and cardiovascular traits have multifactorial etiology with a substantial 
complex genetic components and further studies are required to uncover the genetic nature 
and relations among these traits; therefore, we hypothesized that the links among substance 
use habits, obesity, stress, and related cardiovascular outcomes may be in part due to 
variations in shared genetic factors.  
In this study consistent with the observed phenotyping correlations among these 
traits. Following genome wide scans, we found numerous significantly shared SNPs among 
these traits which further support the hypothesis indicates phenotypic correlation is a 
predictor of genotypic overlaps in polygenic disorders.  
 
4.2 Synaptic plasticity 
The identified shared loci were not unrelated; in contrast, their products interact 
with one another through protein–protein interactions, display higher expression and 
similar expression profiles in brain-related tissues and finally cluster in synaptic plasticity 
related pathways. Together, these findings suggest that synaptic plasticity, an important 
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foundation of learning and memory is a common interface behind substance use, stress, 
obesity, HR and BP. 
This is consistent with previous implications of synaptic plasticity for these traits. 
For instance, physiological studies have also shown that both substance use and stress 
influence the synaptic plasticity and substance use can change the sensitivity of synaptic 
plasticity to stressors;22; 23 moreover, an influential hypothesis suggests that addiction is a 
strong form of learning. Synaptic plasticity also appears to be involved in the regulation of 
energy homeostasis and is acting as an important path through which peripheral metabolic 
hormones influence brain functions.24 In fact, similar to psychoactive drugs, palatable foods 
can activate the brain reward system and pharmacological blockade of, or experimental 
damage to forebrain dopamine systems attenuates free feeding and lever-pressing for food 
reward, as well as the rewarding effects of psychoactive substances;25; 26 moreover, synaptic 
sensitization, an attribute of thalamocortical and memory neurons, is responsible for 
hypothalamic hyperresponsiveness to environmental stimuli, it ensures that repeated 
stimulation of the defense pathway makes it respond to ever milder stresses, so that 
hypertension eventually becomes permanent.59 
We assume the interaction between genetic make-up of synapses with 
environmental factors including stress influence individuals’s life styles and habits; in the 
other side, the taken habits and lifestyle influence the body’s systems including 
cardiovascular system and modify the cardiovascular outcomes as well as cardiovascular 
risk factors including body weight; nonetheless, similar to different routes ended to the 
same location, there are other factors that influence the cardiovascular system through other 
mechanisms. Our results also suggest that synaptic plasticity may be a common interface 
behind many of other complex disorders in which life style is a contributing factor.6; 7; 27  
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4.3 Network thinking 
The observation that identified shared genes among substance use, obesity, stress 
and hemodynamic traits tend to cluster and share interaction and function in synaptic 
processes indicates that these genes rather than being unrelated, are components of a 
functional module. Consistent with our findings,  by comparing GWAS results of bipolar 
disorder, coronary artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 
1 diabetes, and type 2 diabetes performed in WTCCC dataset,  Torkamnai et al8 found set 
of signaling factors including G-protein, adenylate cyclase, protein kinase A and C, inositol 
trisphosphate (IP3), and calcium signaling mechanisms are behind general morbidity of 
these traits; therefore, considering network-based approaches can help elucidate common 
biological interfaces underlie comorbidity of disorders 
Our findings also support network-based model proposed for polygenic disorders 
which indicates cellular networks are modular, consisting of groups of highly 
interconnected proteins responsible for specific cellular functions and a disorder represents 
the perturbation or breakdown of a specific functional module caused by variations in 
components of the network producing recognizable developmental and/or physiological 
abnormalities.  
 
4.4 Epistasis and pleiotropy 
Such Network-based view also leads to the conclusion that unlike Mendelian 
disorders, epistasis and pleiotropy are not rare occurrences, but ubiquitous and inherent 
genetic properties of polygenic disorders. Pleiotropy, in which one mutation causes 
multiple phenotypes, has traditionally been seen as a deviation from the traditional 
observation in which one gene affects one phenotype. Epistasis, or gene–gene interaction, 
has also been treated as an exception to the Mendelian one gene–one phenotype paradigm; 
however, assuming dysregulation of a modular network is behind a polygenic disorder and 
considering the widespread connectivity of networks; therefore, epistasis and pleiotropy are 
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expected byproducts of bimolecular networks; hence, these phenomena should not be 
ignored or treated as rare occurrences in genetic analysis of complex disorders, but rather as 
features that can help to elucidate the genetic nature and underlying mechanisms.28 
 
4.5 Sex and hypertension differences 
We found that large portions of variations of studied traits are attributed to sex and 
hypertension status, focusing on tobacco use we noted that even degree and the direction of 
correlations of obesity, hemodynamic and stress related traits with tobacco use vary 
according to sex and hypertension status; for instance, while in males, analysis of both 
global and regional measurements of obesity indicated that current tobacco users are less 
obese compared to never or former tobacco users, obesity related measures were not 
significantly different among tobacco use statues in females and even, unlike males, 
subscapular skinfold measurement was higher in female smokers compared to non smokers. 
Consistent with above findings, subgroup analysis revealed shared loci among 
substance use, obesity, stress and hemodynamic traits; moreover, we also found sex- and 
hypertension differences in heritabilities of many of these traits.29; 30 Detection of such 
specific loci may be due to their sex- and hypertension-specific effects or co-segregation 
with epistatic sex- and hypertension specific genetic factors that modify their effects;29-32 
therefore, adjustment for sex and hypertension status can obscure identification of such 
variations. 
Hypertension-specific analysis uncovered SNP, rs4687150 inside IL1RAP gene 
which was negatively associated (P = 0.0004) to coffee use in hypertensives and positively 
associated (P = 0.0002) in normotensives.  Sex specific genetic analysis revealed SNPs, 
rs4888197 and rs847936 inside PLCG2 and near SCIN which were negatively associated 
(P < 0.001) in females and positively associated (P < 0.001) in males. All three genes, 
IL1RAP, PLCG2, and SCIN shared synaptic function and consistent with the finding of 
SCIN gene for tobacco use, it is reported that nicotinic-receptor stimulation induces the 
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intracellular redistribution of SCIN protein;33 therefore, it is obvious that mixing the two 
groups together as it is carried out in general analysis will eliminate such association 
signals. 
Identification of hypertension specific loci also indicates that there are genetic links 
between these traits and hypertension which further support the phenotypic relatedness of 
substance use, stress response and obesity with hypertension. Consistently previous 
findings from our group also found that hypertensive and normotensive siblings drawn from 
the same families differ significantly by both degree and distribution of body fat 
accumulation and that genetic factors that co-segregate with hypertension appear to play a 
significant role in this difference.31 Sex-specific genetic architecture has also been found to 
be an important mechanism underlying many complex traits; moreover, sex-specific 
genetic differences have been already reported for obesity, stress, substance use and 
hemodynamic data.15; 29; 30; 34; 35 
Commonly associated genes driven from sex-specific and hypertension-specific 
analysis tended to display similar expression profiles and functional characteristics to those 
from general results; moreover, we found shared genes and numerous interactions among 
gene sets driven from general analysis and sex and hypertension-specific analysis, 
suggesting sex-specific and hypertension-specific genetic differences appear to be also due 
to variations in synaptic processes; therefore, by increasing genetic homogeneity, subgroup 
analysis can uncover additional components of functional modules underlying complex 
disorder that otherwise remain obscure following statistical adjustments; moreover, such 
findings can shed lights into the observed sex and hypertension differences in prevalence of 
these disorders. Overall these findings point to the importance of subgroup analysis in 
genetic studies as well as personalized medicine programs and underline the weakness of 
statistical adjustments. 
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4.6 Smoking initiation and persistence 
In addition to environmental factors, smoking behavior also has genetic 
underpinnings; moreover, it has been reported that genetic factors contribute differently to 
the determination of smoking initiation and persistence in male and female smokers.36 
Consistent with these results we found that both initiation (61% in former vs. never tobacco 
users) and persistence of tobacco use (46% in current vs. former tobacco users) are highly 
attributed to genetic factors; sex-specific heritability estimates for tobacco use showed that 
genetic factors are more important in initiation (males = 81%, females = 56%) and 
persistence of tobacco use (males = 97%, females = 23%) in males compared to females; 
since hypertensive subjects are recommended to stop smoking therefore comparing the 
heritability differences of smoking behavior between smokers and non smokers seems 
inappropriate; however, compared to general population heritability of smoking initiation 
was higher in normotensive subjects while the heritability of smoking persistence was 
lower.  
 Inclusion of former smokers in this study allows us to determine whether smoking 
cession is associated with a similar magnitude of change to that typical of non smokers and 
also if the shared genetic factors between former and current tobacco users contribute to the 
differences. In this regard, we found several obesity related traits that their relatedness with 
smoking behavior seemingly are mediated by genetic factors. Thigh skinfold in whole 
cohort subscapular skinfold in females, superaialic skinfold and body fat percentage in 
normotensives along with hip thigh proximal ratio in both normotensives and hypertensives 
were significantly correlated with current and former tobacco users as compared to subjects 
with no history of tobacco use; moreover, the differences between current and former 
tobacco users were insignificant for these traits which suggest that the observed correlations 
probably roots in genetic factors that are shared between former and current tobacco users 
rather than smoking effect itself. 
Moreover, detected SNPs following search for genotypic links between tobacco use 
and significantly correlated obesity, stress and hymedynamic traits with tobacco use, 
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highlighted the presence of genetic similarities and differences between current and former 
tobacco users; SNP, rs679783 was significantly associated to both smoking initiation and 
persistence while rs947084 was significantly associated to smoking initiation and SNP, 
rs36950 was significantly associated to smoking persistence.  
 
4.7 Network based genome-wide scan 
Genome-wide association studies (GWAS) armed with efficient genotyping 
technologies have been emerged as a major tool to identify disease susceptibility loci and 
have been successful detecting novel genes for several complex diseases.37 The current 
GWAS have focused on single SNP analysis in which allelic frequencies of each marker 
are compared between affected and unaffected subjects; however, due to the factors like 
large multiple testing involved in these studies or the limited power of study, very few 
numbers of SNPs exceed the genome-wide significance threshold. The detected SNPs 
typically have only mild effects and account for small fraction of both the heritable 
component and the population disease burden; moreover, they may not be reproducible in 
other samples which point to presence of locus heterogeneity;38-40 therefore, it is likely that 
alternative analysis approaches to GWAS data that focus on the combined effects of many 
loci, each making a small contribution to overall disease liability, may reveal novel insights 
into genetic underpinnings of complex disorders; for instance, it has been shown that any 
single gene polymorphism explains just 1-8% of total disease risk for a polygenic trait in 
studied population; however, the additive effects of several polymorphisms can be 20-70% 
of total genetic risk.41 
Such approach is also supported in network-based view, namely, if a disorders is as 
a result of accumulating effect of several variations in a functional module producing 
recognizable developmental and/or physiological changes;7; 42; 43 single SNP analysis offers 
limited understanding of biological mechanisms behind complex disorders; moreover, in a 
network-based view, locus heterogeneity appears to be inherent property of a complex 
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disorder since variations in different components of a network can result into the same 
outcome; therefore, to understand molecular mechanisms behind complex disorders; in 
addition, to identify the list of disease genes; understanding the detailed wiring diagram of 
the variations or viewing the genes in the context of biological process is important too.44 
Previous studies also reported that common human diseases are modulated by a 
large number of low-risk variations which tend to localize in the functional periphery of a 
modular network, and these variations are not likely to be easily detectable through the use 
of standard single-locus-oriented univariate GWAS analysis techniques; in addition, 
network-based genome wide scans have already provided novel insights into the 
pathogenesis of polygenic disorders which are not evident in single SNP analysis 
approach.7; 8; 27; 45 
Therefore, network-based genetic analysis which seeks to extract large amounts of 
biologically relevant information from variants that have small genetic effects; however, 
their joint actions will play a significant role in the development of disease, appeared to be 
extremely useful approach for extending current single-locus-oriented, univariate GWAS 
analysis techniques, such approach can compensate for the lack of statistical power due to 
insufficient sample size in single based GWAS. Replication of association finding at a 
pathway level is also much easier than replication at the SNP level.  Besides, since SNPs 
and genes carry on their functions through intricate pathways of reactions and interaction; 
therefore, attempting to understand and interpret a number of significant SNPs without any 
unifying biological theme can be challenging and demanding.46 
Altogether it appears that network-based approaches can help overcome the 
limitations imposed by univariate single-locus analysis of GWAS data and offer a powerful 
methodology for revealing the polygenic nature of common chronic disease susceptibility; 
moreover, network based approaches provide a new perspective on how large human 
genomic data set information can be processed to uncover pathways that otherwise would 
remain unrecognized; thus, beyond replication of particular SNP associations arising from 
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future GWAS and sequencing studies, consideration and further validation of pathway 
analysis may be an useful and insightful research aspect. 
 
4.8 Disease classification and profiling 
This study highlights the presence of genetic similarities among obesity, stress, 
substance use and hemodynamic traits. Similarly notable connections between even 
seemingly unrelated diseases have been observed previously, and many more will definitely 
be revealed by upcoming studies. For example, macular degeneration and myocardial 
infarction, diseases whose phenotypes appear to be unrelated, have been connected by 
susceptibility polymorphisms in complement factor H (CFH).47; 48 Myocardial infarction 
was also connected to other inflammatory diseases, such as multiple sclerosis and 
rheumatoid arthritis, by MHC2TA polymorphisms;49 P35/CDK5 signaling pathway has 
been implicated in both, alzheimer’s disease and type 2 diabetes;50 Several genes including 
ENPP1, PPARA, and FTO gene are already implicated in both obesity and diabetes;44; 51; 52 
and as mentioned earlier, Torkamnai et al8 found shared SNPs among even seemingly 
unrelated traits.  
The existence of intricate molecular links between sub cellular components and 
disease genes raises another possibility that polygenic diseases may not be as independent 
of one another as medical practitioners currently consider them to be and indicates that such 
studies can be used to indentify genetic similarities and differences among polygenic 
disorders and therefore may have applications for the field of nosology or disease 
classification. Current classification of human disease derives from observational 
correlation between pathological and physiological measurements with clinical syndromes. 
Characterizing disease in this way established a nosology that has served clinicians well to 
the current time. Yet, this diagnostic strategy has significant shortcomings that reflect both 
a lack of sensitivity in identifying preclinical disease, and a lack of specificity in defining 
disease unequivocally.11; 53 
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Previous genetic studies have already provided evidences of seemingly unrelated 
diseases are being lumped together. What were thought to be a single disease appears to 
root in different genotypes. Such studies point that focusing on underlying molecular 
signature of disorders in addition to conventional prognosis may have several benefits 
including; providing new insights into mechanisms of co morbidity of disorders; allowing 
to understand the basis of disease susceptibility and environmental effects; offering an 
explanation for the different phenotypic manifestations of the same disease; helping to 
define disease prognosis more precisely with optimal sensitivity and specificity; and 
eventually individualizing disease treatment for best possible therapeutic approach.11; 53-55 
Sub-classifying histologically similar cancers by differences in surface biomarkers, 
transcription profiling, genetic variations or proteomic analysis is currently being applied to 
several malignancies, including adenocarcinoma of the breast and lymphomas, in an effort 
to provide better information about prognosis and response to therapy;53; 55-57 moreover, as 
molecular underpinnings of many disorders were identified and the genetic similarities and 
differences among disorders becoming more characterized. This approach appears to 
eventually become more objective as an essential part of the overall diagnostic paradigm. 
Considering these findings, we are aiming to classify and map our studied 
phenotypes by measuring the extent of genetic similarities and differences among them as 
well as their genetic distances with other phenotypes in our database by use of findings 
driven from GWAS as wells as shared heritability estimates. The constructed phenotype 
map can subsequently be overlaid with drug-target network to explore potential therapeutic 
implications.  
 
4.9 Drug network 
Identification of common molecular interface among polygenic disorders can also 
provides new applications for current medications; for instance, if two disorders are sharing 
similar modular network, perhaps drugs which are used for one, can be tested against the 
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other; moreover, such studies will provide further insight into possible drug side effects and 
contribute to development of more rational therapeutic approaches. Such Network-based 
thinking also raise the question whether directly targeting the product of mutated genes is 
efficient or targeting network properties and then accounting for indirect effects of drug is 
more productive; either way, a good understanding of underlying factors is essential.58 
 
4.10  Conclusion 
In this study, we found significant phenotypic correlations among substance use, 
obesity, stress and hemodynamic traits. For instance, Alcohol and tobacco users had 
attenuated heart rate response to mental stress; moreover, tobacco users had lower blood 
pressure compared to non users; Hypertensives had stronger HR and SBP response to 
mental stress and higher BMI compared to normotensives; Use of tobacco seemed to 
increase the epinephrine level in body and higher epinephrine level was correlated with 
lower BMI.  
Consistent with phenotypic relatedness, We found shared genes associated / linked 
to substance use, obesity-related traits, response to mental and physical stress and 
hemodynamic traits including CAMK4, CNTN4, DLG2, DAG1, FHIT, GRID2, ITPR2, 
NOVA1, NRG3 and PRKCE forming protein interaction network, involved in synaptic 
plasticity and highly expressed in brain related tissues; moreover, pathway analysis on 
identified genes pointed (P = 0.03) to Long-Term Potentiation pathway, an important form 
of synaptic plasticity. 
We found that large portions of variations of studied traits are attributed to sex and 
hypertension status, focusing on tobacco use we noted that even degree and the direction of 
correlations of obesity, hemodynamic and stress related traits with tobacco use vary 
according to sex and hypertension status; for instance, while in males, current tobacco users 
were less obese compared to never or former tobacco users, there were no such differences 
in females; moreover, we found several obesity related traits that their correlations with 
206 
 
 
smoking behavior seemingly root in genetic factors rather than smoking effect itself. Sex- and 
hypertension differences in heritabilities of many of these traits were also observed; 
meanwhile, specific subgroup genetic analyses uncovered additional shared synaptic genes 
including CAMK4, CNTN5, DNM3, KCNAB1 (Hypertension-specific), CNTN4, DNM3, 
FHIT, ITPR1 and NRXN3 (Sex-specific) having protein interactions with genes driven 
from general analysis; moreover, the results of pathway analysis and reported gene 
expression profiles of resultant genes from specific analyses revealed similar characteristics 
to those from general analysis. In addition, subgroup analysis uncovered variants inside 
synaptic genes, IL1RAP, PLCG1 and SCIN genes that were positively associated (P < 
0.001) to a trait in one group and negatively associated (P < 0.001) to the same trait in 
contrary group. These findings indicate that by increasing genetic homogeneity, subgroup 
analysis can uncover additional components of functional modules underlying complex 
traits in which remain obscure following statistical adjustments; moreover, such findings 
can shed lights into the observed sex and hypertension differences in prevalence of these 
traits. 
The substantial overlap among genomic determinants of substance use, stress, 
obesity, heart rate and blood pressure supports the notion that the genetic variations in 
pathways of synaptic plasticity may be a common interface behind these traits and observed 
sex and hypertension genetic differences. We assume the interaction between genetic make-
up of synapses with environmental factors including stress influence individuals’s life 
styles and habits; in the other side, the taken habits and lifestyle influence the body’s 
systems including cardiovascular system and modify the cardiovascular outcomes as well 
as cardiovascular risk factors e.g. body weight; nonetheless, similar to different routes 
ended to the same location, there are other factors that influence the cardiovascular system 
through other mechanisms. Our results also suggest that synaptic plasticity may be a 
common interface behind many other complex disorders in which life style is a contributing 
factor, an assumption that requires further investigations. 
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Appendice 1 
 
Article1: 
Table S1. List of the genes driven from general and specific genetic scans along their evidence of 
synaptic function 
Synaptic 
function 
Symbol1 Description Type of analysis 
 
A2BP1 Ataxin 2-Binding Protein 1 General (commonly associated) 
 ADAMTS3 ADAM Metallopeptidase with 
Thrombospondin Type 1 Motif, 3 
Hypertension-specific (under 
linkage peak) 
 
ADCY8 Adenylate Cyclase 8 (Brain) 
Sex-specific (commonly 
associated) 
 
AGBL4 ATP/GTP Binding Protein-Like 4 General (commonly associated) 
 
AGTR1 Angiotensin II Receptor, Type 1 General (under linkage peak) 
 ANKS1B Ankyrin Repeat and Sterile Alpha 
Motif Domain Containing 1B 
General (commonly associated) 
 
ARHGAP12 Hypothetical Protein FLJ10971 
Hypertension-specific (under 
linkage peak) 
 
ARHGAP18 Rho GTPase Activating Protein 18 General (commonly associated) 
 
ASAP1 
ArfGAP with SH3 domain, ankyrin 
repeat and PH domain 
Sex-specific (commonly 
associated) 
 
BACE2 Beta-Site APP-Cleaving Enzyme 2 
Hypertension-specific (under 
linkage peak) 
                                                            
1 Genes appeared in more than one set of result are underlined.  
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 BAI3 Brain-Specific Angiogenesis 
Inhibitor 3 
Sex-specific (commonly 
associated) 
 
C14orf25 
Chromosome 14 Open Reading 
Frame 25 
Sex-specific (commonly 
associated) 
 
C14orf37 
Chromosome 14 Open Reading 
Frame 37 
Hypertension-specific 
(commonly associated) 
 
C1orf110 
Chromosome 1 Open Reading 
Frame 110 
Hypertension-specific (under 
linkage peak) 
 
C6orf191 
Chromosome 6 Open Reading 
Frame 191 
General (commonly associated) 
 
CADPS 
Ca2+-Dependent Secretion 
Activator 
Sex-specific (commonly 
associated) 
 CAMK4 Calcium/Calmodulin-Dependent 
Protein Kinase Iv 
General (commonly associated) 
 CAMK4 Calcium/Calmodulin-Dependent 
Protein Kinase Iv 
Hypertension-specific 
(commonly associated) 
 
CBLN2 Cerebellin 2 Precursor General (under linkage peak) 
 
CD300LB 
Cd300 Antigen Like Family 
Member B 
Sex-specific (under linkage 
peak) 
 CDH12 Cadherin 12, Type 2 (N-Cadherin 2) Hypertension-specific (under 
linkage peak) 
 
CDH17 
Cadherin 17, LI Cadherin (Liver-
Intestine) 
Sex-specific (commonly 
associated) 
 
CDH6 
Cadherin 6, Type 2, K-Cadherin 
(Fetal Kidney) 
Sex-specific (commonly 
associated) 
 
CHORDC1 
Cysteine and Histidine-Rich 
Domain (Chord)-Containing 1 
General (commonly associated) 
 CHRM2 Cholinergic Receptor, Muscarinic 2 General (under linkage peak) 
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 CNTN4 Contactin 4 General (commonly associated) 
 CNTN4 Contactin 4 Sex-specific (commonly 
associated) 
 CNTN5 Neural Adhesion Molecule Hypertension-specific 
(commonly associated) 
 
COL24A1 Collagen, Type XXIV, Alpha 1 General (under linkage peak) 
 
COMMD10 Comm Domain Containing 10 
Hypertension-specific (under 
linkage peak) 
 
CPE Carboxypeptidase E 
Hypertension-specific 
(commonly associated) 
 CPS1 Carbamoyl-Phosphate Synthetase 
1, Mitochondrial 
General (commonly associated) 
 
CSGALNACT1 
Chondroitin Sulfate N-
Acetylgalactosaminyltransferase 1 
General (commonly associated) 
 
CSMD1 Cub and Sushi Multiple Domains 1 General (commonly associated) 
 
CSMD1 Cub and Sushi Multiple Domains 1 
Hypertension-specific 
(commonly associated) 
 CTNNA2 Catenin (Cadherin-Associated 
Protein), Alpha 2 
General (commonly associated) 
 
CTNNA3 
Catenin (Cadherin-Associated 
Protein), Alpha 3 
Hypertension-specific 
(commonly associated) 
 DAB2 
Disabled Homolog 2, Mitogen-
Responsive Phosphoprotein 
(Drosophila) 
General (under linkage peak) 
 DAG1 Dystroglycan 1 (Dystrophin-
Associated Glycoprotein 1) 
General (commonly associated) 
 DCLK1 Doublecortin and Cam Kinase-Like 
1 
Sex-specific (commonly 
associated) 
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 DGKB Diacylglycerol Kinase, Beta 90Kda General (commonly associated) 
 DLG2 Discs, Large Homolog 2, Chapsyn-
110 (Drosophila) 
General (commonly associated) 
 DNM3 Dynamin 3 Hypertension-specific (under 
linkage peak) 
 DNM3 Dynamin 3 Sex-specific (under linkage 
peak) 
 
DSCAM 
Down Syndrome Cell Adhesion 
Molecule 
Hypertension-specific (under 
linkage peak) 
 DTNBP1 Dystrobrevin Binding Protein 1 Hypertension-specific (under 
linkage peak) 
 
EDEM1 
ER Degradation Enhancer, 
Mannosidase Alpha-Like 1 
General (commonly associated) 
 ELTD1 
EGF, Latrophilin and Seven 
Transmembrane Domain 
Containing 1 
General (commonly associated) 
 EPB41L3 Erythrocyte Membrane Protein 
Band 4.1-Like 3 
General (commonly associated) 
 
EYS Eyes Shut Homolog 
Sex-specific (commonly 
associated) 
 
FAM134B Hypothetical Protein Flj20152 General (commonly associated) 
 FAM13A1 Family with Sequence Similarity 
13, Member A1 
General (commonly associated) 
 
FAM155A 
Family with Sequence Similarity 
155, Member A 
Hypertension-specific 
(commonly associated) 
 
FAM174A 
Family with Sequence Similarity 
174, Member A 
General (commonly associated) 
 
FAM190A Family with Sequence Similarity General (commonly associated) 
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190, Member A 
 
FARS2 
Phenylalanine-Trna Synthetase 2 
(Mitochondrial) 
General (commonly associated) 
 FHIT Fragile Histidine Triad Gene General (commonly associated) 
 FHIT Fragile Histidine Triad Gene Sex-specific (commonly 
associated) 
 GLRA3 Glycine Receptor, Alpha 3 Hypertension-specific 
(commonly associated) 
 
GPC6 Glypican 6 General (commonly associated) 
 GRID2 Glutamate Receptor, Ionotropic, 
Delta 2 
General (commonly associated) 
 GRID2 Glutamate Receptor, Ionotropic, 
Delta 2 
General (under linkage peak) 
 
HBEGF 
Heparin-Binding Egf-Like Growth 
Factor 
Hypertension-specific 
(commonly associated) 
 HTR2A 5-Hydroxytryptamine (Serotonin) 
Receptor 2A 
General (under linkage peak) 
 
IL12A 
Interleukin 12A (Natural Killer Cell 
Stimulatory Factor 1, Cytotoxic 
Lymphocyte Maturation Factor 1, 
P35) 
Sex-specific (commonly 
associated) 
 IL1RAP Interleukin 1 Receptor Accessory 
Protein 
Hypertension-specific  
 INHBA Inhibin, Beta A (Activin A, Activin 
Ab Alpha Polypeptide) 
Sex-specific (commonly 
associated) 
 ITPR1 Inositol 1,4,5-Triphosphate 
Receptor, Type 1 
Sex-specific (commonly 
associated) 
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 ITPR2 Inositol 1,4,5-Triphosphate 
Receptor, Type 2 
General (commonly associated) 
 ITPR2 Inositol 1,4,5-Triphosphate 
Receptor, Type 2 
General (under linkage peak) 
 KCNAB1 
Potassium Voltage-Gated Channel, 
Shaker-Related Subfamily, Beta 
Member 1 
Hypertension-specific (under 
linkage peak) 
 KCNH1 
Potassium Voltage-Gated Channel, 
Subfamily H (Eag-Related), 
Member 1 
General (commonly associated) 
 KIF5B Kinesin Family Member 5B Hypertension-specific (under 
linkage peak) 
 
KRT12 
Keratin 12 (Meesmann Corneal 
Dystrophy) 
General (commonly associated) 
 
KSR2 Kinase Suppressor Of Ras 2 
Sex-specific (commonly 
associated) 
 
L3MBTL4 L(3)Mbt-Like 4 (Drosophila) General (commonly associated) 
 LPHN2 Latrophilin 2 General (under linkage peak) 
 
LRP1B 
Low Density Lipoprotein-Related 
Protein 1B (Deleted In Tumors) 
General (commonly associated) 
 
LRP1B 
Low Density Lipoprotein-Related 
Protein 1B (Deleted In Tumors) 
General (under linkage peak) 
 
LRRIQ1 
Leucine-Rich Repeats and IQ Motif 
Containing 1 
Sex-specific (commonly 
associated) 
 
MACROD2 
Chromosome 20 Open Reading 
Frame 133 
General (commonly associated) 
 
MAN1A1 
Mannosidase, Alpha, Class 1A, 
Member 1 
Hypertension-specific 
(commonly associated) 
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MDM1 Hypothetical Protein Loc54104 General (commonly associated) 
 
MTPN Myotrophin General (under linkage peak) 
 
MYLIP 
Myosin Regulatory Light Chain 
Interacting Protein 
Hypertension-specific (under 
linkage peak) 
 MYO10 Myosin X General (commonly associated) 
 NETO1 Neuropilin (NRP) and Tolloid (TLL)-
Like 1 
General (under linkage peak) 
 
NKAIN2 
T-Cell Lymphoma Breakpoint 
Associated Target 1 
Hypertension-specific 
(commonly associated) 
 NLGN1 Neuroligin 1 Sex-specific (commonly 
associated) 
 NOVA1 Neuro-Oncological Ventral Antigen 
1 
General (commonly associated) 
 NR4A2 Nuclear Receptor Subfamily 4, 
Group A, Member 2 
General (commonly associated) 
 NRG3 Neuregulin 3 General (commonly associated) 
 NRXN3 Neurexin 3 Sex-specific (commonly 
associated) 
 
ODF2L 
Outer Dense Fiber Of Sperm Tails 
2-Like 
General (under linkage peak) 
 
ODZ2 
Odz, odd Oz/Ten-M Homolog 2 
(Drosophila) 
General (commonly associated) 
 
ODZ3 
Odz, odd Oz/Ten-M Homolog 3 
(Drosophila) 
General (commonly associated) 
 ODZ4 Odz, odd Oz/Ten-M Homolog 4 
(Drosophila) 
General (commonly associated) 
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OLFM4 Olfactomedin 4 General (commonly associated) 
 
OLFM4 Olfactomedin 4 
Sex-specific (under linkage 
peak) 
 
PAPPA2 Pappalysin 2 
Hypertension-specific (under 
linkage peak) 
 
PCDH18 Protocadherin 18 
Sex-specific (commonly 
associated) 
 
PCDH9 Protocadherin 9 
Sex-specific (commonly 
associated) 
 
PCM1 Pericentriolar Material 1 General (commonly associated) 
 
PCM1 Pericentriolar Material 1 General (under linkage peak) 
 
PDP1 
Pyruvate Dehyrogenase 
Phosphatase Catalytic Subunit 1 
Sex-specific (commonly 
associated) 
 
PFDN1 Prefoldin Subunit 1 
Hypertension-specific 
(commonly associated) 
 
PHLDB2 
Pleckstrin Homology-Like Domain, 
Family B, Member 2 
General (commonly associated) 
 PKIA Protein Kinase (Camp-Dependent, 
Catalytic) Inhibitor Alpha 
General (commonly associated) 
 PLCG2 Phospholipase C, Gamma 2 
(Phosphatidylinositol-Specific) 
Sex-specific  
 
PRDM9 PR Domain Containing 9 
Hypertension-specific (under 
linkage peak) 
 PRKCE Protein Kinase C, Epsilon General (commonly associated) 
 
PRR20 Proline Rich 20A General (under linkage peak) 
 
PRRX1 Paired Related Homeobox 1 Hypertension-specific (under 
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linkage peak) 
 
PTGER4 
Prostaglandin E Receptor 4 
(subtype EP4) 
General (under linkage peak) 
 PTPRD Protein Tyrosine Phosphatase, 
Receptor Type, D 
General (commonly associated) 
 PTPRD Protein Tyrosine Phosphatase, 
Receptor Type, D 
Hypertension-specific 
(commonly associated) 
 
PTPRM 
Protein Tyrosine Phosphatase, 
Receptor Type, M 
General (commonly associated) 
 PTPRR Protein Tyrosine Phosphatase, 
Receptor Type, R 
Sex-specific (commonly 
associated) 
 
PVT1 
Pvt1 Oncogene Homolog, Myc 
Activator (Mouse) 
Sex-specific (commonly 
associated) 
 
PXMP3 
Peroxisomal Membrane Protein 3, 
35Kda (Zellweger Syndrome) 
General (commonly associated) 
 RAP1B RAP1B, Member Of Ras Oncogene 
Family 
General (commonly associated) 
 RGS4 Regulator of G-Protein Signalling 4 Hypertension-specific (under 
linkage peak) 
 
RIT2 Ras-Like Without Caax 2 General (commonly associated) 
 
RMI1 
Chromosome 9 Open Reading 
Frame 76 
General (commonly associated) 
 
RORA RAR-Related Orphan Receptor A General (commonly associated) 
 
RORA RAR-Related Orphan Receptor A 
Hypertension-specific 
(commonly associated) 
 
RORA RAR-Related Orphan Receptor A 
Hypertension-specific (under 
linkage peak) 
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 SCIN Scinderin Sex-specific (commonly 
associated) 
 SCIN Scinderin Sex-specific 
 
SDK1 Sidekick Homolog 1 (Chicken) 
Hypertension-specific 
(commonly associated) 
 SEMA6A Ht018 Protein Hypertension-specific (under 
linkage peak) 
 
SGCG 
Sarcoglycan, Gamma (35Kda 
Dystrophin-Associated 
Glycoprotein) 
Sex-specific (commonly 
associated) 
 SGCZ Sarcoglycan Zeta General (commonly associated) 
 
SLC25A21 Oxodicarboxylate Carrier 
Sex-specific (commonly 
associated) 
 
SLC28A3 
Solute Carrier Family 28 (Sodium-
Coupled Nucleoside Transporter), 
Member 3 
General (commonly associated) 
 
SLCO4C1 Hypothetical Protein Pro2176 General (commonly associated) 
 SNCAIP Synuclein, Alpha Interacting 
Protein (Synphilin) 
General (commonly associated) 
 
SNX2 Sorting Nexin 2 General (commonly associated) 
 
SOX6 
SRY (Sex Determining Region Y)-
Box 6 
Hypertension-specific (under 
linkage peak) 
 SPINK5 Serine Peptidase Inhibitor, Kazal 
Type 5 
Hypertension-specific 
(commonly associated) 
 
ST8SIA4 
ST8 Alpha-N-Acetyl-Neuraminide 
Alpha-2,8-Sialyltransferase 4 
General (commonly associated) 
 
STRN3 Striatin, Calmodulin Binding Sex-specific (commonly 
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Protein 3 associated) 
 
SYT17 Synaptotagmin XVII 
Hypertension-specific (under 
linkage peak) 
 SYT4 Synaptotagmin IV General (commonly associated) 
 
TDRD3 Tudor Domain Containing 3 General (commonly associated) 
 
TLL1 Tolloid-Like 1 General (under linkage peak) 
 
TMC5 Transmembrane Channel-Like 5 
Hypertension-specific (under 
linkage peak) 
 
TMEM99 Transmembrane Protein 99 General (commonly associated) 
 
TTLL7 
Tubulin Tyrosine Ligase-Like 
Family, Member 7 
General (under linkage peak) 
 
UBR4 Zinc Finger, Ubr1 Type 1 General (commonly associated) 
 
ZNF532 Zinc Finger Protein 532 
Hypertension-specific 
(commonly associated) 
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Article2: 
Table S1. Descriptive statistics of obesity, stress and hemodynamic related traits distributed by sex and hypertension status along with their 
correlations1 with sex, age2 and hypertension3 
Trait 
Females Males 
Total Sex (females) Aging 
Hypertension 
(hypertensives) Norm Hyper Norm Hyper 
N Mean±SE N Mean±SE N Mean±SE N Mean±SE N Mean±SE Z P Z P Z P 
BMI (kg/m2) 175 24.7±0.4 254 27.5±0.3 162 26.3±0.4 201 28.1±0.3 792 26.8±0.2 -4.9 5.E-07 2.7 4.E-03 5.4 3.E-08 
Waist Hip ratio 171 0.8±0 251 0.8±0 161 0.9±0 202 1±0 785 0.9±0 -24.4 7.E-132 8.8 5.E-19 4.5 3.E-06 
Waist circumference (cm) 172 80.1±1 251 87.7±0.9 161 92.9±0.9 203 99.3±0.8 787 90.1±0.5 -16 1.E-57 5.3 6.E-08 4.8 1.E-06 
Hip circumference (cm) 171 99.2±0.8 251 102.9±0.7 161 98±0.5 202 100.8±0.5 785 100.6±0.3 2.1 2.E-02 1 2.E-01 3.8 7.E-05 
Hip Thigh Proximal ratio 171 1.7±0 238 1.7±0 158 1.7±0 193 1.7±0 760 1.7±0 -4 3.E-05 15.5 1.E-54 -0.6 3.E-01 
Thigh proximal circumference 
(cm) 
171 59±0.6 238 58.8±0.4 159 57.2±0.5 194 58.1±0.4 762 58.3±0.2 4.1 2.E-05 -5.5 2.E-08 3 2.E-03 
Thigh mid circumference (cm) 171 52.3±0.5 241 52.8±0.4 159 52.7±0.5 195 53.4±0.4 766 52.8±0.2 -0.8 2.E-01 -4.6 2.E-06 4.1 2.E-05 
Thigh distal circumference (cm) 171 39.8±0.4 239 40.6±0.3 159 40±0.3 194 40.9±0.3 763 40.4±0.2 -0.8 2.E-01 -1.6 6.E-02 3.2 7.E-04 
Skinfold bicep1 (mm) 160 21.9±1.1 202 23.7±0.8 154 16.4±1 180 16.8±1 696 19.9±0.5 6.2 2.E-10 1.2 1.E-01 4.4 7.E-06 
Skinfold bicep2 (mm) 160 22.1±1.1 202 23.9±0.8 154 16.7±1 180 16.9±1 696 20.1±0.5 6 1.E-09 1.1 1.E-01 4.3 7.E-06 
Skinfold bicep3 (mm) 160 22.3±1.1 201 24±0.9 154 16.7±1 180 16.8±1 695 20.1±0.5 5.9 2.E-09 1 2.E-01 4 3.E-05 
Mean skinfold biceps (mm) 160 22.1±1.1 202 23.9±0.8 154 16.6±1 180 16.8±1 696 20±0.5 6 7.E-10 1.1 1.E-01 4.3 1.E-05 
Skinfold triceps1 (mm) 161 30±1 202 34.1±0.8 154 23±1 180 23.8±1 697 28±0.5 8 9.E-16 0.9 2.E-01 4.1 2.E-05 
Skinfold triceps2 (mm) 161 30.2±1 202 34.5±0.8 154 23.3±1.1 179 23.6±0.9 696 28.2±0.5 7.7 6.E-15 1 2.E-01 4.2 1.E-05 
Skinfold triceps3 (mm) 161 30.4±1 201 34.5±0.8 154 23.2±1.1 179 23.6±1 695 28.2±0.5 7.7 9.E-15 1 2.E-01 4.1 2.E-05 
                                                            
1 Correlation test was performed using GEE. The sign of Z (Z-score) shows the direction of correlation, the positive Z means a positive correlation and vice versa.  
2 Correlation model is trait ~ sex + age. 
3 Correlation model is hypertension status ~ sex + age + substance use + trait. 
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Mean skinfold triceps (mm) 161 30.2±1 202 34.4±0.8 154 23.1±1.1 180 23.8±1 697 28.2±0.5 7.7 5.E-15 1 2.E-01 4.2 1.E-05 
Skinfold subscapular1 (mm) 161 24±1 201 28.1±0.8 154 22.8±0.8 177 25.9±0.8 693 25.4±0.4 2.2 2.E-02 1.3 1.E-01 4.1 2.E-05 
Skinfold subscapular2 (mm) 161 24.3±1 201 28.2±0.9 154 22.7±0.8 177 25.7±0.8 693 25.5±0.4 2.3 1.E-02 1.2 1.E-01 4 4.E-05 
Skinfold subscapular3 (mm) 161 24.4±1 201 28.3±0.9 154 22.9±0.9 177 25.8±0.8 693 25.5±0.5 2.3 1.E-02 1.1 1.E-01 4 3.E-05 
Mean skinfold subscapular (mm) 161 24.2±1 201 28.2±0.9 154 22.8±0.8 177 25.8±0.8 693 25.5±0.4 2.2 1.E-02 1.2 1.E-01 4 3.E-05 
Skinfold suprailiac1 (mm) 159 23.7±1.1 201 26.9±0.7 153 21.6±1 177 24.8±0.9 690 24.5±0.5 3.1 9.E-04 -1 2.E-01 3.8 7.E-05 
Skinfold suprailiac2 (mm) 159 23.7±1.1 201 27.2±0.7 153 21.9±1 177 24.8±0.9 690 24.6±0.5 3.2 8.E-04 -1 2.E-01 4.1 2.E-05 
Skinfold suprailiac3 (mm) 159 23.8±1.1 201 27.2±0.7 153 21.9±1 177 25.1±0.9 690 24.7±0.5 2.9 2.E-03 -0.9 2.E-01 4.1 2.E-05 
Mean skinfold suprailiac (mm) 159 23.7±1.1 201 27.1±0.7 153 21.8±1 177 24.9±0.9 690 24.6±0.5 3 1.E-03 -0.9 2.E-01 4 3.E-05 
Skinfold thigh1 (mm) 145 39.2±1.1 191 43±0.9 149 26.9±1.3 175 24.3±1.1 660 33.5±0.6 13.2 4.E-40 -1.1 1.E-01 2.5 6.E-03 
Skinfold thigh2 (mm) 144 39.2±1.1 191 43.3±0.9 149 27.1±1.3 175 24.5±1.1 659 33.7±0.6 12.3 4.E-35 -1 2.E-01 2.5 6.E-03 
Skinfold thigh3 (mm) 144 39.5±1.1 191 43.6±0.9 148 27±1.3 175 24.6±1.1 658 33.9±0.6 13.4 3.E-41 -1.2 1.E-01 2.7 4.E-03 
Mean skinfold thigh (mm) 145 39.4±1.1 191 43.3±0.9 149 27.1±1.3 175 24.5±1.1 660 33.8±0.6 12.9 2.E-38 -1.1 1.E-01 2.6 5.E-03 
Body fat percentage 
bioimpedance 
137 30.4±0.8 177 37.4±0.8 128 21.2±0.7 158 24.6±0.6 600 28.9±0.4 18.7 5.E-78 9.7 1.E-22 3.5 2.E-04 
Body fat (%) 158 36.3±0.6 201 39.1±0.4 153 25±0.5 175 26±0.4 687 32±0.3 27.7 3.E-169 1 2.E-01 4.4 5.E-06 
Supine EP (pg/ml) 66 41.9±2.1 40 40.5±2.6 57 43.3±2.3 49 46±3.2 212 42.9±1.3 -1.5 7.E-02 0.5 3.E-01 0 5.E-01 
Standing EP (pg/ml) 68 50.5±3.3 37 38.6±2.4 54 57±4.7 52 54.9±3.7 211 51.2±1.9 -3.1 1.E-03 -2.6 5.E-03 -0.7 2.E-01 
Response EP (pg/ml) 63 9.6±3.6 31 -1.1±2.8 54 13.8±4.6 43 6±4 191 8.2±2 -1 2.E-01 -2.4 9.E-03 -1.2 1.E-01 
Supine NE (pg/ml) 73 171.7±7.1 48 167.3±9.8 57 169.4±8.6 60 160.2±9.5 238 167.4±4.3 0.7 2.E-01 -0.2 4.E-01 -0.9 2.E-01 
Standing NE (pg/ml) 73 391.8±14.9 48 407.9±24.6 55 397.1±23.3 61 395.9±20.7 237 397.4±10.1 0.4 4.E-01 1.6 5.E-02 0.2 4.E-01 
Response NE (pg/ml) 73 220.1±11.2 48 240.6±18.8 55 230.3±20.5 60 235.8±15.2 236 230.7±8 0 5.E-01 2.1 2.E-02 0.6 3.E-01 
DBP response to mental stress 
(mmHg) 
77 10±0.8 57 12.1±1 64 9.6±0.9 71 9.4±0.9 269 10.2±0.4 1.5 7.E-02 -1.3 1.E-01 1.4 8.E-02 
DBP recovery mental stress 
(mmHg) 
77 10.5±0.8 57 13.9±1 64 10.5±0.9 71 9.9±0.8 269 11.1±0.5 1.4 8.E-02 -0.9 2.E-01 1.5 6.E-02 
Delta DBP (mmHg) 77 0.4±0.4 57 1.7±0.6 64 0.9±0.4 71 0.5±0.5 269 0.8±0.2 0.6 3.E-01 0.9 2.E-01 0.1 5.E-01 
SBP response to mental stress 
(mmHg) 
77 12.1±1.3 56 18.4±1.6 64 14.9±1.4 71 19.5±1.6 268 16.1±0.7 -1.5 7.E-02 0.9 2.E-01 2 2.E-02 
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SBP recovery from mental stress 
(mmHg) 
77 19.2±1.3 56 30.1±1.5 64 22.1±1.4 71 28.5±1.6 268 24.7±0.7 -0.9 2.E-01 2.6 4.E-03 3 1.E-03 
Delta SBP (mmHg) 77 7.1±0.6 56 11.8±1 64 7.2±0.7 71 9±0.9 268 8.6±0.4 1.7 4.E-02 3.5 2.E-04 1.9 3.E-02 
HR response to mental stress 
(beast/min) 
78 7.8±1.4 57 9.4±1.1 64 7±1.1 71 8.5±1 270 8.1±0.6 0.7 2.E-01 -0.6 3.E-01 1.8 3.E-02 
HR recovery from mental stress 
(beast/min) 
78 8.8±1.4 57 10.4±1.1 64 6.7±1.2 71 8.5±1 270 8.6±0.6 1.7 4.E-02 -0.4 3.E-01 1.5 7.E-02 
Delta HR (mmHg) 78 1±0.5 57 1.1±0.6 64 -0.3±0.4 71 0±0.5 270 0.4±0.2 2.3 1.E-02 0.2 4.E-01 -0.2 4.E-01 
Average sitting DBP (mmHg) 77 69.2±0.9 57 79±1.4 64 75.1±1.1 69 86±1.3 267 77.1±0.7 -5.1 2.E-07 6.8 4.E-12 4.1 2.E-05 
Average sitting SBP (mmHg) 77 109±1.3 57 136.8±2.6 64 118.1±1.3 69 136±2.1 267 124.1±1.2 -2.6 4.E-03 6.2 3.E-10 5.8 4.E-09 
Average sitting HR (beast/min) 77 71.1±1.2 57 73.8±1.5 64 64.7±1.2 67 67.1±1.2 265 69.1±0.7 4.4 6.E-06 -1.5 6.E-02 2.1 2.E-02 
Mean ambulatory DBP (mmHg) 61 67.4±0.8 43 79.3±1.5 48 73.3±1.1 51 84.7±1.2 203 75.6±0.7 -6.2 3.E-10 9.3 5.E-21 5.9 2.E-09 
Mean ambulatory SBP (mmHg) 61 110.3±1 43 130.6±2.4 48 120.7±1.3 51 133.7±1.9 203 122.9±1 -5.3 8.E-08 5.6 9.E-09 5.4 3.E-08 
Mean ambulatory HR (mmHg) 61 74.9±1 43 79.9±1.4 48 70.5±1.6 51 76.3±1.5 203 75.3±0.7 1.7 4.E-02 0.3 4.E-01 2.9 2.E-03 
Sleep DBP (mmHg) 74 61.4±1 50 70.3±1.6 61 67.2±1.1 63 74.8±1.3 248 68±0.7 -5.8 3.E-09 5.5 2.E-08 3.8 8.E-05 
Sleep SBP (mmHg) 74 102.5±1.1 50 117.6±2.4 61 112.6±1.2 63 122.2±2 248 113±1 -5.5 2.E-08 4.1 2.E-05 4.3 1.E-05 
Sleep HR (beast/min) 74 71.2±1.2 49 74.8±1.4 60 65.8±1.3 63 67.3±1.6 246 69.6±0.7 3.4 4.E-04 0.3 4.E-01 1.2 1.E-01 
Sleep MAP (mmHg) 74 75.1±1 50 86.1±1.8 61 82.3±1 63 90.6±1.4 248 83±0.7 -5.9 2.E-09 5 2.E-07 4.2 1.E-05 
Sleep PP (mmHg) 74 41.1±0.7 50 47.4±1.6 61 45.4±0.9 63 47.4±1.4 248 45±0.6 -2.5 6.E-03 0.7 2.E-01 3.1 9.E-04 
Wake DBP (mmHg) 73 71±0.9 49 79.6±1.6 62 75.5±1 63 84.4±1.3 247 77.2±0.7 -5 3.E-07 5.5 2.E-08 3.8 8.E-05 
Wake SBP (mmHg) 73 115.3±1.2 49 131.3±2.5 62 124.4±1.3 63 136.5±1.9 247 126.2±1 -5.4 4.E-08 4.7 1.E-06 4.5 4.E-06 
Wake HR (beast/min) 73 81.6±1 49 85±1.6 62 76.6±1.4 63 81.7±1.8 247 81±0.8 2.1 2.E-02 0.6 3.E-01 2.2 1.E-02 
Wake MAP (mmHg) 73 85.8±0.9 49 96.8±1.7 62 91.8±1 63 101.8±1.4 247 93.6±0.7 -5.9 2.E-09 5.6 1.E-08 4.5 4.E-06 
Wake PP (mmHg) 73 44.3±0.9 49 51.8±1.7 62 48.9±1 63 52.1±1.4 247 48.9±0.6 -2.8 2.E-03 1.6 6.E-02 2.9 2.E-03 
Overall PP (mmHg) 61 42.9±0.7 43 51.3±1.6 48 47.4±0.9 51 48.9±1.2 203 47.3±0.6 -2.2 1.E-02 0.5 3.E-01 3.2 7.E-04 
 
 
